Cochrane
Library

Cochrane Database of Systematic Reviews

Second trimester serum tests for Down's Syndrome screening (Review)

Allred SK, Deeks JJ, Guo B, Neilson JP, Alfirevic Z

Allred SK, Deeks JJ, Guo B, Neilson JP, Alfirevic Z.
Second trimester serum tests for Down's Syndrome screening.
Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD009925.
DOI: [10.1002/14651858.CD009925](https://doi.org/10.1002/14651858.CD009925).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	7
OBJECTIVES	8
METHODS	9
RESULTS	11
Figure 1.	12
Figure 2.	13
Figure 3.	14
Figure 4.	15
Figure 5.	16
Figure 6.	17
Figure 7.	18
Figure 8.	19
Figure 9.	20
Figure 10.	21
Figure 11.	22
DISCUSSION	23
AUTHORS' CONCLUSIONS	25
ACKNOWLEDGEMENTS	25
REFERENCES	26
CHARACTERISTICS OF STUDIES	53
DATA	157
Test 1. Inhibin A at mixed cutpoints.	161
Test 2. Inhibin A at 5% FPR.	161
Test 3. Inhibin A at 2.4MoM.	161
Test 4. Inhibin A at 2 MoM.	161
Test 5. SP1 at mixed cutpoints.	161
Test 6. SP1 at 2.5MoM.	161
Test 7. SP1 at 5% FPR.	161
Test 8. AFP at mixed cutpoints.	161
Test 9. AFP at 0.8MoM.	161
Test 10. AFP at 5% FPR.	161
Test 11. AFP at SD (specified in paper).	161
Test 12. Total hCG at 5% FPR.	162
Test 13. Total hCG at 2.5MoM.	162
Test 14. Total hCG at mixed cutpoints.	162
Test 15. Free β hCG at 5% FPR.	162
Test 16. uE3 at 5% FPR.	162
Test 17. Troponin at 5% FPR.	162
Test 18. Free β hCG to AFP ratio at 5% FPR.	162
Test 19. PAPP-A at 5% FPR.	162
Test 20. PGF at 95th percentile.	162
Test 21. CA125 at 1.5MoM.	162
Test 22. Age and Total hCG at 5% FPR/95th percentile.	162
Test 23. Age and Total hCG at mixed cutpoints.	162
Test 24. Age and Total hCG at 1:384 risk.	162
Test 25. Age and AFP at 1:270 risk.	163
Test 26. Age and AFP at 5% FPR.	163

Test 27. Age and AFP at mixed cutpoints.	163
Test 28. Age and Free β hCG at mixed cutpoints.	163
Test 29. Age and Free β hCG at 1:384 risk.	163
Test 30. Age and uE3 at mixed cutpoints.	163
Test 31. Age and uE3 at 1:384 risk.	163
Test 32. Age and Free β hCG to AFP at 5% FPR.	163
Test 33. Age and inhibin at 5% FPR.	163
Test 34. Age and PAPP-A at 5% FPR.	163
Test 35. Age and ProMBP at 1:250 risk.	163
Test 36. Age and Free α hCG at 1:384 risk.	163
Test 37. Age, Total hCG and Free β hCG at 1:384 risk.	163
Test 38. Age, Total hCG and uE3 at 5% FPR.	164
Test 39. Age, Total hCG and uE3 at 1:384 risk.	164
Test 40. Age, Total hCG and uE3 at mixed cutpoints.	164
Test 41. Age, Total hCG and AFP at 5% FPR.	164
Test 42. Age, Total hCG and AFP at 1:250 risk.	164
Test 43. Age, Total hCG and AFP at mixed cutpoints.	164
Test 44. Age, Total hCG and SP1 at 5% FPR.	164
Test 45. Age, Total hCG and Free α hCG at 1:384 risk.	164
Test 46. Age, Free β hCG and uE3 at 1:384 risk.	164
Test 47. Age, Free β hCG and AFP at 1:250 risk.	164
Test 48. Age, Free β hCG and AFP at 5% FPR.	164
Test 49. Age, Free β hCG and AFP at mixed cutpoints.	164
Test 50. Age, Free β hCG and Free α hCG at 1:384 risk.	164
Test 51. Age, AFP and uE3 at 1:384 risk.	165
Test 52. Age, AFP and uE3 at 5% FPR.	165
Test 53. Age, AFP and uE3 at mixed cutpoints.	165
Test 54. Age, uE3 and Free α hCG at 1:384 risk.	165
Test 55. Age, uE3 and SP1 at 5% FPR.	165
Test 56. Age, AFP and SP1 at 5% FPR.	165
Test 57. Age, AFP and Hyperglycosylated hCG at 5% FPR.	165
Test 58. Age, AFP and Free α hCG 1:384 risk.	165
Test 59. Age, Total hCG, Free β hCG and AFP at 1:266 risk.	165
Test 60. Age, Total hCG, AFP and uE3 at 5% FPR.	165
Test 61. Age, Total hCG, AFP and uE3 at 1:250 risk.	165
Test 62. Age, Total hCG, AFP and uE3 at mixed cutpoints.	165
Test 63. Age, Total hCG, uE3 and SP1 at 5% FPR.	165
Test 64. Age, Total hCG, AFP and Inhibin A at 1:190 risk.	166
Test 65. Age, Total hCG, AFP and Inhibin A at 1:250 risk.	166
Test 66. Age, Total hCG, AFP and SP1 at 5% FPR.	166
Test 67. Age, Total hCG, AFP and CA125 at 1:190 risk.	166
Test 68. Age, Free β hCG, AFP and uE3 at 5% FPR.	166
Test 69. Age, Free β hCG, AFP and uE3 at 1:250 risk.	166
Test 70. Age, Free β hCG, AFP and uE3 at mixed cutpoints.	166
Test 71. Age, Free β hCG, AFP and Inhibin A at 1:190 risk.	166
Test 72. Age, Free β hCG, AFP and ProMBP at 5% FPR.	166
Test 73. Age, Free β hCG, AFP and ProMBP at 1:250 risk.	166
Test 74. Age, AFP, uE3 and Free α hCG at 1:384 risk.	166
Test 75. Age, AFP, uE3 and Inhibin A at 1:233 risk.	166
Test 76. Age, AFP, uE3 and SP1 at 5% FPR.	166
Test 77. Age, Total hCG, Free β hCG, AFP and uE3 at 1:384 risk.	167
Test 78. Age, Total hCG, AFP, uE3 and Inhibin A at 5% FPR.	167

Test 79. Age, Total hCG, AFP, uE3 and Inhibin A at 1:150 risk.	167
Test 80. Age, Total hCG, AFP, uE3 and Inhibin A at 1:250 risk.	167
Test 81. Age, Total hCG, AFP, uE3 and Inhibin A at mixed cutpoints.	167
Test 82. Age, Total hCG, AFP, uE3 and Free α hCG at 1:384 risk.	167
Test 83. Age, Total hCG, AFP, uE3 and SP1 at 5% FPR.	167
Test 84. Age, Free β hCG, AFP, uE3 and Inhibin A at 5% FPR.	167
Test 85. Age, Free β hCG, AFP, uE3 and Inhibin A at 1:250 risk.	167
Test 86. Age, Free β hCG, AFP, uE3 and Inhibin A at mixed cutpoints.	167
Test 87. Age, Total hCG, AFP, uE3, Inhibin A and PAPP-A at 5% FPR.	167
Test 88. Age, Total hCG, Free β hCG, AFP, uE3 and Free α hCG at 1:384 risk.	167
Test 89. Age, Free β hCG, AFP, uE3, Inhibin A and PAPP-A at 5%FPR.	167
ADDITIONAL TABLES	167
APPENDICES	174
CONTRIBUTIONS OF AUTHORS	182
DECLARATIONS OF INTEREST	182
SOURCES OF SUPPORT	182
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	182
NOTES	183
INDEX TERMS	183

[Diagnostic Test Accuracy Review]

Second trimester serum tests for Down's Syndrome screening

S Kate Alldred¹, Jonathan J Deeks², Boliang Guo³, James P Neilson¹, Zarko Alfirevic¹

¹Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK. ²Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, UK. ³School of Community Health Science, University of Nottingham, Nottingham, UK

Contact address: S Kate Alldred, Department of Women's and Children's Health, The University of Liverpool, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. k.alldred@liv.ac.uk.

Editorial group: Cochrane Pregnancy and Childbirth Group.

Publication status and date: New, published in Issue 6, 2012.

Citation: Alldred SK, Deeks JJ, Guo B, Neilson JP, Alfirevic Z. Second trimester serum tests for Down's Syndrome screening. *Cochrane Database of Systematic Reviews* 2012, Issue 6. Art. No.: CD009925. DOI: [10.1002/14651858.CD009925](https://doi.org/10.1002/14651858.CD009925).

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Down's syndrome occurs when a person has three copies of chromosome 21 - or the specific area of chromosome 21 implicated in causing Down's syndrome - rather than two. It is the commonest congenital cause of mental retardation. Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing.

Objectives

To estimate and compare the accuracy of second trimester serum markers for the detection of Down's syndrome.

Search methods

We carried out a sensitive and comprehensive literature search of MEDLINE (1980 to May 2007), EMBASE (1980 to 18 May 2007), BIOSIS via EDINA (1985 to 18 May 2007), CINAHL via OVID (1982 to 18 May 2007), The Database of Abstracts of Reviews of Effectiveness (*The Cochrane Library* 2007, Issue 1), MEDION (May 2007), The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine (May 2007), The National Research Register (May 2007), Health Services Research Projects in Progress database (May 2007). We studied reference lists and published review articles.

Selection criteria

Studies evaluating tests of maternal serum in women at 14-24 weeks of gestation for Down's syndrome, compared with a reference standard, either chromosomal verification or macroscopic postnatal inspection.

Data collection and analysis

Data were extracted as test positive/test negative results for Down's and non-Down's pregnancies allowing estimation of detection rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS criteria. We used hierarchical summary ROC meta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses.

Main results

Fifty-nine studies involving 341,261 pregnancies (including 1,994 with Down's syndrome) were included. Studies were generally high quality, although differential verification was common with invasive testing of only high-risk pregnancies. Seventeen studies made direct comparisons between tests. Fifty-four test combinations were evaluated formed from combinations of 12 different tests and maternal age; alpha-fetoprotein (AFP), unconjugated oestriol (uE3), total human chorionic gonadotrophin (hCG), free beta human chorionic

gonadotrophin (β hCG), free alpha human chorionic gonadotrophin (α hCG), Inhibin A, SP2, CA125, troponin, pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PGF) and proform of eosinophil major basic protein (ProMBP).

Meta-analysis of 12 best performing or frequently evaluated test combinations showed double and triple tests (involving AFP, uE3, total hCG, free β hCG) significantly outperform individual markers, detecting six to seven out of every 10 Down's syndrome pregnancies at a 5% false positive rate. Tests additionally involving inhibin performed best (eight out of every 10 Down's syndrome pregnancies) but were not shown to be significantly better than standard triple tests in direct comparisons. Significantly lower sensitivity occurred in women over the age of 35 years. Women who miscarried in the over 35 group were more likely to have been offered an invasive test to verify a negative screening results, whereas those under 35 were usually not offered invasive testing for a negative screening result. Pregnancy loss in women under 35 therefore leads to under ascertainment of screening results, potentially missing a proportion of affected pregnancies and affecting the accuracy of the sensitivity.

Authors' conclusions

Tests involving two or more markers in combination with maternal age are significantly more sensitive than those involving one marker. The value of combining four or more tests or including inhibin have not been proven to show statistically significant improvement. Further study is required to investigate reduced test performance in women aged over 35 and the impact of differential pregnancy loss on study findings.

PLAIN LANGUAGE SUMMARY

[Summary title]

[Summary text]

SUMMARY OF FINDINGS

Summary of findings 1. Performance of the 12 most evaluated and best performing second trimester serum strategies

	Studies	Women (cases)	Sensitivity* (95% CI) at a 5% FPR	Tests shown inferior in direct comparisons (P < 0.05)	Tests shown inferior in indirect comparisons (P < 0.05)
Quintuple Tests (with maternal age)					
free β hCG AFP uE3 Inhibin A and PAPP-A	1	1,092 (82)	84 (71,92)	All single tests; total-hCG +AFP	All single tests; All double tests; total-hCG +AFP+uE3
Quadruple Tests (with maternal age)					
total hCG AFP uE3 Inhibin PAPP-A	1	1,092 (82)	83 (69, 92)	All single tests; total-hCG +AFP	All single tests; All double tests; total-hCG +AFP+uE3
total hCG AFP uE3 Inhibin	5	38,342 (232)	77 (68, 84)	All single tests; total-hCG +AFP	All single tests; All double tests; total-hCG +AFP+uE3
free β hCG AFP uE3 Inhibin	2	2,348 (95)	74 (58, 85)	All single tests; total-hCG +AFP	All single tests
Triple Tests (with maternal age)					
total hCG AFP Inhibin	2	564 (51)	82 (63, 92)		All single tests; total-hCG+AFP+uE3
total hCG AFP uE3	24	89,047 (648)	61 (55, 66)	All single tests	total-hCG, AFP
free β hCG AFP uE3	7	10,541 (249)	70 (62, 77)	All single tests	All single tests
Double Tests (with maternal age)					
total hCG AFP	15	133,783 (473)	66 (60, 72)	All single tests	All single tests
free β hCG AFP	12	45,597 (341)	65 (58, 72)	total-hCG; AFP	All single tests
Single Tests (with maternal age)					

free β hCG	4	14,985 (192)	52 (42, 62)	AFP
total hCG	4	57,768 (280)	50 (40, 59)	
AFP	4	13,764 (173)	41 (31, 53)	

* these figures for sensitivity can be interpreted as the number of women out of every hundred carrying a Down's syndrome fetus who would be detected when the test is used at a cut off point corresponding to a 5% false positive rate. They have been calculated based on all available data using a single meta-analytical model.

Summary of findings 2. Performance of the remaining 31 second trimester serum strategies (all involving maternal age)

	Studies	Women (cases)	Sensitivity* (95% CI)	Specificity* (95% CI)	Threshold
Single tests (with maternal age)					
uE3	2	1603 (93)	65 (33, 87)	92 (81, 97)	mixed
Free β hCG to AFP ratio	1	8265 (47)	62 (46,75)	95	5% FPR
Inhibin	2	1117 (87)	59 (48, 68)	95	5% FPR
PAPP-A	2	1117 (87)	38 (20, 59)	95	5% FPR
ProMBP	1	256 (105)	49 (39,59)	95 (90,98)	1:250 risk
Free β hCG	1	511 (11)	73 (39,94)	89 (86,91)	1:384 risk
Double tests (with maternal age)					
Total hCG and free β hCG	1	511 (11)	55 (23,83)	82 (79,86)	1:384 risk
Total hCG and uE3	2	881 (61)	63 (27,89)	92 (79,97)	mixed
Total hCG and SP1	1	370 (50)	44 (30,59)	95	5% FPR
Total hCG and free β hCG	1	511 (11)	82 (48,98)	86 (83,89)	1:384 risk
Free β hCG and uE3	1	511 (11)	73 (39,94)	83 (79,86)	1:384 risk
Free β hCG and free α hCG	1	511 (11)	73 (39, 94)	87 (84,90)	1:384 risk

AFP and uE3	2	881 (61)	49 (14,85)	92 (81,97)	mixed
uE3 and free β hCG	1	511 (11)	82 (48,98)	85 (82,88)	1:384 risk
uE3 and SP1	1	370 (50)	36 (23,51)	95	5% FPR
AFP and SP1	1	370 (50)	34 (21,49)	95	5% FPR
AFP and Hyperglycosylated hCG	1	328 (50)	54 (39,68)	95	5% FPR
AFP and free β hCG	1	511 (11)	82 (48,98)	85 (82,88)	1:384 risk
Triple tests (with maternal age)					
Total hCG, free β hCG and AFP	1	344 (31)	87 (70,96)	82 (77,86)	1:266 risk
Total hCG, uE3 and SP1	1	370 (50)	44 (30,59)	95	5% FPR
Total hCG, AFP and SP1	1	370 (50)	50 (36,64)	95	5% FPR
Total hCG, AFP and CA125	1	328 (22)	82 (60,95)	84 (80,88)	1:190 risk
Free β hCG, AFP and Inhibin A	1	1256 (13)	62 (32,86)	80 (78,82)	1:190 risk
Free β hCG, AFP and ProMBP	1	334 (107)	60 (50,69)	95	5% FPR
Free β hCG, AFP and uE3	1	511 (11)	100 (72,100)	78 (74,81)	1:384 risk
AFP, uE3 and Inhibin A	1	346 (33)	88 (72,97)	79 (74,83)	1:233 risk
AFP, uE3 and SP1	1	370 (50)	38 (25,53)	95	5% FPR
Quadruple tests (with maternal age)					
Total hCG, free β hCG, AFP and uE3	1	511 (11)	64 (31,89)	85 (82,88)	1:384 risk
Total hCG, AFP, uE3 and free α hCG	1	511 (11)	91 (59,100)	85 (81,88)	1:384 risk
Total hCG, AFP, uE3 and SP1	1	370 (50)	50 (36, 64)	95	5% FPR
Quintuple tests (with maternal age)					
Total hCG, free β hCG, AFP, uE3, and free α hCG	1	511 (1)	91 (59,100)	86 (82,89)	1:384 risk

* Sensitivity and specificity values obtained by separate pooling of sensitivities and specificities where there are two studies.

BACKGROUND

This is one of a series of reviews on antenatal screening for Down's syndrome following a generic protocol ([Allred 2010](#)) - see [Published notes](#) for more details.

Target condition being diagnosed

Down's syndrome

Down's syndrome affects approximately 1 in 800 live-born babies ([Cuckle 1987a](#)). It results from a person having three, rather than two, copies of chromosome 21 - or the specific area of chromosome 21 implicated in causing Down's syndrome - as a result of trisomy or translocation. If not all cells are affected, the pattern is described as 'mosaic'. Down's syndrome can cause a wide range of physical and mental problems. It is the commonest cause of mental retardation, and is also associated with a number of congenital malformations, notably affecting the heart. There is also an increased risk of cancers such as leukaemia, and numerous metabolic problems including diabetes and thyroid disease. Some of these problems may be life threatening, or lead to considerable ill health, while some individuals with Down's syndrome have only mild problems and can lead a relatively normal life.

There is no cure for Down's syndrome, and antenatal diagnosis allows for preparation for the birth and subsequent care of a baby with Down's syndrome, or for the offer of a termination of pregnancy. Having a baby with Down's syndrome is likely to have a significant impact on family and social life, relationships and parents' work. Special provisions may need to be made for education and care of the child, as well as accommodating the possibility of periods of hospitalisation.

Definitive invasive tests (amniocentesis and chorionic villus sampling (CVS)) exist that allow the diagnosis of Down's syndrome before birth but carry a risk of miscarriage. No test can predict the severity of problems a person with Down's syndrome will have. Noninvasive screening tests based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allow an estimate of the risk of a pregnancy being affected and provide parents with information to enable them to make choices about definitive testing. Such screening tests are used during the first and second trimester of pregnancy.

Initially, screening was determined solely by using maternal age to classify a pregnancy as high or low risk for trisomy 21, as it was known that older women had a higher chance of carrying a baby with Down's syndrome ([Penrose 1933](#)).

Further advances in screening were made in the early 1980s, when Merkatz et al investigated the possibility that low maternal serum alpha-fetoprotein (AFP), obtained from maternal blood in the second trimester of pregnancy could be associated with chromosomal abnormalities in the fetus. Their retrospective case-control study showed a statistically significant relationship between fetal trisomy, such as Down's syndrome, and lowered maternal serum AFP ([Merkatz 1984](#)). This was further explored by Cuckle et al in a larger retrospective trial using data collected as part of a neural tube defect (NTD) screening project ([Cuckle 1984](#)). This work was followed by calculation of risk estimates using maternal serum AFP values and maternal age, which ultimately led to the introduction of the two screening parameters in combination ([Alfirevic 2004](#)).

In 1987 in a small case-control study of women carrying fetuses with known chromosomal abnormalities, Bogart and colleagues investigated maternal serum levels of human chorionic gonadotrophin (hCG) as a possible screening tool for chromosomal abnormalities in the second trimester ([Bogart 1987](#)). This followed the observations that low hCG levels were associated with miscarriages, which are commonly associated with fetal chromosomal abnormalities. They concluded that high hCG levels were associated with Down's syndrome and because hCG levels plateau at 18-24 weeks, that this would be the most appropriate time for screening. Later work suggested that the β sub-unit of hCG was a more effective marker than total hCG ([Macri 1990](#); [Macri 1993](#)).

Second trimester unconjugated oestriol (uE3), produced by the fetal adrenals and the placenta, was also evaluated as a potential screening marker. In another retrospective case-control study, uE3 was shown to be lower in Down's syndrome pregnancies compared with unaffected pregnancies. When used in combination with AFP and maternal age, it appeared to identify more pregnancies affected by Down's syndrome than AFP and age alone ([Canick 1988](#)).

Further work suggested that all three serum markers (AFP, hCG and uE3) showed even higher detection rates when combined with maternal age ([Wald 1988a](#); [Wald 1988b](#)) and appeared to be a cost-effective screening strategy ([Wald 1992a](#)).

Two other serum markers, produced by the placenta, have been linked with Down's syndrome, namely pregnancy-associated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has been shown to be reduced in the first trimester of Down's syndrome pregnancies, with its most marked reduction in the early first trimester ([Bersinger 1995](#)). Inhibin A is high in the second trimester in pregnancies affected by Down's syndrome ([Cuckle 1995](#); [Wallace 1995](#)). There are some issues concerning the biological stability and hence reliability of this marker, and the effect this will have on individual risk.

Antenatal screening is used for several reasons ([Alfirevic 2004](#)), but the most important is to enable parental choice regarding pregnancy management and outcome. Before a woman and her partner opt to have a screening test, they need to be fully informed about the risks, benefits and possible consequences of such a test. This includes the choices they may have to face should the result show that the woman has a high risk of carrying a baby with Down's syndrome and implications of both false positive and false negative screening tests. They need to be informed of the risk of a miscarriage due to invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal. If, following invasive diagnostic testing, the fetus is shown to have Down's syndrome, further decisions need to be made about continuation or termination of the pregnancy, the possibility of adoption and finally, preparation for parenthood. Equally, if a woman has a test that shows she is at a low risk of carrying a fetus with Down's syndrome, it does not necessarily mean that the baby will be born with a normal chromosomal make up. This possibility can only be excluded by an invasive diagnostic test ([Alfirevic 2003](#)). The decisions that may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological morbidity.

Index test(s)

This review examines serum screening tests used in the second trimester of pregnancy (14 to 24 weeks gestation) comprised of the following individual markers; Alpha fetoprotein (AFP), unconjugated oestriol (uE3), total human chorionic gonadotropin (total hCG), free β human chorionic gonadotropin (free β hCG), free alpha human chorionic gonadotropin (free α hCG), Inhibin A, SP2, CA125, troponin, pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PGF), and proform of eosinophil major basic protein (ProMBP). These markers can be used individually, in combination with age, and can also be used in combination with each other. The risks are calculated by comparing a woman's test result for each marker with values for an unaffected population, and multiplying this with her age-related risk. Where several markers are combined, risks are computed using risk equations (often implemented in commercial software) that take into account the correlational relationships between the different markers and marker distributions in affected and unaffected populations.

Alternative test(s)

Down's syndrome can be detected during pregnancy with invasive diagnostic tests such as amniocentesis or CVS, with or without prior screening. These tests are considered to be reference tests rather than index or screening tests. The ability to determine fetal chromosomal make up (also known as a karyotype) from amniotic fluid samples was demonstrated in 1966 by Steele and Breg (Steele 1966), and the first antenatal diagnosis of Down's syndrome was made in 1968 (Vaklenti 1968). Amniocentesis is an invasive procedure which involves taking a small sample of the amniotic fluid (liquor) surrounding the baby, using a needle which goes through the abdominal wall into the uterus, and is usually performed after 15 weeks gestation. Chorionic Villus Sampling involves taking a sample of the placental tissue using a needle which goes through the abdominal wall and uterus or a cannula through the cervix. It is usually performed between 10 and 13 weeks gestation. Amniocentesis and CVS are both methods of obtaining fetal chromosomes material which are then used to diagnose Down's syndrome. Both tests use ultrasound scans to guide placement of the needle. Amniocentesis carries a risk of miscarriage in the order of 1%; transabdominal CVS may carry a similar risk (Alfirevic 2003).

There are many different screening tests which are available and offered which will be the subject of additional Cochrane reviews (currently in preparation) and there are other reviews looking at this area. Tests to be assessed in Cochrane reviews include first trimester serum tests; urine tests; first trimester ultrasound markers; tests that involve combine serum and ultrasound markers; and tests that combine markers from the first trimester with markers from the second trimester. Second trimester ultrasound markers have been assessed in a previous systematic review (Smith-Bindman 2001).

Rationale

This is one of a suite of Cochrane reviews, the aim of which is to identify all screening tests for Down's syndrome used in clinical practice, or evaluated in the research setting, in order to try to identify the most accurate test(s) available, and to provide clinicians, policy-makers and women with robust and balanced evidence on which to base decisions about interpreting test results

and implementing screening policies to triage the use of invasive diagnostic testing. The full set of reviews is described in the generic protocol (Alldred 2010).

The topic has been split into several different reviews to allow for greater ease of reading and greater accessibility of data, and also to allow the reader to focus on separate groups of tests, for example, first trimester serum tests alone, first trimester ultrasound alone, first trimester serum and ultrasound, second trimester serum alone, first and second trimester serum, combinations of serum and ultrasound markers and urine markers alone. An overview review will compare the best tests, focusing on commonly used strategies, from each of these groups to give an comparative results between the best tests in the different categories. This review is written with the global perspective in mind, rather than to conform with any specific local or national policy, as not all tests will be available in all areas where screening for Down's syndrome is carried out.

A systematic review of second trimester ultrasound markers in the detection of Down's syndrome fetuses was published in 2001 which concluded that nuchal fold thickening may be useful in detecting Down's syndrome, but that it was not sensitive enough to use as a screening test. The review concluded that the other second trimester ultrasound markers did not usefully distinguish between Down's syndrome and pregnancies without Down's syndrome (Smith-Bindman 2001). There has yet to be a systematic review and meta-analysis of the observed data on serum, urine and first trimester ultrasound markers, in order to draw rigorous and robust conclusions about the diagnostic accuracy of available Down's syndrome screening tests.

OBJECTIVES

The aim of this review was to estimate and compare the accuracy of second trimester serum markers for the detection of Down's syndrome in the antenatal period, both as individual markers and as combinations of markers. Accuracy is described by the proportion of fetuses with Down's syndrome detected by screening before birth (sensitivity or detection rate) and the proportion of women with a low risk (normal) screening test result who subsequently had a baby unaffected by Down's syndrome (specificity). We grouped our analyses to focus on investigating the value of adding increasing numbers of markers (comparing single, dual, triple and quadruple tests), and of including Inhibin A, the most recent routine addition to serum marker combinations.

Investigation of sources of heterogeneity

We investigated whether a uniform screening test is suitable for all women, or whether different screening methods are more applicable to different groups, defined by advanced maternal age, ethnic groups and aspects of the pregnancy and medical history such as multiple pregnancy, diabetes and family history of Down's syndrome. We also considered whether there existed evidence of overestimation of test accuracy in studies evaluating risk equations in the derivation sample rather than in a separate validation sample.

METHODS

Criteria for considering studies for this review

Types of studies

We included studies in which all women from a given population had one or more index test(s) compared to a reference standard. Both consecutive series and diagnostic case-control study designs were included. Randomised trials where individuals were randomised to different screening strategies and all verified using a reference standard were also eligible for inclusion. Studies in which test strategies were compared head-to-head either in the same women, or between randomised groups were identified for inclusion in separate comparisons of test strategies. Studies were excluded if they included less than five Down's syndrome cases, or > 20% of participants were not followed up.

Participants

Pregnant women at between 14 and less than 24 weeks gestation confirmed by ultrasound, who had not undergone previous testing for Down's syndrome in their pregnancy were eligible. Studies were included if the pregnant women were unselected, or if they represented groups with increased risk of Down's syndrome, or difficulty with conventional screening tests including maternal age greater than 35 years old, multiple pregnancy, diabetes mellitus and family history of Down's syndrome.

Index tests

The following index tests were examined; Alpha feto-protein (AFP), unconjugated oestriol (uE3), total human chorionic gonadotropin (total hCG), free β human chorionic gonadotropin (free β hCG), free alpha human chorionic gonadotropin (free α hCG), Inhibin A, SP2, CA125, Troponin, pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PGF) and proform of eosinophil major basic protein (ProMBP), and combinations of these markers combined with maternal age. Combinations without maternal age were not analysed, however, information on such test combinations is provided.

We looked at comparisons of tests in isolation and in various combinations. These included single (one marker), double (two markers), triple (three markers), quadruple (four markers) and quintuple (five markers) test strategies, all maternal age-adjusted. We also looked at combinations that included Inhibin A as this has been the most recently routinely introduced marker.

Where tests were used in comparison, we looked at the performance of test comparisons according to predicted probabilities computed using risk equations and dichotomised into high risk and low risk.

Target conditions

Down's syndrome in the fetus due to trisomy, translocation or mosaicism.

Reference standards

We considered several reference standards, involving chromosomal verification and postnatal macroscopic inspection.

Amniocentesis and CVS are invasive chromosomal verification tests undertaken during pregnancy. They are highly accurate, but the

process carries a 1% miscarriage rate, and therefore they are only used in pregnancies considered to be at high risk of Down's syndrome, or on the mother's request. All other types of testing (postnatal examination, postnatal karyotyping, birth registers and Down's syndrome registers) are based on information available at the end of pregnancy. The greatest concern is not their accuracy, but the loss of the pregnancy to miscarriage between the serum test and the reference standard. Miscarriage with cytogenetic testing of the fetus is included in the reference standard where available. We anticipated that older studies, and studies undertaken in older women are more likely to have used invasive chromosomal verification tests in all women.

Studies undertaken in younger women and more recent studies were likely to use differential verification as they often only used prenatal karyotypic testing on fetuses considered screen positive/high risk according to the screening test; the reference standard for most unaffected infants being observing a phenotypically normal baby. Although the accuracy of this combined reference standard is considered high, it is methodologically a weaker approach as pregnancies that miscarry between the index test and birth are likely to be lost from the analysis, and miscarriage is more likely to occur in Down's than normal pregnancies. We investigated the impact of the likely missing false negative results in sensitivity analyses.

Search methods for identification of studies

Electronic searches

We applied a sensitive search strategy to search the following databases. We used one generic search strategy to identify studies for all reviews in this series.

Databases searched included;

- MEDLINE via OVID (1980 to 18 May 2007)
- EMBASE via Dialog Datastar (1980 to 18 May 2007)
- BIOSIS via EDINA (1985 to 18 May 2007)
- CINAHL via OVID (1982 to 18 May 2007)
- The Database of Abstracts of Reviews of Effectiveness (*The Cochrane Library* 2007, Issue 1)
- MEDION
- The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine (www.ifcc.org/)
- The National Research Register (May 2007)
- Health Services Research Projects in Progress database (HSRPROJ)

The search strategy combined three sets of search terms (see: [Appendix 1](#)). The first set was made up of named tests, general terms used for screening/diagnostic tests and statistical terms. Note that the statistical terms were used to increase sensitivity and were not used as a methodological filter to increase specificity. The second set was made up of terms that encompass Down's syndrome and the third set made up of terms to limit the testing to pregnant women. All terms within each set were combined with the Boolean operator OR and then the three sets were combined using AND. The terms used were a combination of subject headings and free text terms. The search strategy was adapted to suit each database searched.

We attempted to identify cumulative papers which reported data from the same data set, and contacted authors to obtain clarification of the overlap between data presented in these papers, in order to prevent data from the same women being analysed more than once.

Searching other resources

In addition, we examined references cited in studies identified as being potentially relevant, and those cited by previous reviews. We contacted authors of studies where further information was required. We did not apply a diagnostic test filter, and we did not apply language restrictions to the search.

We carried out forward citation searching of relevant items, using the search strategy in ISI citation indices, Google scholar and PubMed 'related articles'.

Data collection and analysis

Selection of studies

Two review authors screened the titles and abstracts (where available) of all studies identified by the search strategy. Full text versions of studies identified as being potentially relevant were obtained and independently assessed by two review authors for inclusion, using a study eligibility screening pro forma according to the pre-specified inclusion criteria. Any disagreement between the two authors was settled by consensus, or where necessary, by a third party.

Data extraction and management

A data extraction form was developed and piloted using a subset of 20 identified studies. Two review authors independently extracted data, and where disagreement or uncertainty existed, a third author validated the information extracted.

Data on each marker were extracted as binary test positive/test negative results for Down's and non-Down's pregnancies, with a high-risk result - as defined by each individual study - being regarded as test positive (suggestive or diagnostic of Down's syndrome), and a low risk result being regarded as test negative (suggestive of absence of Down's Syndrome). Where results were reported at several thresholds data were extracted at each.

Note was made of those in special groups which posed either increased risk of Down's syndrome or difficulty with conventional screening tests including maternal age greater than 35 years old, multiple pregnancy, diabetes mellitus and family history of Down's syndrome.

Assessment of methodological quality

We used a modified version of the QUADAS tool ([Whiting 2003](#)), a quality assessment tool for use in systematic reviews of diagnostic accuracy studies, to assess the methodological quality of included studies. We anticipated that a key methodological issue would be the potential for differential verification bias arising from the use of different invasive tests (amniocentesis versus CVS). Further bias was likely to arise from follow-up for the reference standard according to index test results. Finally, we expected to find bias as a result of miscarriage, where karyotyping was not performed, as this could potentially influence the false negative and true negative rates. We chose to code this issue as originating from

differential verification in the QUADAS tool: we are aware that it could also be coded under delay in obtaining the reference standard, and reporting of withdrawals. We omitted the QUADAS item assessing quality according to length of time between index and reference tests, as Down's syndrome is either present or absent rather than a condition that evolves and resolves, and disregarding the differential reference standard issue any length of delay is acceptable. Two review authors assessed each included study separately. Any disagreement between the two review authors was settled by consensus, or where necessary, by a third party. Each item in the QUADAS tool was marked as 'yes', 'no' or 'unclear', and scores are presented graphically and in tables. We have not used a summary quality score.

QUADAS criteria included the following ten questions:

1. Was the spectrum of women representative of the women who will receive the test in practice? (Criteria met if the sample was selected from a wide range of childbearing ages, or selected from a specified 'high-risk' group such as over 35s, family history of Down's Syndrome, multiple pregnancy or diabetes mellitus, provided all affected and unaffected fetuses were included that could be tested at the time point when the screening test would be applied; criteria not met if the sample taken from a select or unrepresentative group of women (i.e. private practice), was an atypical screening population or recruited at a later time point when selection could be affected by selective fetal loss.)
2. Is the reference standard likely to correctly classify the target condition? (amniocentesis, CVS, postnatal karyotyping, miscarriage with cytogenetic testing of the fetus, a phenotypically normal baby or birth registers are all regarded as meeting this criteria.)
3. Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless of the index test result?
5. Was the reference standard independent of the index test result (i.e. the index test did not form part of the reference standard)?
6. Were the index test results interpreted without knowledge of the results of the reference standard?
7. Were the reference standard results interpreted without knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight, ethnic origin, gestational age) available when test results were interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?

Statistical analysis and data synthesis

Results of all tests evaluated across all common risk thresholds for screen positive result were initially examined using forest plots and plotting study results in ROC space. Test strategies were selected for further investigation if they were evaluated in four or more studies or, if there were three or fewer studies, but the individual study results indicated performance likely to be superior to a sensitivity of 70% and specificity of 90%.

Estimation of average sensitivity and specificity

The analysis for each test strategy was undertaken first restricting to studies which reported a common threshold to estimate average sensitivity and specificity rates for each test at each threshold. Although data on all thresholds were extracted, we present only key common thresholds close to risks of 1:384, 1:250 and the 5% FPR, unless other thresholds were more commonly reported. The thresholds chosen are those most commonly quoted in studies. There have been recent moves to reduced the FPR from 5% to 3% in some countries, in order to reduce the number of invasive tests performed, but this has only recently become commonplace in the literature. Where combinations of tests were used in a risk score, we extracted the result for the test combination using the risk score and not the individual components that made up the test.

Meta-analyses were undertaken using hierarchical summary ROC curve methods which included estimation of random effects in accuracy and threshold parameters when there were four or more studies. Otherwise, average sensitivity and specificity values were computed using separate univariate random-effects meta-analysis, averaging the logit sensitivity and logit specificity as inadequate data would be available to estimate all parameters in the HSROC model. It is common in this field for studies to report sensitivity for a fixed specificity (usually a 5% false positive rate). This removes the requirement to use a bivariate meta-analytical method for analysis at this threshold as all specificity rates are the same, hence logit sensitivity values were also pooled using a univariate random-effects method. All analyses were undertaken using the METADAS macro for SAS.

Comparisons between tests

Comparisons between tests were first made utilising all available studies, selecting one threshold from each study to estimate a summary ROC curve without restricting to a common threshold. The threshold was chosen for each study according to the following order of preference a) the risk threshold closest to 1 in 250; b) a multiples of the median (MoM) or presence/absence threshold; c) the performance closest to a 5% false positive rate (FPR) or 95th percentile. The 5% false positive rate was chosen as a cut-off point as this is the cut-off most commonly reported in the literature. The analysis including data from all studies fitted a single HSROC model including the 12 selected test strategies, including two indicator terms for each test to allow for differences in accuracy and threshold. As there was limited evidence of differing SROC curve shapes between tests, a single SROC shape parameter was included in the model such that the fitted SROC curves did not cross. An estimate of the sensitivity of each test for a 5% false positive rate was derived from the summary ROC curve, and associated confidence interval obtained using the delta method.

Direct comparisons between tests were based on results of very few studies, and were analysed using a fixed-effect HSROC model with symmetrical underlying SROC curves as there were inadequate data to estimate between study heterogeneity in accuracy and threshold or asymmetric shape. A separate model was used to make each pair wise comparison. Comparisons between tests were assessed by the significance of differences in accuracy, and expressed as relative diagnostic odds ratios reported with 95% confidence intervals. As studies rarely reported data cross-classified by both tests for Down's and normal pregnancies, the analytical method did not take full account of the

pairing of test results, but the restriction to direct head-to-head comparisons should have removed the potential confounding of test comparisons with other features of the studies. The strength of evidence for differences in performance of test strategies relied on evidence from both the direct and indirect comparisons.

Investigations of heterogeneity

Investigations of heterogeneity were only undertaken when there were 10 or more studies available for a test. Subgroup analyses were undertaken by adding covariates for differences in accuracy and threshold to the HSROC meta-analytical model.

Sensitivity analyses

In many of the included studies, mothers with pregnancies identified as high risk for Down's syndrome by the serum testing were offered immediate definitive testing by amniocentesis, whereas, the remainder were assessed for Down's syndrome by inspection at birth. Such delayed and differential verification will introduce bias most likely through there being greater loss to miscarriage in the Down's syndrome pregnancies that were not detected by the serum testing (the false negative diagnoses). Testing and detection of miscarriages is impractical in many situations, and no clear data are available on the magnitude of these miscarriage rates.

To account for the possible bias introduced by such a mechanism, we undertook sensitivity analyses where we inflated the false negative count in studies where delayed verification in test negatives occurred (Mol 1999). This was undertaken for two analyses - the main comparison of the 12 key test combinations, and the investigation of the impact of maternal age on test sensitivity. For both analyses, we increased the percentage of false negatives in each study incrementally from 10% to 50%, the final value representing a scenario where a third more Down's pregnancies than normal pregnancies were likely to miscarry, thought to be higher than the likely value.

RESULTS

Results of the search

The search for the whole suite of reviews identified a total of 13,403 papers, once the results from each bibliographic database were combined and duplicates were removed. After screening out obviously inappropriate papers based on their title and abstract 904 papers remained and copies were obtained for formal assessment of eligibility. From these a total of 239 studies were deemed eligible and included in the suite of reviews. A total of 59 studies (reported in 72 publications) were included in this review of second trimester serum screening, involving 341,261 pregnancies including 1994 Down's syndrome pregnancies.

A total of 54 different test strategies combinations were evaluated in the 59 studies. These tests are produced from combinations of 12 different tests, with and without maternal age; AFP, uE3, total hCG, free β hCG, free α hCG, Inhibin A, SP2, CA125, Troponin, PAPP-A, PGF and ProMBP. Strategies evaluated included three quintuple tests, five quadruple, 12 triple, 14 doubles and nine single tests in combination with age; the remaining 11 assessed single tests without age. Forty-two of the 59 studies only evaluated the performance of a single second trimester serum test or test strategy, seven compared two, a further seven compared between three

and six, one compared 11 (Bartels 1994a), one compared 20 (Wald 2003a) and one compared 21 (Forest 1995).

The following combinations evaluated included four or more studies:

Quadruple tests

- Total hCG, uE3, AFP, Inhibin A and maternal age (five studies, 38,342 women, including 232 Down's syndrome pregnancies)

Triple tests

- Total hCG, uE3, AFP and maternal age (24 studies, 89,047 women, including 648 Down's syndrome pregnancies)
- Free β hCG, AFP and uE3 and maternal age (seven studies, 10,541 women, including 249 Down's syndrome pregnancies)

Double Tests

- Total hCG, AFP and maternal age (15 studies, 133,783 women, including 473 Down's syndrome pregnancies)
- Free β hCG, AFP and maternal age (12 studies, 45,597 women including 341 Down's syndrome pregnancies)

Single tests

- Total hCG and maternal age (four studies, 57,768 women including 280 Down's syndrome)
- AFP and maternal age (four studies, 13,764 women, including 173 Down's syndrome pregnancies)
- Free β hCG and maternal age (four studies, 14,985 women, including 192 Down's syndrome pregnancies)

Of the remaining test combinations, seven were evaluated in two studies and the remaining 28 in single studies only.

Methodological quality of included studies

Methodological quality of the studies was judged to be high in most categories (Figure 1). Due to the nature of testing for Down's syndrome screening and the potential side effects of invasive testing, differential verification is almost universal in the general screening population, as most women whose screening test result is defined as low risk will have their screening test verified at birth, rather than by invasive diagnosis in the antenatal period. Additionally, it was not always possible to ascertain from the included studies whether or not the results of index tests and reference standards were blinded. It would be difficult to blind clinicians performing invasive diagnostic tests (reference standards) to the index test result, unless all women received the same reference standard, which would not be appropriate in most scenarios. However, any biases secondary to a lack of clinician blinding are likely to be minimal.

Figure 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Most studies reported 100% follow-up, however, there will inevitably be losses to follow-up due to women moving out of area, for example. Studies usually accounted for these and it is unlikely to have introduced significant bias. There was definitely under ascertainment of miscarriage, and very few papers accounted for miscarriage or performed tissue karyotyping in pregnancies resulting in miscarriage. Some studies attempted to adjust for predicted miscarriage rate and the incidence of Down's syndrome in this specific population, but most did not. We have not attempted to adjust for expected miscarriage rate in this review but have explored the impact in a sensitivity analysis. This issue has the potential to have more influence with first trimester testing due to a higher miscarriage rate per se in this trimester.

Some studies which provided estimates of risk using multivariable equations used the same data set to evaluate performance of the risk equation as was used to derive the equation. This is often thought to lead to over-estimation of test performance. The impact of inclusion of these studies was investigated in subgroup analyses, reported below.

Findings

1) Total hCG, AFP, uE3, Inhibin A and maternal age (Quadruple test) (Figure 2)

Figure 2. Studies evaluating combination of maternal age, Total hCG, AFP, uE3 and Inhibin showing summary ROC curve

Results for this quadruple test were derived from five studies (Debieve 2000; Malone 2005; Palomaki 2006; Wald 2003a; Wenstrom 1999), and included 38,342 women in whom 150 pregnancies were known to be affected by Down's syndrome. Thirty-five thousand two hundred and thirty-six (95% of total pregnancies) including 87 Down's cases (58%) originated from the FASTER study (Malone 2005). Wald 2003a and Wenstrom 1999 contributed over 1,000 pregnancies each to the data. Studies presented data for cut-points of 5% FPR (Wald 2003a), 1:150 (Debieve 2000; Palomaki 2006; Wenstrom 1999), 1:250 (Debieve 2000; Palomaki 2006), 1:270

(Wenstrom 1999) and 1:300 (Malone 2005). At a cut-point of 5% FPR, Wald estimated a sensitivity of 80.5% (95% confidence interval (CI) 70.3 to 88.4). At a cut-point of 1:250 (two studies), the sensitivity is estimated at 73.9% (95% CI 60.0 to 84.2) and the specificity is 94.8% (CI 92.8 to 96.2); at a cut-point of 1:300 Malone estimated the sensitivity at 85.0% (CI 75.8 to 91.8) and the specificity at 91.5% (CI 91.2 to 91.8).

2) Free β hCG, AFP, uE3 and maternal age (Triple test) (Figure 3)

Figure 3. Studies evaluating combination of maternal age, Free β hCG, AFP and uE3 showing summary ROC curve

Results for this triple test were derived from seven studies (Cioffi 2000; Extermann 1998; Forest 1995; Knight 1998; Sancken 2003;

Wald 2003a; Wenstrom 1997a), including 10,541 women, in whom 249 pregnancies were known to be affected by Down's

syndrome. Over half of the women were derived from Knight's study. Studies presented data from cut-points of 5% FPR (Knight 1998; Sancken 2003; Wald 2003a), 1:250 (Cioffi 2000; Wald 2003a), 1:384 (Forest 1995) and 1:380 (Extermann 1998). At a cut-point of 5% FPR, the estimated sensitivity was 65.1% (95% CI 46.4 to 80.1).

At the cut-point of 1:250, the estimated sensitivity was 81.5% (95% CI 72.5 to 88.1) for an estimated specificity of 97.9% (95% CI 87.7 to 99.7).

3) Total hCG, AFP, uE3 and maternal age (Triple test) (Figure 4)

Figure 4. Studies evaluating combination of maternal age, Total hCG, AFP and uE3 showing summary ROC curve

Results for this triple test were derived from 24 studies (Bahado-Singh 1999a; Bahado-Singh 2000; Bartels 1994a (divided into Bartels 1994a and Bartels 1994b); David 1996; Debieve 2000; Extermann 1998; Forest 1995; Haddow 1994; Heyl 1990; Huderer-Duric 2000; Kishida 2000; Knight 1998; Mancini 1991; Perona 1997; Piggott 1994; Rosen 2002; Sancken 2003; Suzumori 1997; Verloes 1995; Wald 2003a; Ward 1999; Wenstrom 1997a; Wenstrom 1999) and included 89,047 women, in whom 648 were known to be

affected by Down's syndrome. Of the 24 studies, there are four with a sample size of over 5,000 (David 1996; Haddow 1994; Knight 1998; Piggott 1994), two over 10,000 (Verloes 1995; Ward 1999) and one over 20,000 (Perona 1997). Seven studies evaluated sensitivity at 5% FPR (Bahado-Singh 1999a; Bahado-Singh 2000; Bartels 1994a; Haddow 1994; Knight 1998; Sancken 2003; Wald 2003a), five evaluated a cut-point of 1:250 (David 1996; Debieve 2000; Mancini 1991; Piggott 1994; Ward 1999). At a cut-point of 5%

FPR, the estimated sensitivity was 53.5% (95% CI 43.0 to 63.7). At the cut-point of 1:250, the estimated sensitivity was 76.9% (95% CI 52.7 to 90.9) for an estimated specificity of 93.6% (95% CI 87.7 to 96.8).

4) Total hCG, AFP and maternal age (Double test) (Figure 5)

Figure 5. Studies evaluating combination of maternal age, Total hCG and AFP showing summary ROC curve

Results for this double test were derived from 15 studies (Audibert 2001a; Bartels 1994a; Beekhuis 1993; Benattar 1999; Crossley 1994; David 1996; Debieve 2000; Forest 1995; Jou 2000; Knight 1998; Lam 2002; Lemay 1995; Milunsky 1993; Roberts 2000; Wald 2003a) and included 133,783 women, in whom 473 pregnancies were known to be affected by Down's syndrome. Of the 15 studies, four presented data on with sample sizes of greater than 15,000 (Jou 2000; Lam 2002; Lemay 1995; Roberts 2000) and one with greater than 30,000 (Crossley 1994). Four studies gave data for a cut-point of 5% FPR

(Bartels 1994a; Knight 1998; Lam 2002; Wald 2003a), six studies gave data for a cut-point of 1:250 (Audibert 2001a; Beekhuis 1993; Benattar 1999; David 1996; Debieve 2000; Roberts 2000). At a cut-point of 5% FPR, the estimated sensitivity was 61.7% (95% CI 53.5 to 69.2), and at the cut-point of 1:250, the estimated sensitivity was 69.9% (95% CI 60.3 to 78.1) for a specificity of 95.3% (95% CI 94.3 to 96.2).

5) Free β hCG, AFP and maternal age (Double test) (Figure 6)

Figure 6. Studies evaluating combination of maternal age, Free β hCG and AFP showing summary ROC curve

Results for this double test were derived from 12 studies (Anandakumar 1999; Brajenovic 1998; Chao 1999; Extermann 1998; Forest 1995; Hsu 1997a; Kadir 1999; Knight 1998; Milunsky 1993; Rozenberg 2002; Wald 2003a; Wenstrom 1997a) including 45,597 women, of which 341 were affected by Down's syndrome. Of the 12 studies, four presented data on more than 5,000 women (Chao 1999; Hsu 1997a; Knight 1998; Rozenberg 2002). Five studies gave data for a 5% FPR (Anandakumar 1999; Hsu 1997a; Knight 1998;

Rozenberg 2002; Wald 2003a) and three for a cut-point of 1:250 (Brajenovic 1998; Kadir 1999; Rozenberg 2002). At a cut-point of 5% FPR, the estimated sensitivity was 61.7% (95% CI 52.7 to 69.9), and at the cut-point of 1:250, the estimated sensitivity was 75.5% (95% CI 60.1 to 86.4) for a specificity of 91.6% (95% CI 90.5 to 92.6).

6) Total hCG and maternal age (Single test) (Figure 7)

Figure 7. Studies evaluating combination of maternal age and Total hCG showing summary ROC curve

Results for this single test were derived from four studies (Forest 1995; Knight 1998; Muller 1996a; Wald 2003a) including 57,668 pregnancies of which 280 were known to be affected by Down's syndrome. Of the four studies, two presented data on more than 5,000 women (Knight 1998; Muller 1996a). Three studies gave data for a 5% FPR cut-point (Knight 1998; Muller 1996a; Wald 2003a). At

this cut-point the sensitivity was estimated at 56.1% (95% CI 41.0 to 70.2). The cut-point for Forest 1995 was 1:384 and is included on the figure.

7) Free β hCG and maternal age (Single test) (Figure 8)

Figure 8. Studies evaluating combination of maternal age and Free β hCG showing summary ROC curve

Results for this single test were derived from four studies (Forest 1995; Hsu 1997a; Knight 1998; Wald 2003a) including 14,985 pregnancies, of which 192 were known to be affected by Down's syndrome. Of the four studies, Hsu 1997a was the largest, presenting data on more than 9,000 pregnancies. Three studies gave data for a cut-point of 5% FPR (Hsu 1997a; Knight 1998; Wald

2003a). At this cut-point the sensitivity was estimated at 52.6% (95% CI 37.4 to 67.4). The cut-point for Forest 1995 was 1:384 and is included on the figure.

8) AFP and maternal age (Single test) (Figure 9)

Figure 9. Studies evaluating combination of maternal age and AFP showing summary ROC curve

Results for this single test were derived from four studies of 13,764 pregnancies including 173 Down's syndrome pregnancies (Forest 1995; Hsu 1997a; Rose 1994; Wald 2003a). Of the four studies, (Hsu 1997a) was the largest presenting data on 8,265 (48%) of pregnancies including 47 Down's syndrome pregnancies. Studies presented data for cut-points of 5% FPR (Hsu 1997a; Wald 2003a),

1:270 (Rose 1994) and 1:384 (Forest 1995). Two studies gave data for a cut-off of 5% FPR estimating a sensitivity of 41.9% (95% CI 33.7 to 50.5).

9) Other test combinations (Figure 10)

Figure 10. Studies of four promising test combinations evaluated in in only one or two studies

Of the 36 test combinations evaluated in one or two studies, only four test combinations demonstrated estimated sensitivities of more than 70% and estimated specificities of more than 90%.

- A **quintuple** test of **total hCG, AFP, uE3, Inhibin A, PAPP-A and maternal age** evaluated in a single study (Wald 2003a) estimated a sensitivity of 82.9% (CI 73.0 to 90.3%) at a cut-point of 5% FPR.
- A **quintuple** test of **free βhCG, AFP, uE3, Inhibin A, PAPP-A and maternal age** evaluated in a single study (Wald 2003a) estimated a sensitivity of 84.1% (CI 74.4 to 91.3%) at a cut-point of 5% FPR.
- A **quadruple** test of **free βhCG, uE3, AFP, Inhibin A and maternal age** evaluated in Wald 2003a estimated a sensitivity

of 84.1% (CI 74.4 to 91.3) and specificity of 94.3% (CI 92.6 to 95.6) at a cut-point of 1 in 250. However, a second evaluation in Wenstrom 1999 estimated much lower values.

- A **triple** test of **total hCG, Inhibin A, AFP and maternal age** evaluated in a single study (Debieve 2000) estimated a sensitivity of 88.9% (CI 65.3 to 98.6) for a specificity of 93.5% (CI 89.1 to 96.5) at a cut-point of 1:250.

10) Individual markers

There were data available on 10 individual markers, not combined with maternal age, the results of which are presented in the forest plots available in the full review report. There was substantial

heterogeneity noted in the sensitivities of Inhibin A and SP2 in these studies.

Comparative analysis of the eleven selected test strategies

Formal statistical comparison of the 12 test strategies listed above was made using HSROC meta-analytical models, firstly to quantify the difference in test performance (expressed with 95% confidence intervals), and secondly to assess the strength of evidence of real differences in performance between the strategies. Comparative analysis was undertaken by comparing summary ROC curves estimated by first making pair wise comparisons pooling studies which made compared tests in the same mothers, and then by pooling all available studies for the 12 test strategies listed above. Estimates of the differences in accuracy obtained from the HSROC models are expressed as relative DORs which are not easy to interpret. To provide more accessible estimates of performance, we have also computed the detection rate (sensitivity) for a fixed false positive rate (specificity), a metric which is commonly used in Down's syndrome screening to describe performance. We chose to estimate detection rates at a 5% FPR, in common with much of the literature.

Figure 11 shows point estimates of detection rates for a 5% FPR based on all available data for all 12 test combinations described above, and the confidence intervals at a fixed 5% FPR. For example, the plot shows that for the triple test with a marker combination of free β hCG, AFP, uE3 and maternal age the estimated detection rate at a 5% FPR is 70.1% (95% CI 61.8 to 77.3) based on data from seven studies with 249 affected cases and 10,541 total participants. The test combinations in the Figure are ordered according to decreasing detection rates. The three single test strategies (AFP with maternal age; total hCG with maternal age and free β hCG with maternal age) have the worst performance, whereas, the five triple, quadruple and quintuple strategies containing inhibin have the highest performance. In between lie the standard triple tests (total hCG, AFP, uE3 and maternal age; free- β hCG, AFP, uE3 and maternal age) and double tests (total hCG, AFP and maternal age; free β hCG, AFP and maternal age). However, it is noted that the confidence intervals on these estimates are wide (particularly for the inhibin-based combinations) and overlap for the first six strategies, suggesting that any of the differences observed may be explicable by chance.

Figure 11. Detection rates (% sensitivity) at a false positive rate of 5% for the 12 selected test combinations (estimates from summary ROC curves)

Table 1 shows pair wise direct comparisons (head-to-head) where studies were available. Such comparisons are regarded as providing the strongest evidence as they are unconfounded. The table shows the ratios of DOR with 95% CI and P values for each test combination, the number of studies (K) for which data were available. The table shows that the diagnostic accuracy of the single test combinations (AFP and maternal age, total hCG

and maternal age and free β hCG and maternal age) tends to be significantly worse ($P < 0.05$) than the double, triple, quadruple and quintuple tests where data are available. The double test comprised of total hCG, AFP and maternal age also appears to have significantly worse ($P < 0.05$) test accuracy than quadruple and quintuple test combinations containing inhibin. Otherwise, there was no strong evidence of significant differences in test accuracy

between triple, quadruple and quintuple tests containing inhibin and the standard double (total hCG, AFP and maternal age; free β hCG, AFP and maternal age) and triple tests (total hCG, AFP, uE3 and maternal age; free- β hCG, AFP, uE3 and maternal age). However, most comparisons in this table are based on only single studies and are unlikely to be powered to detect differences in detection rates.

Table 2 shows the same comparisons made using all available data (as used to create Figure 10). Results are in agreement with the direct comparisons, and in addition, showed some statistically significance differences ($P < 0.05$) suggesting that quintuple and quadruple tests containing inhibin and total hCG outperform standard double tests (total hCG, AFP and maternal age; free β hCG, AFP and maternal age) and one standard triple test (total hCG, AFP, uE3 and maternal age). However, these comparisons are potentially confounded by differences between the studies.

Investigations of heterogeneity and subgroup analysis

Three test combinations included 10 or more studies allowing investigation of sources of heterogeneity (two double tests (free β hCG, AFP and maternal age; total hCG, AFP and maternal age) and one triple test (total hCG, AFP, uE3, and maternal age)). Adequate data were only available to consider the impact of two potential sources: advanced maternal age and the use of the same data set for deriving and evaluating the risk equation (derivation versus validation). The results of these two comparisons for each of the three tests are presented in Table 3.

There is a significant difference in sensitivity for women over the age of 35 years for two test combinations. The double test comprised of free β hCG, AFP and maternal age showed a significant decrease in sensitivity in women over 35 years of age when compared to a standard screening population (51.7% sensitivity versus 66.4% for a fixed 5% FPR ($P = 0.03$)) with a larger decrease being observed for the triple test comprised of total hCG, AFP, uE3 and maternal age (48.4% versus 68.6% for a fixed 5% FPR ($P < 0.0001$)). A non-significant difference of the same magnitude was noted for the double test comprised of total hCG, AFP and maternal age.

No significant differences or consistent effects were noted when comparing evaluations undertaken in the same data sets used for derivation of the risk equation rather than separate validation data sets for any of the three test combinations.

Results of sensitivity analysis investigating the impact of possible pregnancy loss through delayed verification of test negatives

Figure 11 shows the results of the sensitivity analysis comparing test combinations when the number of false negatives are inflated by 50% in studies with delayed verification of test negatives. The estimate of the sensitivity decreases for all test combinations, with a small degree of variability in magnitude, but not large enough to cause any reordering of the performance of the tests. Thus it appears that the ranking of tests is not affected by delayed verification of test negatives in studies which ascertained Down's syndrome at birth in those at low risk.

Table 4 reports results of the investigation of the effect of maternal age, with similar inflations of false negatives from 10% to 50% in studies with delayed verification of test negatives.

Delayed verification was not common in studies undertaken entirely in women aged 35 or over as they tended to be offered amniocentesis on the basis of the increased risk associated with advanced maternal age alone, and the corrections to the false negatives made very little difference to the estimates of sensitivity. However, in younger mothers the correction reduced sensitivity, and consequently reduced the apparent relationship between maternal age and test performance, observed through the ratio of diagnostic odds ratios approaching one. But even with an increase of 50% in the false negatives cells, the difference in sensitivity between age-groups for the triple test comprised of total hCG, AFP, uE3, and maternal age remained statistically significant, although its magnitude nearly halved from 20% to 12%. The effect seen for the double test comprised of free β hCG, AFP and maternal age combination lost its borderline significance with even the smallest increase in false negatives.

DISCUSSION

Summary of main results

The systematic review found a large number of studies evaluating second trimester Down's syndrome serum screening tests, including studies evaluating the commonly used double and triple tests. Fewer studies were available to evaluate the performance of test strategies involving inhibin, which have been more recently developed, and few studies provided unconfounded comparisons of test strategies by applying and comparing several strategies using the same serum sample, the majority of studies only evaluating a single test combination. A summary of results for the 12 most common and best performing strategies is given in this Summary of findings 1, briefer details for the remaining 31 strategies are given in Summary of findings 2.

Six key findings were noted.

1. Double and triple tests significantly outperform the use of single tests. Single tests (total hCG with maternal age, free β hCG with maternal age and AFP with maternal age) detect only between four and five out of every 10 Down's syndrome pregnancies when used at a threshold corresponding to a 5% false positive rate. Standard triple tests (total hCG, AFP, uE3 and maternal age; free β hCG, AFP, uE3 and maternal age) and double tests (total hCG, AFP and maternal age; free β hCG, AFP and maternal age) detect between six and seven out of every 10 Down's syndrome pregnancies at the same threshold.
2. Whilst the four quintuple, quadruple and triple test combinations including inhibin show the highest detection rates (total hCG, AFP, uE3, inhibin and PAPP-A with maternal age; total hCG, AFP, uE3 and inhibin with maternal age; free β hCG, AFP, uE3 and Inhibin A with maternal age; and total hCG, AFP and inhibin with maternal age), they were not shown to be statistically superior to double and triple tests that do not include inhibin in the direct comparisons. Whilst some significant differences between these categories of tests were noted in the indirect comparisons, the potential for confounding (particularly related to study year) is of concern. Estimates suggest that inhibin-based combinations may detect between seven and eight out of every 10 Down's syndrome pregnancies at a 5% false positive rate. With the exception of the quadruple test comprised of free β hCG, uE3, AFP and inhibin with maternal age ($n = 2348$), the number of pregnancies studied for these combinations was markedly smaller than for test combinations excluding inhibin.

It is therefore difficult to make strong recommendations on the use or exclusion of inhibin as a marker in combined tests, as we cannot conclude there are no differences as there is limited power to detect them.

3. The evidence that quintuple tests are significantly better at detecting Down's syndrome than quadruple tests or triple tests is not strong, and similarly quadruple tests are not shown to be significantly better than triple tests. Whilst the trend suggests that the more markers used in a test, the higher the diagnostic accuracy, the amount of evidence, particularly available for direct comparisons, is insufficient to make strong recommendations.
4. There was no obvious benefit in using free β hCG over total hCG. Six studies made direct comparisons between the two alternative triple tests with no obvious difference in test accuracy (ratio of DOR 1.0; 95%CI (0.7 to 1.6); $P = 0.93$); four studies made direct comparisons between the two alternative double tests also with no obvious difference (ratio of DOR 1.0; 95%CI (0.6 to 1.6); $P = 0.91$).
5. The sensitivity of tests in women over the age of 35 years is markedly reduced. Evidence was available for three tests at a fixed 5% FPR showing reductions in detection rates of between 10% and 20%. Part of this effect may be explained by studies in younger mothers missing false negative cases lost through increased miscarriage in Down's pregnancies, but this does not fully explain the full effect. We are unable to draw any conclusions as to why this may be the case. There was no obvious difference in algorithms used to calculate risk, the marker assays used, nor was there any obvious difference in the dates of the studies involved. There may be differences in placental function in women over 35 years of age that explains the differences in performance of markers, however, this is conjecture.

Strengths and weaknesses of the review

This review is the first comprehensive review of second trimester serum screening. It has examined papers from around the world, covering a wide cross section of women in varying populations. We have contacted authors to verify data where necessary to give as complete a picture as possible while trying to avoid replication of data.

There were a number of factors which have made meta-analysis of the data difficult, which we have tried to adapt for in order to allow for comparability of data presented in different studies.

1. There are many different cut-points used to define pregnancies as high or low risk for Down's syndrome. This means that direct comparison is more difficult than if all studies used the same cut-point to dichotomise their populations.
2. There are many different risk equations and software applications in use for combination of multiple markers, which were often not described in the papers. This means that risks may be calculated by different formulae, and they may not be directly comparable for this reason. It is possible that this is responsible for confounding results.
3. Different laboratories and clinics run different assays and use different machines and methods. This may influence raw results and subsequent risk calculations. Many laboratories have a quality assessment/audit trail, however, this may not necessarily be standard across the board, for example, how

many assays are run, how often medians are calculated and adjusted for a given population and how quickly samples are tested from initially being taken.

4. Few papers make direct comparisons between tests, making it difficult to detect if there is a real difference between tests (i.e. how different tests perform in the same population). There are differences in populations, with assay medians being affected, for example, by race. It is not certain whether it is appropriate to make comparisons between populations which are inherently different.
5. We were unable to perform many of the subgroup analyses that we had originally intended to, as the data simply were not available. The vast majority of papers looking at pregnancies conceived by IVF, affected by diabetes, multiple gestation or a family history of Down's syndrome involved unaffected pregnancies only

The major methodological concern in the primary studies relates to the loss of pregnancies from the studies through miscarriage that occurs between serological testing and obtaining the reference standard. In studies where the patient sample were women attending for an amniocentesis no delay would occur between the serum test and reference standard, and data on all pregnancies would be available. In more standard clinical populations invasive testing is only offered to high-risk pregnancies - in these studies to women with high-risk serum test results. The remainder are assessed at birth for phenotypic features of Down's syndrome, but some will be lost during follow-up due to miscarriage, and are suspected to be omitted from study reports. Even though these problems occur, the sensitivity analysis we have undertaken indicate that the ranking of the included tests is not affected by such differential and delayed verification and drop-out.

Applicability of findings to the review question

Potentially, where planning screening policy or a clinical screening programme, clinicians and policy makers need to make decisions about a finite number of tests or type of tests that can be offered. These policies are often driven by both the needs of a specific population and by financial resources. Economic analysis was considered to be outside of the scope of this review. Many of the tests examined as part of this review are already commercially available and in use in the clinical setting. The studies were carried out on populations of typical pregnant women and therefore, the results should be considered comparable with most pregnant populations encountered in every day clinical practice.

We were also unable to extract information about harms of testing, information about miscarriage rates and uptake of definitive testing as the data were not available the majority of the time. Whilst it is unlikely that major differences between the tests evaluated here exist in terms of direct harms of testing, as they are all based on a single blood sample, differences in accuracy may lead to differences in the use of definitive testing and its consequent adverse outcomes.

In some countries with a defined screening policy (i.e. the UK), second trimester screening no longer plays a major role. In others however, there may only be a limited range of tests or markers available - often second trimester markers. The results of this review should be interpreted and applied in the context of test availability and local restrictions, populations or policies.

AUTHORS' CONCLUSIONS

Implications for practice

The evidence for tests involving inhibin as a marker suggests a superiority that is not found to be statistically significant, and based on small populations of women. We would not recommend that these tests should be introduced into wider clinical practice without careful consideration of cost.

The review has shown that tests involving two or three markers in combination with maternal age are significantly better than those involving one marker. We would therefore recommend that one marker tests are not used for Down's syndrome screening. The choice of multiple markers will depend on the availability of certain assays in local laboratories. There was no test combination shown to be superior to others therefore, we cannot recommend a specific test combination.

The performance of tests at earlier gestations will be the subject of a separate Cochrane review and the alternative first trimester, cross-trimester, ultrasound and combinations of serum and ultrasound should also be considered when making policy decisions.

Implications for research

Further evaluation of inhibin-based test combinations are required to determine whether their apparent advantages are not chance findings. Further study of the attenuated performance of test combinations in women over 35 is required, as this age group has the highest incidence of Down's syndrome and has the greatest requirement for tests with high detection rates.

Future studies should ensure that adequate sample sizes are recruited, and take opportunities to make comparisons of test performance testing several alternative test combinations on the same serum samples. Such direct comparison removes issues of confounding when making test comparisons, and allows a clear focus on testing the incremental benefit of increasingly complex and expensive testing strategies. The reporting of studies of test accuracy can be improved and more closely adhere to the STARD reporting standards. Three key aspects of this are 1) formally testing the statistical significance of differences in test performance in direct comparisons and estimating incremental changes in detection rates (together with confidence intervals), 2) clearly reporting the number of mothers studied and their results, and 3) reporting the numbers of women who are lost to follow-up. Many authors reported results of extrapolating findings to age-standardised national cohorts to demonstrate the performance of the test, and failed to report the actual numbers studied and evaluated.

For the purposes of meta-analysis and to allow for comparisons to be made between different tests and combinations, we would recommend the publication of consensus standard algorithms for estimating risk, and reporting of test performance at a standard set of thresholds. This would be difficult to achieve and implement, but an attempt at consensus should be made.

ACKNOWLEDGEMENTS

We acknowledge the assistance of the Pregnancy and Childbirth Cochrane Review Group Editorial base with writing the searches and other aspects of this review.

REFERENCES

References to studies included in this review

Anandakumar 1999 {published data only}

Anandakumar C, Chew S, Wong YC, Goh VH, Tain CF, Ratnam SS. The sensitivity of the trivariate analysis using maternal serum alpha-feto protein, human chorionic gonadotrophin and maternal age in screening for fetal aneuploidy in mothers above the age of 35. *Journal of Perinatal Medicine* 1999;**27**(3):178-82.

Audibert 2001a {published data only}

Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(1):26-31.

Bahado-Singh 1999a {published data only}

Bahado Singh, Oz U, Rinne K, Hunter D, Cole L, Mahoney MJ, et al. Elevated maternal urine level of β -core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of Down syndrome. *American Journal of Obstetrics and Gynecology* 1999;**181**(4):929-33.

Bahado-Singh 2000 {published data only}

* Bahado Singh, Oz AU, Gomez K, Hunter D, Copel J, Baumgarten A, et al. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation. *Ultrasound in Obstetrics and Gynecology* 2000;**15**(3):199-204.

Bahado-Singh, Oz AU, Kovanci E, Deren O, Copel J, Baumgarten A, et al. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age. *American Journal of Obstetrics and Gynecology* 1998;**179**(6 Pt 1):1627-31.

Bartels 1990 {published data only}

* Bartels I, Thiele M, Bogart MH. Maternal serum hCG and SP1 in pregnancies with fetal aneuploidy. *American Journal of Medical Genetics* 1990;**37**(2):261-4.

Bogart MH, Golbus MS, Sorg ND, Jones OW. Human chorionic gonadotropin levels in pregnancies with aneuploid fetuses. *Prenatal Diagnosis* 1989;**9**(6):379-84.

Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. *Prenatal Diagnosis* 1987;**7**(9):623-30.

Bartels 1994a {published data only}

Bartels I, Bockel B, Caesar J, Krawczak M, Thiele M, Rauskolb R. Risk of fetal Down's syndrome based on maternal age and varying combinations of maternal serum markers. *Archives of Gynecology & Obstetrics* 1994;**255**(2):57-64.

Bartels 1994b {published data only}

Bartels I, Bockel B, Caesar J, Krawczak M, Thiele M, Rauskolb R. Risk of fetal Down's syndrome based on maternal age and varying combinations of maternal serum markers. *Archives of Gynecology & Obstetrics* 1994;**255**(2):57-64.

Beekhuis 1993 {published data only}

Beekhuis JR, Mantingh A, De Wolf BT, Van Lith JM, Breed AS. [Serum screening of pregnant women for fetal neural tube defects and Down syndrome; initial experiences in The Netherlands]. [Dutch]. *Nederlands Tijdschrift voor Geneeskunde* 1993;**137**(26):1303-7.

Benattar 1999 {published data only}

Benattar C, Audibert F, Taieb J, Ville Y, Roberto A, Lindenbaum A, et al. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study. *Fetal Diagnosis & Therapy* 1999;**14**(2):112-7.

Brajenovic 1998 {published data only}

Brajenovic Milic, Tislaric D, Bacic J, Paravic J, Slivar A, Kapovic M, et al. Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study. *Fetal Diagnosis and Therapy* 1998;**13**(6):367-71.

Brizzi 1989a {published data only}

Brizzi L, Cariati E, Periti E, Nannini R, Torricelli F, Cappelli G, et al. Evaluation of maternal serum alpha-fetoprotein and ultrasound examination to screen fetal chromosomal abnormalities. *Journal of Nuclear Medicine & Allied Sciences* 1989;**33**(3 Suppl):85-8.

Chao 1999 {published data only}

Chao AS, Chung CL, Wu CD, Chang SD, Cheng PJ, Lin YT, et al. Second trimester maternal serum screening using alpha fetoprotein, free β human chorionic gonadotropin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. *Acta Obstetrica et Gynecologica Scandinavica* 1999;**78**(5):393-7.

Christiansen 1999 {published data only}

Christiansen M, Oxvig C, Wagner JM, Qin QP, Nguyen TH, Overgaard MT, et al. The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome. *Prenatal Diagnosis*. 1999;**19**(10):905-10.

Christiansen 2004 {published data only}

Christiansen M, Larsen SO, Oxvig C, Qin QP, Wagner JM, Overgaard MT, et al. Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers. *Clinical Genetics* 2004;**65**(1):11-6.

Cioffi 2000 {published data only}

Cioffi M, Gazzerri P, Di Macchia, Vietri MT, Contursi A, Magnetta R, et al. Screening of maternal serum for prenatal Down's syndrome and neural tube defects: An Italian experience. *Immuno-Analyse et Biologie Specialisee* 2000;**15**(3):177-81.

Crossley 1994 {published data only}

Crossley JA, Aitken DA, Berry E, Connor JM. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland. *Journal of Medical Screening* 1994;**1**(3):180-3.

David 1996 {published data only}

David M, Merksamer R, Israel N, Dar H. Unconjugated estriol as maternal serum marker for the detection of Down syndrome pregnancies. *Fetal Diagnosis & Therapy* 1996;**11**(2):99-105.

Debieve 2000 {published data only}

Debieve F, Bouckaert A, Hubinont C, Thomas K. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric Inhibin A and ultrasound. *Gynecologic & Obstetric Investigation* 2000;**49**(4):221-6.

Extermann 1998 {published data only}

Extermann P, Bischof P, Marguerat P, Mermillod B. Second-trimester maternal serum screening for Down's syndrome: free β -human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol. *Human Reproduction* 1998;**13**(1):220-3.

Forest 1995 {published data only}

Forest JC, Masse J, Rousseau F, Moutquin JM, Brideau NA, Belanger M. Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. *Clinical Biochemistry* 1995;**28**(4):443-9.

Greenberg 1991 {published data only}

Greenberg F, Del Junco D, Weyland B, Faucett WA, Schmidt D, Rose E, et al. The effect of gestational age on the detection rate of Down's syndrome by maternal serum alpha-fetoprotein screening. *American Journal of Obstetrics & Gynecology* 1991;**165**(5 Pt 1):1391-3.

Haddow 1994 {published data only}

Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. *New England Journal of Medicine* 1994;**330**(16):1114-8.

Haddow 1998 {published data only}

Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric Inhibin A. *Journal of Medical Screening* 1998;**5**(3):115-9.

Heyl 1990 {published data only}

Heyl PS, Miller W, Canick JA. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol. *Obstetrics & Gynecology* 1990;**76**(6):1025-31.

Hsu 1997a {published data only}

Hsu JJ, Hsieh TT, Soong YK, Spencer K. Comparison of Down's syndrome screening strategies in Asians combining serum free β -hCG and alpha-fetoprotein with maternal age. *Prenatal Diagnosis* 1997;**17**(8):707-16.

Hudrer-Duric 2000 {published data only}

Hudrer-Duric K, Skrablin S, Kuvacic I, Sonicki Z, Rubala D, Suchanek E. The triple-marker test in predicting fetal aneuploidy: a compromise between sensitivity and specificity.

European Journal of Obstetrics, Gynecology, & Reproductive Biology 2000;**88**(1):49-55.

Jou 2000 {published data only}

Jou HJ, Shyu MK, Chen SM, Shih JC, Hsu JJ, Hsieh FJ. Maternal serum screening for down syndrome by using alpha-fetoprotein and human chorionic gonadotropin in an asian population. a prospective study. *Fetal Diagnosis & Therapy*.15(2):108-11, 2000;**15**(2):108-11.

Kadir 1999 {published data only}

Kadir RA, Economides DL. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. *Ultrasound in Obstetrics and Gynecology* 1997;**9**(4):244-7.

* Kadir RA, Pepera T, Economides DL. Second trimester maternal serum biochemical screening for Down's syndrome: Experience of a single obstetric unit. *Journal of Obstetrics and Gynaecology* 1999;**19**(4):373-6.

Kishida 2000 {published data only}

Kishida T, Hoshi N, Hattori R, Negishi H, Yamada H, Okuyama K, et al. Efficacy of maternal serum screening in the prenatal detection of fetal chromosome abnormalities in Japanese women. *Fetal Diagnosis & Therapy* 2000;**15**(2):112-7.

Knight 1998 {published data only}

Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free β -subunit as screening tests for Down syndrome. *Prenatal Diagnosis* 1998;**18**(3):235-45.

Lam 2002 {published data only}

Lam YH, Lee CP, Sin SY, Tang R, Wong HS, Wong SF, et al. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. *Prenatal Diagnosis* 2002;**22**(8):730-5.

Lemay 1995 {published data only}

Lemay C, Roussel-Mizon N, Thepot F, Desmet G. Maternal serum screening for fetal Down's syndrome, a retrospective study. *Clinica Chimica Acta* 1995;**238**(2):151-62.

Malone 2005 {published data only}

Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, et al. for the First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium. Comparison of serum markers in first-trimester down syndrome screening. *Obstetrics & Gynecology* 2006;**108**(5):1192-9.

* Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. for the First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. *New England Journal of Medicine* 2005;**353**(19):2001-11.

Mancini 1991 {published data only}

Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, et al. Screening for fetal Down's syndrome with maternal serum markers--an experience in Italy. *Prenatal Diagnosis* 1991;**11**(4):245-52.

Milunsky 1993 {published data only}

Milunsky A, Nebiolo LM, Bellet D. Maternal serum screening for chromosome defects: human chorionic gonadotropin versus its free- β subunit. *Fetal Diagnosis & Therapy* 1993;**8**(4):221-4.

Muller 1996a {published data only}

Muller F, Aegerter P, Boue A. Prospective maternal serum human chorionic gonadotropin screening for the risk of fetal chromosome anomalies and of subsequent fetal and neonatal deaths. *Prenatal Diagnosis* 1993;**13**(1):29-43.

Muller F, Boue A. A single chorionic gonadotropin assay for maternal serum screening for Down's syndrome. *Prenatal Diagnosis* 1990;**10**(6):389-98.

* Muller F, Bussieres L. Maternal serum markers for fetal trisomy 21 screening. [Review]. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 1996;**65**(1):3-6.

Palomaki 2004 {published data only}

Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Pandian R. Maternal serum invasive trophoblast antigen (hyperglycosylated hCG) as a screening marker for Down syndrome during the second trimester. *Clinical Chemistry* 2004;**50**(10):1804-8.

Palomaki 2006 {published data only}

Palomaki GE, Wright DE, Summers AM, Neveux LM, Meier C, O'donnell A, et al. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. *Prenatal Diagnosis* 2006;**26**(8):730-9.

Pandian 2004 {published data only}

Pandian R, Cole LA, Palomaki GE. Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening. *Clinical Chemistry* 2004;**50**(8):1433-5.

Perona 1997 {published data only}

Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, et al. Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. *International Journal of Clinical & Laboratory Research* 1994;**24**(1):49-53.

* Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A. Repeat testing of mothers with high human chorionic gonadotrophin levels in Down's syndrome screening. *International Journal of Clinical & Laboratory Research* 1997;**27**(4):253-6.

Piggott 1994 {published data only}

Piggott M, Wilkinson P, Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. *Journal of Medical Screening* 1994;**1**(1):45-9.

Qin 1997 {published data only}

Qin QP, Christiansen M, Nguyen TH, Sorensen S, Larsen SO, Norgaard-Pedersen B. Schwangerschaftsprotein 1 (SP1) as a maternal serum marker for Down syndrome in the first and second trimesters. *Prenatal Diagnosis* 1997;**17**(2):101-8.

Roberts 2000 {published data only}

Roberts D, Walkinshaw SA, McCormack MJ, Ellis J. Prenatal detection of trisomy 21: combined experience of two British hospitals. *Prenatal Diagnosis*. 2000;**20**(1):17-22.

Rose 1994 {published data only}

Rose NC, Palomaki GE, Haddow JE, Goodman DBP, Mennuti MT. Maternal serum alpha-fetoprotein screening for chromosomal abnormalities: A prospective study in women aged 35 and older. *American Journal of Obstetrics and Gynecology* 1994;**170**(4):1073-8.

Rosen 2002 {published data only}

Rosen DJ, Kedar I, Amiel A, Ben-Tovim T, Petel Y, Kaneti H, et al. A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%. *Prenatal Diagnosis* 2002;**22**(1):59-63.

Rozenberg 2002 {published data only}

Rozenberg P, Malagrida L, Cuckle H, Durand-Zaleski I, Nisand I, Audibert F, et al. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study. *Human Reproduction* 2002;**17**(4):1093-8.

Sancken 2003 {published data only}

Sancken U, Bahner D. Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free β -subunit (free β hCG). *Fetal Diagnosis & Therapy* 2003;**18**(2):122-7.

Su 2002 {published data only}

Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ. Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome. *Prenatal Diagnosis* 2002;**22**(1):8-12.

Suzumori 1997 {published data only}

Suzumori K, Tanemura M, Murakami I, Okada S, Natori M, Tanaka M, et al. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy. *Prenatal Diagnosis* 1997;**17**(9):861-6.

Talbot 2003 {published data only}

Talbot JA, Spencer K, Abushoufa RA. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay. *Prenatal Diagnosis* 2003;**23**(1):1-5.

Van Lith 1992 {published data only}

Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive Inhibin A as a marker for fetal Down's syndrome. *Prenatal Diagnosis* 1992;**12**(10):801-6.

Verloes 1995 {published data only}

Verloes A, Schoos R, Herens C, Vintens A, Koulischer L. A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays

on maternal dried blood. *American Journal of Obstetrics & Gynecology* 1995;**172**(1 pt 1):167-74.

Wald 2003a {published data only}

Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. *Lancet* 2003;**361**(9360):835-6.

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. *BJOG: An International Journal of Obstetrics & Gynaecology* 2004;**111**(6):521-31.

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. *Seminars in Perinatology* 2005;**29**(4):225-35.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *Journal of Medical Screening* 2003;**10**(2):56-104.

* Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *Health Technology Assessment* 2003;**7**(11):1-77.

Ward 1999 {published data only}

Marcus SF, Ward PA, Wood PL. Maternal serum screening for Down syndrome in women aged 40 years and over. *Journal of Obstetrics and Gynaecology* 1999;**19**(6):604-8.

* Ward PA, Wilson H, Wood PL. The outcome of five years' implementation of maternal serum screening for Down's syndrome comparing actual age risks and mode of delivery. *Journal of Obstetrics and Gynaecology* 1999;**19**(3):257-61.

Watanabe 2002 {published data only}

Watanabe H, Hamada H, Yamada N, Ogura T, Yasuoka MO, Okuno S, et al. Second-trimester maternal pregnancy-associated plasma protein a and Inhibin Aa levels in fetal trisomies. *Fetal Diagnosis & Therapy* 2002;**17**(3):137-41.

Wenstrom 1997 {published data only}

Wenstrom KD, Owen J, Chu DC, Boots L. Elevated second-trimester dimeric Inhibin A levels identify Down syndrome pregnancies. *American Journal of Obstetrics & Gynecology* 1997;**177**(5):992-6.

Wenstrom 1997a {published data only}

Wenstrom KD, Owen J, Chu DC, Boots L. Free β -hCG subunit versus intact hCG in Down syndrome screening. *Obstetrics & Gynecology* 1997;**90**(3):370-4.

Wenstrom 1997b {published data only}

Wenstrom KD, Owen J, Boots L. Second-trimester maternal serum CA-125 versus estriol in the multiple-marker screening test for Down syndrome. *Obstetrics & Gynecology* 1997;**89**(3):359-63.

Wenstrom 1999 {published data only}

Wenstrom KD, Owen J, Chu D, Boots L. Prospective evaluation of free β -subunit of human chorionic gonadotropin and dimeric Inhibin A for aneuploidy detection. *American Journal of Obstetrics & Gynecology* 1999;**181**(4):887-92.

References to studies excluded from this review

Abbas 1995 {published data only}

Abbas A, Chard T, Nicolaides K. Fetal and maternal hCG concentration in aneuploid pregnancies. *British Journal of Obstetrics and Gynaecology* 1995;**102**(7):561-3.

Abdul-Hamid 2004 {published data only}

Abdul-Hamid S, Fox R, Martin I. Maternal serum screening for trisomy 21 in women with a false positive result in last pregnancy. *Journal of Obstetrics & Gynaecology* 2004;**24**(4):374-6.

Abraha 1999 {published data only}

Abraha HD, Noble PL, Nicolaides KH, Sherwood RA. Maternal serum S100 protein in normal and Down syndrome pregnancies. *Prenatal Diagnosis* 1999;**19**(4):334-6.

Adekunle 1999 {published data only}

Adekunle O, Gopee A, el-Sayed M, Thilaganathan B. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. *British Journal of Radiology* 1999;**72**(857):457-60.

Aitken 1993 {published data only}

Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM, Spencer K, et al. First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. *Prenatal Diagnosis* 1993;**13**(8):681-9.

Aitken 1996a {published data only}

Aitken DA, Syvetsen BS, Crossley JA, Berry E, Connor JM. Heat-stable and immunoreactive placental alkaline phosphatase in maternal serum from Down's syndrome and trisomy 18 pregnancies.[see comment]. *Prenatal Diagnosis* 1996;**16**(11):1051-4.

Aitken 1996b {published data only}

Aitken DA, Wallace EM, Crossley JA, Swanston IA, Van Pareren Y, Van Maarle M, et al. Dimeric Inhibin A as a marker for Down's syndrome in early pregnancy. *New England Journal of Medicine* 1996;**334**(19):1231-6.

Akbas 2001 {published data only}

Akbas SH, Ozben T, Alper O, Ugur A, Yucel G, Luleci G. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18. *Clinical Chemistry & Laboratory Medicine* 2001;**39**(6):487-90.

Antona 1998 {published data only}

Antona D, Wallace EM, Shearing C, Ashby JP, Groome NP. Inhibin A and pro-alphaC Inhibin A in Down syndrome and normal pregnancies. *Prenatal Diagnosis* 1998;**18**(11):1122-6.

Antsaklis 1999 {published data only}

Antsaklis A, Papantoniou N, Mesogitis S, Michalas S, Aravantinos D. Pregnant women of 35 years of age or more: Maternal serum markers or amniocentesis?. *Journal of Obstetrics and Gynaecology* 1999;**19**(3):253-6.

Ashwood 1987 {published data only}

Ashwood ER, Cheng E, Luthy DA. Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs. *American Journal of Medical Genetics* 1987;**26**(3):531-9.

Asrani 2005 {published data only}

Asrani CH. Triple marker. *National Journal of Homoeopathy* 2005;**7**(3):174.

Audibert 2001b {published data only}

Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(1):26-31.

Axt-Fleidner 2006 {published data only}

Axt Flidner, Schwarze A, Kreiselmaier P, Krapp M, Smrcek J, Diedrich K. Umbilical cord diameter at 11-14 weeks of gestation: Relationship to nuchal translucency, ductus venous blood flow and chromosomal defects. *Fetal Diagnosis and Therapy* 2006;**21**(4):390-5.

Azuma 2002 {published data only}

Azuma M, Yamamoto R, Wakui Y, Minobe S, Satomura S, Fujimoto S. A novel method for the detection of Down syndrome with the use of four serum markers. *American Journal of Obstetrics & Gynecology* 2002;**187**(1):197-201.

Baghagho 2004 {published data only}

Baghagho EE, Kharboush IF, El-Kaffash DM, KarKour TA, Ismail SR, Mortada MM. Maternal serum alpha fetoprotein among pregnant females in Alexandria. *Journal of the Egyptian Public Health Association* 2004;**79**(1-2):59-81.

Bahado-Singh 1995 {published data only}

Bahado Singh, Goldstein I, Uerpaiojkit B, Copel JA, Mahoney MJ, Baumgarten A. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1106-0.

Bahado-Singh 1996 {published data only}

Bahado Singh, Tan A, Deren O, Hunter D, Copel J, Mahoney MJ. Risk of Down syndrome and any clinically significant chromosome defect in pregnancies with abnormal triple-screen and normal targeted ultrasonographic results. *American Journal of Obstetrics and Gynecology* 1996;**175**(4 I):824-9.

Bahado-Singh 1999b {published data only}

Bahado Singh, Oz AU, Flores D, Cermik D, Acuna E, Mahoney MJ, et al. Nuchal thickness, urine β -core fragment level, and maternal age for down syndrome screening. *American Journal of Obstetrics and Gynecology* 1999;**180**(2 I):491-5.

Bahado-Singh 2002 {published data only}

Bahado Singh, Shahabi S, Karaca M, Mahoney MJ, Cole L, Oz UA. The comprehensive midtrimester test: High-sensitivity Down syndrome test. *American Journal of Obstetrics and Gynecology* 2002;**186**(4):803-8.

Bahado-Singh 2003 {published data only}

Bahado Singh, Cheng CC, Matta P, Small M, Mahoney MJ. Combined serum and ultrasound screening for detection of fetal aneuploidy. *Seminars in Perinatology* 2003;**27**(2):145-51.

Bar-Hava 2001 {published data only}

Bar-Hava I, Yitzhak M, Krissi H, Shohat M, Shalev J, Czitron B, et al. Triple-test screening in in vitro fertilization pregnancies. *Journal of Assisted Reproduction and Genetics* 2001;**18**(4):226-9.

Barkai 1996 {published data only}

Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction. *Prenatal Diagnosis* 1996;**16**(12):1111-4.

Barnabei 1995 {published data only}

Barnabei VM, Krantz DA, Macri JN, Larsen JW Jr. Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free- β hCG and AFP. *Prenatal Diagnosis* 1995;**15**(12):1131-4.

Bartels 1988 {published data only}

Bartels I, Lindemann A. Maternal levels of pregnancy-specific β 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. *Human Genetics* 1988;**80**(1):46-8.

Bartels 1993 {published data only}

Bartels I, Hoppe-Sievert B, Bockel B, Herold S, Caesar J. Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol to maternal weight and smoking. *Prenatal Diagnosis* 1993;**13**(2):123-30.

Barth 1991 {published data only}

Barth WH Jr, Frigoletto FD Jr, Krauss CM, MacMillin MD, Stryker JM, Benacerraf BR. Ultrasound detection of fetal aneuploidy in women with elevated maternal serum alpha-fetoprotein. *Obstetrics & Gynecology* 1991;**77**(6):897-900.

Baviera 2004 {published data only}

Baviera G, Carbone C, Corrado F, Mastrantonio P. Placental growth hormone in Down's syndrome screening. *Journal of Maternal-Fetal & Neonatal Medicine* 2004;**16**(4):241-3.

Bazzett 1998 {published data only}

Bazzett LB, Yaron Y, O'Brien JE, Critchfield G, Kramer RL, Ayoub M, et al. Fetal gender impact on multiple-marker screening results. *American Journal of Medical Genetics* 1998;**76**(5):369-71.

Bellver 2005 {published data only}

Bellver J, Lara C, Soares SR, Ramirez A, Pellicer A, Remohi J, et al. First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction. *Human Reproduction*. 2005;**20**(9):2623-7.

Benn 1995 {published data only}

Benn PA, Horne D, Briganti S, Greenstein RM. Prenatal diagnosis of diverse chromosome abnormalities in a population of women identified by triple-marker testing as screen positive for Down syndrome. *American Journal of Obstetrics & Gynecology* 1995;**173**(2):496-501.

Benn 1996 {published data only}

Benn PA, Horne D, Craffey A, Collins R, Ramsdell L, Greenstein R. Maternal serum screening for birth defects: results of a Connecticut regional program. *Connecticut Medicine* 1996;**60**(6):323-7.

Benn 1997 {published data only}

Benn PA, Clive JM, Collins R. Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. *Clinical Chemistry* 1997;**43**(2):333-7.

Benn 1998 {published data only}

Benn PA. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies. *Prenatal Diagnosis* 1998;**18**(4):319-24.

Benn 2001 {published data only}

Benn PA, Ying J, Beazoglou T, Egan JF. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. *Prenatal Diagnosis* 2001;**21**(1):46-51.

Benn 2002 {published data only}

Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF. Combined second-trimester biochemical and ultrasound screening for Down syndrome. *Obstetrics & Gynecology* 2002;**100**(6):1168-76.

Benn 2003a {published data only}

Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. *Obstetrics and Gynecology* 2003;**101**(3):451-4.

Benn 2003b {published data only}

Benn P. Improved antenatal screening for Down's syndrome. *Lancet* 2003;**361**(9360):794-5.

Benn 2005a {published data only}

Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. *Prenatal Diagnosis* 2005;**25**(8):645-52.

Benn 2005b {published data only}

Benn P, Donnenfeld AE. Sequential Down syndrome screening: the importance of first and second trimester test correlations when calculating risk. *Journal of Genetic Counseling* 2005;**14**(6):409-13.

Berry 1995 {published data only}

Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Analysis of maternal serum alpha-fetoprotein and free β human chorionic

gonadotrophin in the first trimester: implications for Down's syndrome screening. *Prenatal Diagnosis* 1995;**15**(6):555-65.

Berry 1997 {published data only}

Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. *British Journal of Obstetrics & Gynaecology* 1997;**104**(7):811-7.

Bersinger 1994 {published data only}

Bersinger NA, Brizot ML, Johnson A, Snijders RJ, Abbott J, Schneider H, et al. First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific β 1-glycoprotein in fetal trisomies. *British Journal of Obstetrics & Gynaecology* 1994;**101**(11):970-4.

Bersinger 2000 {published data only}

Bersinger NA, Xin WZ. Glycosylation of pregnancy-associated plasma protein a (PAPP-A) and pregnancy-specific (β)(1)-glycoprotein (SP1): Relevance for fetal down syndrome screening and for placental function studies. *Immuno-Analyse et Biologie Specialisee* 2000;**15**(6):402-8.

Bersinger 2001 {published data only}

Bersinger NA, Chanson A, Crazzolaro S, Hänggi W, Pescia G, Scheier M, et al. Serum levels of placenta protein markers: The relevance of differences between spontaneous and after in vitro fertilization pregnancies for fetal trisomy screening. *Journal fur Fertilitat und Reproduktion* 2001;**11**(3):7-13.

Bersinger 2003 {published data only}

Bersinger NA, Noble P, Nicolaides KH. First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies. *Prenatal Diagnosis* 2003;**23**(2):157-62.

Bersinger 2004 {published data only}

Bersinger NA, Wunder D, Vanderlick F, Chanson A, Pescia G, Janecek P, et al. Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening. *Prenatal Diagnosis* 2004;**24**(6):471-7.

Bersinger 2005 {published data only}

Bersinger NA, Vanderlick F, Birkhäuser MH, Janecek P, Wunder D. First trimester serum concentrations of placental proteins in singleton and multiple IVF pregnancies: Implications for Down syndrome screening. *Immuno-Analyse et Biologie Specialisee* 2005;**20**(1):21-7.

Biggio 2004 {published data only}

Biggio Jr, Morris TC, Owen J, Stringer JSA. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. *American Journal of Obstetrics and Gynecology* 2004;**190**(3):721-9.

Bindra 2002 {published data only}

Bindra R, Heath V, Nicolaides KH. Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks. *Clinical Obstetrics and Gynecology* 2002;**45**(3):661-70.

Blundell 1999 {published data only}

Blundell G, Ashby JP, Martin C, Shearing CH, Langdale-Brown B, Keeling J, et al. Clinical follow-up of high mid-trimester maternal serum intact human chorionic gonadotrophin concentrations in singleton pregnancies. *Prenatal Diagnosis*. 1999;**19**(3):219-23.

Boots 1989 {published data only}

Boots LR, Davis RO, Foster JM, Goldenberg RL. Maternal serum alpha-fetoprotein prenatal screening for Down syndrome. *Alabama Medicine* 1989;**59**(1):25-7.

Borruto 2002 {published data only}

Borruto F, Comparetto C, Acanfora L, Bertini G, Rubaltelli FF. Role of ultrasound evaluation of nuchal translucency in prenatal diagnosis. *Clinical & Experimental Obstetrics & Gynecology* 2002;**29**(4):235-41.

Boue 1990 {published data only}

Boue A, Muller F. Screening for Down's syndrome with maternal serum human chorionic gonadotropin at midtrimester. *Current Opinion in Pediatrics* 1990;**2**(6):1157-60.

Bradley 1994 {published data only}

Bradley LA, Horwitz JA, Dowman AC, Ponting NR, Peterson LM. Triple marker screening for fetal Down syndrome. *International Pediatrics* 1994;**9**(3):168-74.

Braithwaite 1996 {published data only}

Braithwaite JM, Economides DL. Nuchal translucency and screening for Down's syndrome. *Contemporary Reviews in Obstetrics and Gynaecology* 1996;**8**(2):75-81.

Brambati 1995 {published data only}

Brambati B, Cislighi C, Tului L, Alberti E, Amidani M, Colombo U, et al. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in women undergoing chorionic villus sampling. *Ultrasound in Obstetrics & Gynecology* 1995;**5**(1):9-14.

Brambati 1996 {published data only}

Brambati B, Tului L, Alberti E. Sonography in the first trimester screening of trisomy 21 and other fetal aneuploidies. [Review] [73 refs]. *Early Pregnancy* 1996;**2**(3):155-67.

Brizot 1995a {published data only}

Brizot ML, Bersinger NA, Xydias G, Snijders RJ, Nicolaidis KH. Maternal serum Schwangerschafts protein-1 (SP1) and fetal chromosomal abnormalities at 10-13 weeks' gestation. *Early Human Development*. 1995;**43**(1):31-6.

Brizot 1995b {published data only}

Brizot ML, Kuhn P, Bersinger NA, Snijders RJ, Nicolaidis KH. First trimester maternal serum alpha-fetoprotein in fetal trisomies. *British Journal of Obstetrics & Gynaecology* 1995;**102**(1):31-4.

Brizzi 1989b {published data only}

Brizzi L, Cariati E, Periti E, Nannini R, Torricelli F, Cappelli G, et al. Evaluation of maternal serum alpha-fetoprotein and ultrasound examination to screen fetal chromosomal

abnormalities. *Journal of Nuclear Medicine & Allied Sciences* 1989;**33**(3 Suppl):85-8.

Brock 1990 {published data only}

Brock DJ, Barron L, Holloway S, Liston WA, Hillier SG, Seppala M. First-trimester maternal serum biochemical indicators in Down syndrome. *Prenatal Diagnosis* 1990;**10**(4):245-51.

Campogrande 2001 {published data only}

Campogrande M, Viora E, Errante G, Bastonero S, Sciarrone A, Grassi Pirrone P, et al. Correlations between first and second trimester markers for Down's syndrome screening. *Journal of Medical Screening* 2001;**8**(3):163-4.

Canick 1988 {published data only}

Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. *British Journal of Obstetrics & Gynaecology* 1988;**95**(4):330-3.

Canick 1995b {published data only}

Canick JA, Kellner LH, Saller Jr, Palomaki GE, Walker RP, Osathanondh R. Second-trimester levels of maternal urinary gonadotropin peptide in down syndrome pregnancy. *Prenatal Diagnosis* 1995;**15**(8):739-44.

Canini 2002 {published data only}

Canini S, Prefumo F, Famularo L, Venturini PL, Palazzese V, De Biasio P. Comparison of first trimester, second trimester and integrated Down's syndrome screening results in unaffected pregnancies. *Clinical Chemistry & Laboratory Medicine* 2002;**40**(6):600-3.

Cans 1998 {published data only}

Cans C, Amblard F, Devillard F, Pison H, Jalbert P, Jouk PS. Population screening for aneuploidy using maternal age and ultrasound. *Prenatal Diagnosis* 1998;**18**(7):683-92.

Carreras 1991 {published data only}

Carreras de Paz JJ, Silva Mendoza JM, Violante Diaz M, Cerrillo Hinojosa M, Hued Ahued JR. [Proposed normal values for alpha fetoprotein in maternal serum for the detection of neural tube closure defects and Down syndrome. Preliminary study]. [Spanish]. *Ginecologia y Obstetricia de Mexico* 1991;**59**:261-4.

Chen 1999 {published data only}

Chen FM. Integrated screening for Down's syndrome. *Journal of Family Practice* 1999;**48**(11):846-7.

Chen 2002 {published data only}

Chen M, Lam YH, Tang MH, Lee CP, Sin SY, Tang R, et al. The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation. *Prenatal Diagnosis* 2002;**22**(7):576-8.

Chen 2004 {published data only}

Chen M, Lam YH, Lee CP, Tang MHY. Ultrasound screening of fetal structural abnormalities at 12 to 14 weeks in Hong Kong. *Prenatal Diagnosis* 2004;**24**(2):92-7.

Chen 2005 {published data only}

Chen CP, Lin CJ, Wang W. Impact of second-trimester maternal serum screening on prenatal diagnosis of Down syndrome and the use of amniocentesis in the Taiwanese population. *Taiwanese Journal of Obstetrics and Gynecology* 2005;**44**(1):31-5.

Cheng 1993 {published data only}

Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. *Obstetrics & Gynecology* 1993;**81**(1):72-7.

Cheng 1999 {published data only}

Cheng PJ, Liu CM, Chang SD, Lin YT, Soong YK. Elevated second-trimester maternal serum hCG in women undergoing haemodialysis. *Prenatal Diagnosis*. 1999;**19**(10):955-8.

Cheng 2004a {published data only}

Cheng CC, Bahado-Singh RO, Chen SC, Tsai MS. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. *International Journal of Gynaecology & Obstetrics* 2004;**84**(1):5-9.

Cheng 2004b {published data only}

Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng DR. Elevated maternal midtrimester serum free β -human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results. *American Journal of Obstetrics & Gynecology*. 2004;**190**(2):442-7.

Chitayat 2002 {published data only}

Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR, Summers AM. Double-positive maternal serum screening results for down syndrome and open neural tube defects: An indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. *American Journal of Obstetrics & Gynecology* 2002;**187**(3):758-63.

Christiansen 2002 {published data only}

Christiansen M, Hogdall EV, Larsen SO, Hogdall C. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. *Prenatal Diagnosis* 2002;**22**(5):385-7.

Christiansen 2007 {published data only}

Christiansen M, Sorensen TL, Norgaard-Pedersen B. Human placental lactogen is a first-trimester maternal serum marker of Down syndrome. *Prenatal Diagnosis* 2007;**27**(1):1-5.

Chung 2000 {published data only}

Chung BL, Kim YP, Nam MH. The application of three-dimensional ultrasound to nuchal translucency thickness measurement at 10-14 weeks of gestation. *Prenatal and Neonatal Medicine* 2000;**5**(1):17-21.

CNGOF 1996 {published data only}

Anon. Blood screening of Down's syndrome (Trisomy 21) and reimbursement of karyotype for women under 38. *Revue Francaise de Gynecologie et d'Obstetrique* 1996;**91**(11):575-7.

Cole 1996 {published data only}

Cole L, Iozaki T, Palomaki G, Canick J, Iles R, Kellner L, et al. Detection of β -core fragment in second trimester Down's syndrome pregnancies. [Review]. *Early Human Development* 1996;**47** Suppl:S47-S8.

Comas 2001 {published data only}

Comas C, Antolín E, Torrents M, Muñoz A, Figueras F, Echevarría M, et al. Early screening for chromosomal abnormalities: New strategies combining biochemical, sonographic and doppler parameters. *Prenatal and Neonatal Medicine* 2001;**6**(2):95-102.

Comas 2002a {published data only}

Comas C, Torrents M, Munoz A, Antolin E, Figueras F, Echevarría M. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?. *Obstetrics & Gynecology* 2002;**100**(4):648-54.

Comas 2002b {published data only}

Comas C, Carrera JM. Early sonographic screening for chromosomal abnormalities. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(2):88-91.

Comstock 2006 {published data only}

Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade GR, Berkowitz RL, et al. FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?. *American Journal of Obstetrics & Gynecology*. 2006;**195**(3):843-7.

Conde 1998 {published data only}

Conde Agudelo, Kafury Goeta. Triple-marker test as screening for down syndrome: A meta-analysis. *Obstetrical and Gynecological Survey* 1998;**53**(6):369-76.

Crossley 1991 {published data only}

Crossley JA, Aitken DA, Connor JM. Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein, and age. *Prenatal Diagnosis* 1991;**11**(2):83-101.

Crossley 1993 {published data only}

Crossley JA, Aitken DA, Connor JM. Second-trimester unconjugated oestriol levels in maternal serum from chromosomally abnormal pregnancies using an optimized assay.[see comment]. *Prenatal Diagnosis* 1993;**13**(4):271-80.

Crossley 1996 {published data only}

Crossley JA, Berry E, Aitken DA, Connor JM. Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme. *Prenatal Diagnosis* 1996;**16**(11):1039-42.

Crossley 2002a {published data only}

Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor JM. Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. *Prenatal Diagnosis* 2002;**22**(3):247-55.

Cuckle 1984 {published data only}

Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. *Lancet* 1984;**i**(8383):926-9.

Cuckle 1987a {published data only}

Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. *British Journal of Obstetrics & Gynaecology* 1987;**94**(5):387-402.

Cuckle 1987b {published data only}

Cuckle HS, Nanchahal K, Wald NJ. Maternal serum alpha-fetoprotein and ethnic origin. *British Journal of Obstetrics and Gynaecology* 1987;**94**(11):1111-2.

Cuckle 1990 {published data only}

Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, et al. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. *British Journal of Obstetrics & Gynaecology* 1990;**97**(3):272-4.

Cuckle 1996 {published data only}

Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM. Combining Inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(12):1095-100.

Cuckle 1999a {published data only}

Cuckle HS, Sehmi I, Jones R, Evans LW. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome. *Prenatal Diagnosis*. 1999;**19**(6):513-6.

Cuckle 1999b {published data only}

Cuckle HS, Van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome.[see comment]. *Prenatal Diagnosis*. 1999;**19**(6):505-12.

Cullen 1990 {published data only}

Cullen MT, Gabrielli S, Green JJ, Rizzo N, Mahoney MJ, Salafia C, et al. Diagnosis and significance of cystic hygroma in the first trimester. *Prenatal Diagnosis* 1990;**10**(10):643-51.

Cusick 2004 {published data only}

Cusick W, Provenzano J, Sullivan CA, Gallousis FM, Rodis JF. Fetal nasal bone length in euploid and aneuploid fetuses between 11 and 20 weeks' gestation: a prospective study. *Journal of Ultrasound in Medicine* 2004;**23**(10):1327-33.

D'Ottavio 1997 {published data only}

D'Ottavio G, Meir YJ, Rustico MA, Pecile V, Fischer-Tamaro L, Conoscenti G, et al. Screening for fetal anomalies by ultrasound at 14 and 21 weeks. *Ultrasound in Obstetrics and Gynecology* 1997;**10**(6):375-80.

Dancoine 2001 {published data only}

Dancoine F, Couplet G, Mainardi A, Sukno F, Jaumain P, Nowak E, et al. Antenatal screening for Down's syndrome with serum markers: Influence of maternal weight, smoking

habits and diabetes. *Immuno-Analyse et Biologie Specialisee* 2001;**16**(6):381-9.

De Biasio, 1999 {published data only}

De Biasio, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. First-trimester screening for down syndrome using nuchal translucency measurement with free β -hCG and PAPP-A between 10 and 13 weeks of pregnancy - The combined test. *Prenatal Diagnosis* 1999;**19**(4):360-3.

De Biasio, 2001 {published data only}

De Biasio, Ferrero S, Prefumo F, Canini S, Marchini P, Bruzzone I, et al. Down's syndrome: First trimester approach. *Italian Journal of Gynaecology and Obstetrics* 2001;**13**(1):22-6.

De Biasio 2000 {published data only}

De Biasio P, Canini S, Prefumo F, Famularo L, Venturini PL. Extent of correlation between first and second trimester markers for Down's syndrome screening. *Journal of Medical Screening* 2000;**7**(3):163.

De Graaf 1991 {published data only}

De Graaf I, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, Van Lith JM. Co-variables in first trimester maternal serum screening. *Prenatal Diagnosis*. 1991;**20**(3):186-9.

De Graaf 1999 {published data only}

De Graaf I, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, Van Lith JM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. *Prenatal Diagnosis*. 1999;**19**(5):458-62.

DeVore 2001 {published data only}

DeVore GR, Romero R. Combined use of genetic sonography and maternal serum triple-marker screening: an effective method for increasing the detection of trisomy 21 in women younger than 35 years.[see comment]. *Journal of Ultrasound in Medicine*. 2001;**20**(6):645-54.

Dickerson 1994 {published data only}

Dickerson VM. Multiple marker screening. *Western Journal of Medicine* 1994;**161**(2):161.

Dimaio 1987 {published data only}

Dimaio MS, Baumgarten A, Greenstein RM, Saal HM, Mahoney MJ. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels. *New England Journal of Medicine* 1987;**317**(6):342-6.

Doran 1986 {published data only}

Doran TA, Cadesky K, Wong PY, Mastrogiacomo C, Capello T. Maternal serum alpha-fetoprotein and fetal autosomal trisomies. *American Journal of Obstetrics & Gynecology* 1986;**154**(2):277-81.

Drugan 1996a {published data only}

Drugan A, Reichler A, Bronstein M, Johnson MP, Sokol RJ, Evans MI. Abnormal biochemical serum screening versus 2nd-trimester ultrasound-detected minor anomalies as predictors of aneuploidy in low-risk women. *Fetal Diagnosis & Therapy* 1996;**11**(5):301-5.

Drugan 1996b {published data only}

Drugan A, O'Brien JE, Dvorin E, Krivchenia EL, Johnson MP, Sokol RJ, et al. Multiple marker screening in multifetal gestations: failure to predict adverse pregnancy outcomes. *Fetal Diagnosis & Therapy* 1996;**11**(1):16-9.

Drysdale 2002 {published data only}

Drysdale K, Ridley D, Walker K, Higgins B, Dean T. First-trimester pregnancy scanning as a screening tool for high-risk and abnormal pregnancies in a district general hospital setting. *Journal of Obstetrics & Gynaecology* 2002;**22**(2):159-65.

Ebell 1999 {published data only}

Ebell M. Is the integrated test better for screening for Down's syndrome than the traditional triple test?. *Evidence-Based Practice* 1999;**2**(11):4-5.

Economides 1998 {published data only}

Economides DL, Whitlow BJ, Kadir R, Lazanakis M, Verdin SM. First trimester sonographic detection of chromosomal abnormalities in an unselected population. *British Journal of Obstetrics & Gynaecology* 1998;**105**(1):58-62.

Erickson 2004 {published data only}

Erickson JA, Ashwood ER, Gin CA. Evaluation of a dimeric inhibin-A assay for assessing fetal Down syndrome: establishment, comparison, and monitoring of median concentrations for normal pregnancies. *Archives of Pathology & Laboratory Medicine* 2004;**128**(4):415-20.

Evans 1996 {published data only}

Evans MI, O'Brien JE, Dvorin E, Krivchenia EL, Drugan A, Hume RF Jr, et al. Similarity of insulin-dependent diabetics' and non-insulin-dependent diabetics' levels of β -hCG and unconjugated estriol with controls: no need to adjust as with alpha-fetoprotein. *Journal of the Society for Gynecologic Investigation* 1996;**3**(1):20-2.

Falcon 2005 {published data only}

Falcon O, Cavoretto P, Peralta CF, Csapo B, Nicolaides KH. Fetal head-to-trunk volume ratio in chromosomally abnormal fetuses at 11 + 0 to 13 + 6 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2005;**26**(7):755-60.

Falcon 2006 {published data only}

Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method. *Ultrasound in Obstetrics & Gynecology* 2006;**27**(6):609-12.

Ford 1998 {published data only}

Ford C, Moore AJ, Jordan PA, Bartlett WA, Wyldes MP, Jones AF, et al. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population. [see comment]. *British Journal of Obstetrics & Gynaecology* 1998;**105**(8):855-9.

Frishman 1997 {published data only}

Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN Jr. Serum triple-marker screening in vitro

fertilization and naturally conceived pregnancies. *Obstetrics & Gynecology* 1997;**90**(1):98-101.

Fukada 2000 {published data only}

Fukada Y, Takizawa M, Amemiya A, Yoda H, Kohno K, Hoshi K. Detection of aneuploidy with fetal nuchal translucency and maternal serum markers in Japanese women. *Acta Obstetrica et Gynecologica Scandinavica* 2000;**79**(12):1124-5.

Ghidini 1998 {published data only}

Ghidini A, Spong CY, Grier RE, Walker CN, Pezzullo JC. Is maternal serum triple screening a better predictor of Down syndrome in female than in male fetuses?. *Prenatal Diagnosis* 1998;**18**(2):123-6.

Goldie 1995 {published data only}

Goldie DJ, Astley JP, Beaman JM, Bickley DA, Gunneberg A, Jones SR. Screening for Down's syndrome: the first two years experience in Bristol. *Journal of Medical Screening* 1995;**2**(4):207-10.

Gonçalves 2004 {published data only}

Gonçalves LF, Espinoza J, Lee W, Schoen ML, Devers P, Mazor M, et al. Phenotypic characteristics of absent and hypoplastic nasal bones in fetuses with down syndrome: Description by 3-dimensional ultrasonography and clinical significance. *Journal of Ultrasound in Medicine* 2004;**23**(12):1619-27.

Goodburn 1994 {published data only}

Goodburn SF, Yates JR, Raggatt PR, Carr C, Ferguson-Smith ME, Kershaw AJ, et al. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. *Prenatal Diagnosis* 1994;**14**(5):391-402.

Grozdea 2002 {published data only}

Grozdea J, De La Farge F, Bourrouillou G, Calot M, Cambus JP, Valdiguié P. Maternal serum urea resistant alkaline phosphatase in Down syndrome pregnancy. *Early Human Development* 2002;**67**(1-2):55-9.

Gyselaers 2004a {published data only}

Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP, Martens GE, De Jonge ET, et al. Screening for trisomy 21 in Flanders: a 10 years review of 40.490 pregnancies screened by maternal serum. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 2004;**115**(2):185-9.

Gyselaers 2004b {published data only}

Gyselaers WJA, Vereecken AJ, Van Herck, Straetmans DPL, De Jonge, Ombelet WUA, et al. Single-step maternal serum screening for trisomy 21 in the era of combined or integrated screening. *Gynecologic and Obstetric Investigation* 2004;**58**(4):221-4.

Gyselaers 2006a {published data only}

Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP, Ombelet WU, Nijhuis JG. Nuchal translucency thickness measurements for fetal aneuploidy screening: Log NT-MoM or Delta-NT, performer-specific medians and ultrasound training. *Journal of Medical Screening* 2006;**13**(1):4-7.

Gyselaers 2006b {published data only}

Gyselaers WJ, Roets ER, Van Holsbeke CD, Vereecken AJ, Van Herck EJ, Straetmans DP, et al. Sequential triage in the first trimester may enhance advanced ultrasound scanning in population screening for trisomy 21. *Ultrasound in Obstetrics & Gynecology* 2006;**27**(6):622-7.

Hackshaw 1995 {published data only}

Hackshaw AK, Densem J, Wald NJ. Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free alpha and free β -hCG. *Prenatal Diagnosis* 1995;**15**(12):1125-30.

Hackshaw 2001 {published data only}

Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. *Prenatal Diagnosis* 2001;**21**(1):58-61.

Haddow 1992 {published data only}

Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick J, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. *New England Journal of Medicine* 1992;**327**(9):588-93.

Hafner 1995 {published data only}

Hafner E, Schuchter K, Philipp K. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. *Ultrasound in Obstetrics & Gynecology* 1995;**6**(5):330-3.

Hallahan 1998 {published data only}

Hallahan TW, Krantz DA, Tului L, Alberti E, Buchanan PD, Orlandi F, et al. Comparison of urinary free β (hCG) and β -core (hCG) in prenatal screening for chromosomal abnormalities. *Prenatal Diagnosis* 1998;**18**(9):893-900.

Harrison 2006 {published data only}

Harrison G, Goldie D. Second-trimester Down's syndrome serum screening: double, triple or quadruple marker testing?. *Annals of Clinical Biochemistry* 2006;**43**(1):67-72.

Harry 2006 {published data only}

Harry WG, Reed KL. Nuchal translucency and first-trimester screening. *Journal of the Society for Gynecologic Investigation* 2006;**13**(3):153-4.

Hayashi 1995 {published data only}

Hayashi M, Kozu H. Maternal urinary β -core fragment of hCG/creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. *Prenatal Diagnosis* 1995;**15**(1):11-6.

Hayashi 1996 {published data only}

Hayashi M, Kozu H, Takei H. Maternal urinary free β -subunit of human chorionic gonadotrophin: Creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. *British Journal of Obstetrics and Gynaecology* 1996;**103**(6):577-80.

Heikkila 1997 {published data only}

Heikkila A, Ryyanen M, Kirkinen P, Saarikoski S. Results and views of women in population-wide pregnancy screening for trisomy 21 in east Finland. *Fetal Diagnosis & Therapy* 1997;**12**(2):93-6.

Heinonen 1996 {published data only}

Heinonen S, Ryyanen M, Kirkinen P, Hippelainen M, Saarikoski S. Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening. *Fertility and Sterility* 1996;**66**(3):398-403.

Herman 2000 {published data only}

Herman A, Weinraub Z, Dreazen E, Arieli S, Rozansky S, Bukovsky I, et al. Combined first trimester nuchal translucency and second trimester biochemical screening tests among normal pregnancies. *Prenatal Diagnosis*. 2000;**20**(10):781-4.

Herman 2003 {published data only}

Herman A, Dreazen E, Tovbin Y, Reish O, Bukovsky I, Maymon R. Correlation and overlapping between nuchal translucency and triple test among Down syndrome-affected pregnancies. *Fetal Diagnosis and Therapy* 2003;**18**(3):196-200.

Herrou 1992 {published data only}

Herrou M, Leporrier N, Leymarie P. Screening for fetal Down syndrome with maternal serum hCG and oestriol: a prospective study. *Prenatal Diagnosis* 1992;**12**(11):887-92.

Hershey 1985 {published data only}

Hershey DW, Crandall BF, Schroth PS. Maternal serum alpha-fetoprotein screening of fetal trisomies. *American Journal of Obstetrics & Gynecology* 1985;**153**(2):224-5.

Hershey 1986 {published data only}

Hershey DW, Crandall BF, Perdue S. Combining maternal age and serum alpha-fetoprotein to predict the risk of Down syndrome. *Obstetrics & Gynecology* 1986;**68**(2):177-80.

Hewitt 1993 {published data only}

Hewitt B. Nuchal translucency in the first trimester. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 1993;**33**(4):389-91.

Hogdall 1992 {published data only}

Hogdall CK, Hogdall EV, Arends J, Norgaard-Pedersen B, Smidt-Jensen S, Larsen SO. CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters. *Prenatal Diagnosis* 1992;**12**(3):223-7.

Hong Kong Practitioner {published data only}

Anon. Screening tests in pregnancy. *Hong Kong Practitioner* 2001;**23**(10):461-5.

Howe 2000 {published data only}

Howe DT, Gornall R, Wellesley D, Boyle T, Barber J. Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans. *BMJ* 2000;**320**(7235):606-10.

Hsiao 1991 {published data only}

Hsiao KJ, Lee SY, Chuang HC. [Antenatal screening of maternal alpha-fetoprotein with dried-blood spot samples on filter paper]. [Chinese]. *Journal of the Formosan Medical Association* 1991;**90**(6):598-604.

Hsieh 1999 {published data only}

Hsieh TT, Hsu JJ, Lo LM, Liou JD, Soong YK. Maternal urine alpha-fetoprotein concentrations between 14 and 21 weeks of gestation. *Changgeng Yi Xue Za Zhi* 1999;**22**(2):234-9.

Hsu 1997b {published data only}

Hsu JJ, Hsieh TT, Soong YK. Influence of maternal age and weight on second-trimester serum alpha-fetoprotein, total and free β human chorionic gonadotropin levels. *Changgeng Yi Xue Za Zhi*. 1997;**20**(3):181-6.

Hsu 1998a {published data only}

Hsu JJ, Hsieh TT, Hung TH, Chiang CH. Midtrimester maternal serum free β -human chorionic gonadotropin levels: normal reference values for Taiwanese women. *Changgeng Yi Xue Za Zhi* 1998;**21**(3):277-82.

Hsu 1999b {published data only}

Hsu JJ, Hsieh TT, Hung TH, Chen KC, Soong YK. Urine free β -human chorionic gonadotropin levels between 14 and 21 weeks of gestation in Taiwanese pregnancies. *Changgeng Yi Xue Za Zhi* 1999;**22**(1):11-6.

Huang 2003 {published data only}

Huang T, Summers AM, Wyatt PR, Meier C, Cote GB. Maternal serum marker medians in Aboriginal Canadian women. *Prenatal Diagnosis* 2003;**23**(2):98-100.

Huggon 2004 {published data only}

Huggon IC, Turan O, Allan LD. Doppler assessment of cardiac function at 11-14 weeks' gestation in fetuses with normal and increased nuchal translucency. *Ultrasound in Obstetrics & Gynecology* 2004;**24**(4):390-8.

Hui 2003 {published data only}

Hui PW, Tang MH, Lam YH, NG EH, Yeung WS, Ho PC. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. *Human Reproduction* 2003;**18**(3):572-5.

Hui 2005 {published data only}

Hui PW, Tang MH, Lam YH, Yeung WS, NG EH, Ho PC. Nuchal translucency in pregnancies conceived after assisted reproduction technology. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(3):234-8.

Hultén 2004 {published data only}

Hultén M. Combined serum and nuchal translucency screening in the first trimester achieves 85% to 90% detection rate for Down and Edward syndromes. *Evidence-Based Healthcare* 2004;**8**(2):82-4.

Hung 2003 {published data only}

Hung JH, Fu CY, Yuan CC, Chen CL, Yang ML, Shu LP, et al. Nuchal translucence incorporated into a one-stage multifactorial

screening model for Down syndrome prediction at second-trimester pregnancy. *Ultrasound in Medicine & Biology* 2003;**29**(12):1667-74.

Hurley 1993 {published data only}

Hurley PA, Ward RH, Teisner B, Iles RK, Lucas M, Grudzinskas JG. Serum PAPP-A measurements in first-trimester screening for Down syndrome. *Prenatal Diagnosis* 1993;**13**(10):903-8.

Huttly 2004 {published data only}

Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. *Prenatal Diagnosis* 2004;**24**(10):804-7.

Hwa 2004 {published data only}

Hwa HL, Yen MF, Hsieh FJ, Ko TM, Chen TH. Evaluation of second trimester maternal serum screening for Down's Syndrome using the Spiegelhalter-Knill-Jones (S-KJ) approach. *Journal of Perinatal Medicine* 2004;**32**(5):407-12.

Iles 1996 {published data only}

Iles RK. Urinary analysis for Down's syndrome: Is the measurement of urinary β -core the future of biochemical screening for Down's syndrome. *Early Human Development* 1996;**47**(Suppl.):S41-S45.

Ind 1994 {published data only}

Ind TEJ, Iles RK, Cuckle HS, Chard T. Second trimester maternal serum placental alkaline phosphatase concentrations in Down's syndrome. *Journal of Obstetrics and Gynaecology* 1994;**14**(5):305-8.

Jean-Pierre 2005 {published data only}

Jean Pierre. Fetal nasal bone: Review of first trimester findings. *Ultrasound Review of Obstetrics and Gynecology* 2005;**5**(2):102-4.

Johnson 1991 {published data only}

Johnson A, Cowchock FS, Darby M, Wapner R, Jackson LG. First-trimester maternal serum alpha-fetoprotein and chorionic gonadotropin in aneuploid pregnancies. *Prenatal Diagnosis* 1991;**11**(7):443-50.

Johnson 1993 {published data only}

Johnson MP, Johnson A, Holzgreve W, Isada NB, Wapner RJ, Treadwell MC, et al. First-trimester simple hygroma: cause and outcome. *American Journal of Obstetrics & Gynecology* 1993;**168**(1):156-61.

Jorgensen 1999 {published data only}

Jorgensen FS, Valentin L, Salvesen KA, Jorgensen C, Jensen FR, Bang J, et al. MULTISCAN--a Scandinavian multicenter second trimester obstetric ultrasound and serum screening study. *Acta Obstetrica et Gynecologica Scandinavica* 1999;**78**(6):501-10.

Josefsson 1998 {published data only}

Josefsson A, Molander E, Selbing A. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination. *Acta Obstetrica et Gynecologica Scandinavica* 1998;**77**(5):497-9.

Jou 2001 {published data only}

Jou HJ, Shih JC, Wu SC, Li TC, Tzeng CY, Hsieh FJ. First-trimester Down's syndrome screening by fetal nuchal translucency measurement in Taiwan. *Journal of the Formosan Medical Association* 2001;**100**(4):257-61.

Jun-Tao 2003 {published data only}

Liu JT, Hao N, Sun NH, Wang FY, Xu YH, Gai MY, et al. [Screening by maternal serum markers for Down's syndrome]. [Chinese]. *Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae* 2003;**25**(2):156-9.

Kagan 2006 {published data only}

Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects.[see comment]. *Obstetrics & Gynecology* 2006;**107**(1):6-10.

Kautzmann 1995 {published data only}

Kautzmann M, Solis RL, Luberta A, Fernandez JL, Navarro J, Rodriguez L, et al. Study of the efficiency of screening for trisomy 21 based on maternal serum levels of AFP and hCG combined with maternal age. *Journal of Clinical Ligand Assay* 1995;**18**(3):181-5.

Keith 1992 {published data only}

Keith D. Maternal serum screening for neural tube defects and Down syndrome. *Clinical Laboratory Science* 1992;**5**(5):274-6.

Kelekci 2004 {published data only}

Kelekci S, Yazicioglu HF, Oguz S, Inan I, Yilmaz B, Sonmez S. Nasal bone measurement during the 1st trimester: is it useful?. *Gynecologic & Obstetric Investigation* 2004;**58**(2):91-5.

Kellner 1995a {published data only}

Kellner LH, Weiner Z, Weiss RR, Neuer M, Martin GM, Mueenuddin M, et al. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free- β subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.[see comment]. *American Journal of Obstetrics & Gynecology* 1995;**173**(4):1306-9.

Kellner 1995b {published data only}

Kellner LH, Weiss RR, Weiner Z, Neuer M, Martin GM, Schulman H, et al. The advantages of using triple-marker screening for chromosomal abnormalities. *American Journal of Obstetrics & Gynecology* 1995;**172**(3):831-6.

Kellner 1997 {published data only}

Kellner LH, Canick JA, Palomaki GE, Neveux LM, Saller DN Jr, Walker RP, et al. Levels of urinary β -core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome. *Prenatal Diagnosis* 1997;**17**(12):1135-41.

Knight 1990 {published data only}

Knight GJ, Palomaki GE. Maternal serum alpha fetoprotein screening for fetal down syndrome. *Journal of Clinical Immunoassay* 1990;**13**(1):23-9.

Knight 2001 {published data only}

Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. *Journal of Medical Screening* 2001;**8**(1):2-7.

Knight 2005 {published data only}

Knight GJ, Palomaki GE, Neveux LM, Smith DE, Kloza EM, Pulkkinen A, et al. Integrated serum screening for Down syndrome in primary obstetric practice. *Prenatal Diagnosis* 2005;**25**(12):1162-7.

Koos 2006 {published data only}

Koos BJ. First-trimester screening: Lessons from clinical trials and implementation. *Current Opinion in Obstetrics and Gynecology* 2006;**18**(2):152-5.

Kornman 1996 {published data only}

Kornman LH, Morssink LP, Beekhuis JR, de Wolf BT, Heringa MP, Mantingh A. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice.[see comment]. *Prenatal Diagnosis* 1996;**16**(9):797-805.

Kornman 1997 {published data only}

Kornman LH, Morssink LP, Wortelboer MJ, Beekhuis JR, de Wolf BT, Pratt JJ, Mantingh A. Maternal urinary β -core hCG in chromosomally abnormal pregnancies in the first trimester. *Prenatal Diagnosis* 1997;**17**(2):135-9.

Kramer 1998 {published data only}

Kramer RL, Yaron Y, O'Brien JE, Critchfield G, Ayoub M, Johnson MP, et al. Effect of adjustment of maternal serum alpha-fetoprotein levels in insulin-dependent diabetes mellitus. *American Journal of Medical Genetics* 1998;**75**(2):176-8.

Krantz 1996 {published data only}

Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free β -human chorionic gonadotropin and pregnancy-associated plasma protein A. *American Journal of Obstetrics & Gynecology* 1996;**174**(2):612-6.

Krantz 2005 {published data only}

Krantz DA, Hallahan TW, Macri VJ, Macri JN. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program. *Prenatal Diagnosis* 2005;**25**(8):635-40.

Kulch 1993 {published data only}

Kulch P, Keener S, Matsumoto M, Crandall BF. Racial differences in maternal serum human chorionic gonadotropin and unconjugated oestriol levels. *Prenatal Diagnosis* 1993;**13**(3):191-5.

Lai 1998 {published data only}

Lai FM, Yeo GS. Down syndrome screening in Singapore--the effectiveness of a second trimester serum screening policy modelled on 29,360 pregnancies in KK Women's and Children's Hospital. *Singapore Medical Journal* 1998;**39**(2):69-75.

Lai 2003 {published data only}

Lai Tsung Hsuan, Chen Su Chee, Tsai Ming Song, Lee Fa Kung, Wei Chi Feng. First-trimester screening for down syndrome in singleton pregnancies achieved by intrauterine insemination. *Journal of Assisted Reproduction and Genetics* 2003;**20**(8):327-31.

Laigaard 2006a {published data only}

Laigaard J, Cuckle H, Wewer UM, Christiansen M. Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9-12 weeks' gestation. *Prenatal Diagnosis* 2006;**26**(8):689-91.

Laigaard 2006b {published data only}

Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, et al. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(10):973-9.

Lam 1997 {published data only}

Lam YH, Tang MH, Tang LC, Lee CP, Ho PK. Second-trimester maternal urinary gonadotrophin peptide screening for fetal Down syndrome in Asian women. *Prenatal Diagnosis* 1997;**17**(12):1101-6.

Lam 1998 {published data only}

Lam YH, Ghosh A, Tang MH, Tang LC, Lee CP, Sin SY, et al. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. *Prenatal Diagnosis* 1998;**18**(6):585-89.

Lam 1999a {published data only}

Lam YH, Yeung WS, Tang MH, NG EH, So WW, Ho PC. Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. *Human Reproduction* 1999;**14**(8):2120-3.

Lam 1999b {published data only}

Lam YH, Tang MH. Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women. *Prenatal Diagnosis*. 1999;**19**(5):463-7.

Lam 2000 {published data only}

Lam YH, Tang MH, Lee CP, Sin SY, Tang R, Wong HS, et al. Acceptability of serum screening as an alternative to cytogenetic diagnosis of down syndrome among women 35 years or older in Hong Kong. *Prenatal Diagnosis*. 2000;**20**(6):487-90.

Lam 2001 {published data only}

Lam YH, Tang MH. The effect of fetal gender on second-trimester maternal serum inhibin-A concentration. *Prenatal Diagnosis* 2001;**21**(8):662-4.

Lambert-Messerlian 1996 {published data only}

Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. *Journal of Medical Screening* 1996;**3**(2):58-62.

Lambert-Messerlian 1998 {published data only}

Lambert Messerlian, Luisi S, Florio P, Mazza V, Canick JA, Petraglia F. Second trimester levels of maternal serum total activin A and placental inhibin/activin alpha and β A subunit messenger ribonucleic acids in Down syndrome pregnancy. *European Journal of Endocrinology* 1998;**138**(4):425-9.

Lehavi 2005 {published data only}

Lehavi O, Aizenstein O, Evans MI, Yaron Y. 2nd-trimester maternal serum human chorionic gonadotropin and alpha-fetoprotein levels in male and female fetuses with Down syndrome. *Fetal Diagnosis & Therapy* 2005;**20**(3):235-8.

Leung 2006 {published data only}

Leung TY, Spencer K, Leung TN, Fung TY, Lau TK. Higher median levels of free β -hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population. *Fetal Diagnosis & Therapy* 2006;**21**(1):140-3.

Leymarie 1993 {published data only}

Leymarie P, Leporrier N. Maternal serum markers and prenatal screening for Down syndrome. *Archives Francaises de Pediatrie* 1993;**50**(5):455-7.

Li 1998 {published data only}

Li G, Huang X. [Clinical uses of maternal serum markers in the prenatal diagnosis] [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1998;**33**(4):252-4.

Li 1999 {published data only}

Li W, Zhou Y. [Measurement of pregnancy-associated plasma protein A in maternal peripheral blood and Down syndrome] [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1999;**34**(10):631-3.

Liao 1997 {published data only}

Liao S, Wang Y, Ye G. [AFP, uE3, β -hCG levels applied for prenatal diagnosis of Down's syndrome]. [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1997;**32**(11):655-8.

Liao 2001 {published data only}

Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. *Human Reproduction* 2001;**16**(7):1501-4.

Lim 2002 {published data only}

Lim KI, Pugash D, Dansereau J, Wilson RD. Nuchal index: a gestational age independent ultrasound marker for the detection of Down syndrome. *Prenatal Diagnosis* 2002;**22**(13):1233-7.

Lippman 1987 {published data only}

Lippman A, Evans JA. Screening for maternal serum alpha-fetoprotein: what about the low side?. *Canadian Medical Association Journal* 1987;**136**(8):801-4.

Lustig 1988 {published data only}

Lustig L, Clarke S, Cunningham G, Schonberg R, Tompkinson G. California's experience with low MS-AFP results. *American Journal of Medical Genetics* 1988;**31**(1):211-22.

MacDonald 1991 {published data only}

MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.[see comment]. *Obstetrics & Gynecology* 1991;**77**(1):63-8.

Macintosh 1994 {published data only}

Macintosh MCM, Iles R, Teisner B, Sharma K, Chard T, Grudzinkas J, et al. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks. *Prenatal Diagnosis* 1994;**14**(3):203-8.

Macintosh 1997 {published data only}

Macintosh MCM, Nicolaides KH, Noble P, Chard T, Gunn L, Iles R. Urinary β -core hCG: Screening for aneuploidies in early pregnancy (11-14 weeks' gestation). *Prenatal Diagnosis* 1997;**17**(5):401-5.

Macri 1994 {published data only}

Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: free β -protein is a more effective marker than human chorionic gonadotropin. [see comment]. *American Journal of Obstetrics & Gynecology* 1990;**163**(4):1248-53.

Macri JN, Spencer K, Garver K, Buchanan PD, Say B, Carpenter NJ, Muller F, Boue A. Maternal serum free β hCG screening: results of studies including 480 cases of Down syndrome.[see comment]. *Prenatal Diagnosis* 1994;**14**(2):97-103.

Spencer K, Macri JN. Early detection of Down's syndrome using free β human choriogonadotropin. *Annals of Clinical Biochemistry* 1992;**19**(3):349-50.

Macri 1996 {published data only}

Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan PD. Prenatal maternal dried blood screening with alpha-fetoprotein and free β -human chorionic gonadotropin for open neural tube defect and Down syndrome. *American Journal of Obstetrics & Gynecology* 1996;**174**(2):566-72.

Malone 1998 {published data only}

Malone FD, D'Alton ME. Ultrasound clinics. Fetal nuchal fold translucency screening. *Contemporary OB/GYN* 1998;**43**(3):117-8.

Malone 2003 {published data only}

Malone FD, D'Alton ME. First-trimester sonographic screening for Down syndrome. *Obstetrics and Gynecology* 2003;**102**(5):1066-79.

Mangione 2001 {published data only}

Mangione R, Guyon F, Taine L, Wen ZQ, Roux D, Vergnaud A, et al. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. *Fetal Diagnosis & Therapy* 2001;**16**(6):360-3.

Maymon 2001a {published data only}

Maymon R, Shulman A. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. *Human Reproduction* 2001;**16**(4):691-5.

Maymon 2001b {published data only}

Maymon R, Dreazen E, Buckovsky I, Weinraub Z, Herman A. Does a 'notched' nuchal translucency indicate Down syndrome fetuses or other adverse pregnancy outcome?. *Prenatal Diagnosis* 2001;**21**(5):403-8.

Maymon 2002 {published data only}

Maymon R, Shulman A. Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. *Human Reproduction* 2002;**17**(4):1081-5.

Maymon 2004 {published data only}

Maymon R, Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies. *Prenatal Diagnosis* 2004;**24**(2):125-9.

Maymon 2005 {published data only}

Maymon R, Cuckle H, Jones R, Reish O, Sharony R, Herman A. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: A new concept in Down syndrome screening. *Prenatal Diagnosis* 2005;**25**(12):1102-6.

McDuffie 1996 {published data only}

McDuffie Jr, Haverkamp AD, Stark CF, Haverkamp C, Barth CK. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: Two-year experience in a health maintenance organization. *Journal of Maternal-Fetal Medicine* 1996;**5**(2):70-3.

Meier 2002 {published data only}

Meier C, Huang T, Wyatt PR, Summers AM. Accuracy of expected risk of Down syndrome using the second-trimester triple test. *Clinical Chemistry* 2002;**48**(4):653-5.

Merkatz 1984 {published data only}

Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. *American Journal of Obstetrics & Gynecology* 1984;**148**(7):886-94.

Merz 2005 {published data only}

Merz E. The fetal nasal bone in the first trimester - Precise assessment using 3D sonography. *Ultraschall in der Medizin* 2005;**26**(5):365-6.

Metzenbauer 2001 {published data only}

Metzenbauer M, Hafner E, Hoefinger D, Schuchter K, Stangl G, Ogris E, Philipp K. Three-dimensional ultrasound measurement of the placental volume in early pregnancy: method and correlation with biochemical placenta parameters. *Placenta* 2001;**22**(6):602-5.

Metzenbauer 2002 {published data only}

Metzenbauer M, Hafner E, Schuchter K, Philipp K. First-trimester placental volume as a marker for chromosomal anomalies:

preliminary results from an unselected population. *Ultrasound in Obstetrics & Gynecology* 2002;**19**(3):240-2.

Mikic 1999 {published data only}

Mikic TS, Johnson P. Second trimester maternal serum β human chorionic gonadotrophin and pregnancy outcome. *British Journal of Obstetrics & Gynaecology* 1999;**106**(6):598-600.

Miller 1991 {published data only}

Miller CH, O'Brien TJ, Chatelain S, Butler BB, Quirk JG. Alteration in age-specific risks for chromosomal trisomy by maternal serum alpha-fetoprotein and human chorionic gonadotropin screening. *Prenatal Diagnosis* 1991;**11**(3):153-8.

Milunsky 1989 {published data only}

Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung Y-K, Jick H, et al. Predictive values relative risks and overall benefits of high and low maternal serum alpha fetoprotein screening in singleton pregnancies - new epidemiological data. *American Journal of Obstetrics and Gynecology* 1989;**161**(2):291-7.

Milunsky 1996 {published data only}

Milunsky A, Nebiolo L. Maternal serum triple analyte screening and adverse pregnancy outcome. *Fetal Diagnosis & Therapy* 1996;**11**(4):249-53.

Minobe 2002 {published data only}

Minobe S. [A study on the screening of prenatal trisomy 21 using the fucosylated alpha-fetoprotein ratio measured by a liquid-phase binding assay]. [Japanese]. *Hokkaido Igaku Zasshi - Hokkaido Journal of Medical Science* 2002;**77**(6):527-32.

Miyamura 1999 {published data only}

Miyamura T, Saito N, Touno A, Nagata S, Hidaki T, Ishimaru T, et al. Multicenter study for maternal serum triple markers to establish Japanese standards: Maternal serum marker study group, Japan Association of Prenatal Diagnostics. *Acta Obstetrica et Gynaecologica Japonica* 1999;**51**(11):1042-8.

Moghadam 1998 {published data only}

Moghadam S, Engel W, Bougoussa M, Hennen G, Igout A, Sancken U. Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21. *Fetal Diagnosis & Therapy* 1998;**13**(5):291-7.

Monni 2000 {published data only}

Monni G, Zoppi MA, Ibba RM, Putzolu M, Floris M. Nuchal translucency in multiple pregnancies. *Croatian Medical Journal* 2000;**41**(3):266-9.

Monni 2002 {published data only}

Monni G, Zoppi MA. New ultrasonographic markers of aneuploidies: Nasal bones. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(4):229-34.

Mooney 1994 {published data only}

Mooney RA, Peterson J, French CA, Saller Jr, Arvan DA. Effectiveness of combining maternal serum alpha-fetoprotein

and hCG in a second-trimester screening program for Down syndrome. *Obstetrics and Gynecology* 1994;**84**(2):298-303.

Muller 1994 {published data only}

Muller F, Bussieres L, Pelissier MC, Oury JF, Boue C, Uzan S, et al. Do racial differences exist in second-trimester maternal hCG levels? A study of 23,369 women. *Prenatal Diagnosis* 1994;**14**(7):633-6.

Muller 1996b {published data only}

Muller F, Dommergues M, Bussieres L, Aegerter P, Le Fiblec B, Uzan S, et al. Prenatal screening for Down syndrome: should first trimester ultrasound replace maternal serum screening?. *Early Human Development* 1996;**47** Suppl:S37-S39.

Muller 1999 {published data only}

Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D. Maternal serum s100b protein is ineffective for Down syndrome screening. *Prenatal Diagnosis*. 1999;**19**(11):1086.

Muller 2002a {published data only}

Muller F, Dreux S, Oury JF, Luton D, Uzan S, Uzan M, et al. Down syndrome maternal serum marker screening after 18 weeks' gestation. *Prenatal Diagnosis* 2002;**22**(11):1001-4.

Muller 2002b {published data only}

Muller F, Forestier F, Dineon B, for the ABA Study Group. Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854,902 women. *Prenatal Diagnosis* 2002;**22**(10):925-9.

Muller 2003 {published data only}

Muller F, Dreux S, Lemeur A, Sault C, Desgres J, Bernard MA, et al. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. *Prenatal Diagnosis* 2003;**23**(13):1073-6.

Murta 2002 {published data only}

Murta CG, Moron AF, Avila MA, Weiner CP. Application of ductus venosus Doppler velocimetry for the detection of fetal aneuploidy in the first trimester of pregnancy. *Fetal Diagnosis & Therapy* 2002;**17**(5):308-14.

Musone 2000 {published data only}

Musone R, Bonafiglia R, Menditto A, Paccone M, Cassese E, Russo G, et al. Fetuses with cystic hygroma. A retrospective study. *Panminerva Medica* 2000;**42**(1):39-43.

Musto 1986 {published data only}

Musto JD, Pizzolante JM, Chesaron VP, Sassi AM, Sane R. Alpha-fetoprotein: an enhanced-sensitivity assay for neural tube defect and Down syndrome evaluation. *Clinical Chemistry* 1986;**32**(7):1412.

Myrick 1990 {published data only}

Myrick JE, Caudill SP, Hubert IL, Robinson MK, Adams MJ Jr, Pueschel SM. Identification of haptoglobin alpha-2FF variants in mid-trimester maternal serum as potential markers for Down syndrome. *Applied & Theoretical Electrophoresis* 1990;**1**(5):233-41.

Neveux 1996a {published data only}

Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. *Prenatal Diagnosis* 1996;**16**(12):1115-9.

Neveux 1996b {published data only}

Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. *Prenatal Diagnosis* 1996;**16**(1):29-34.

Ng 2004 {published data only}

Ng EK, El-Sheikhah A, Chiu RW, Chan KC, Hogg M, Bindra R, et al. Evaluation of human chorionic gonadotropin β -subunit mRNA concentrations in maternal serum in aneuploid pregnancies: a feasibility study. *Clinical Chemistry* 2004;**50**(6):1055-7.

Nicolaides 1992 {published data only}

Nicolaides KH, ZAR G, Snijders RJM, Gosden CM. Fetal nuchal oedema associated malformations and chromosomal defects. *Fetal Diagnosis and Therapy* 1992;**7**(2):123-31.

Nicolaides 2000 {published data only}

Nicolaides KH, Cicero S, Liao AW. One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation. *Prenatal and Neonatal Medicine* 2000;**5**(3):145-54.

Nicolaides 2004 {published data only}

Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. *American Journal of Obstetrics and Gynecology* 2004;**191**(1):45-67.

Nicolaides 2005a {published data only}

Nicolaides KH, Wegrzyn P. [First trimester diagnosis of chromosomal defects][Polish]. *Ginekologia Polska*. 76(1):1-8, 2005;**76**(1):1-8.

Nicolaides 2005b {published data only}

Nicolaides KH, Wegrzyn P. [Sonographic features of chromosomal defects at 11(+0) to 13(+6) weeks of gestation] [Polish]. *Ginekologia Polska* 2005;**76**(6):423-30.

Nicolaides 2005c {published data only}

Nicolaides KH, Wegrzyn P. [Increased nuchal translucency with normal karyotype]. [Polish]. *Ginekologia Polska* 2005;**76**(8):593-601.

Nicolaides 2005d {published data only}

Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency]. [Polish]. *Ginekologia Polska* 2005;**76**(3):179-86.

Nicolaides 2005e {published data only}

Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency thickness and risk for chromosomal defects]. [Polish]. *Ginekologia Polska*. 76(4):257-63, 2005;**76**(4):257-63.

Nicolaides 2005f {published data only}

Nicolaides Kypros H. First-trimester screening for chromosomal abnormalities. *Seminars in Perinatology (Philadelphia)* 2005;**29**(4):190-4.

Niemimaa 2001 {published data only}

Niemimaa M, Heinonen S, Seppala M, Hippelainen M, Martikainen H, Ryynanen M. First-trimester screening for Down's syndrome in in vitro fertilization pregnancies. *Fertility & Sterility* 2001;**76**(6):1282-3.

Niemimaa 2002 {published data only}

Niemimaa M, Suonpaa M, Heinonen S, Seppala M, Bloigu R, Ryynanen M. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A in twin pregnancies in the first trimester. *Prenatal Diagnosis* 2002;**22**(3):183-5.

Niemimaa 2003 {published data only}

Niemimaa M, Heinonen S, Seppala M, Ryynanen M. The influence of smoking on the pregnancy-associated plasma protein A, free β human chorionic gonadotrophin and nuchal translucency. *BJOG* 2003;**110**(7):664-7.

Noble 1997 {published data only}

Noble PL, Snijders RJ, Abrahams HD, Sherwood RA, Nicolaides KH. Maternal serum free β -hCG at 10 to 14 weeks of gestation in trisomic twin pregnancies. *British Journal of Obstetrics & Gynaecology* 1997;**104**(6):741-3.

Norgaard 1990 {published data only}

Norgaard Pedersen, Larsen SO, Arends J, Svenstrup B, Tabor A. Maternal serum markers in screening for Down syndrome. *Clinical Genetics* 1990;**37**(1):35-43.

Norton 1992 {published data only}

Norton ME, Golbus MS. Maternal serum CA 125 for aneuploidy detection in early pregnancy. *Prenatal Diagnosis* 1992;**12**(9):779-81.

O'Brien 1997a {published data only}

Brien JE, Dvorin E, Yaron Y, Ayoub M, Johnson MP, Hume RF Jr, et al. Differential increases in AFP, hCG, and uE3 in twin pregnancies: Impact on attempts to quantify Down syndrome screening calculations. *American Journal of Medical Genetics* 1997;**73**(2):109-12.

O'Brien 1997b {published data only}

Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-marker biochemical screening: Alpha-fetoprotein, hCG, and estriol. *Obstetrics and Gynecology* 1997;**89**(3):355-8.

Odibo 2004 {published data only}

Odibo AO, Sehdev HM, Dunn L, McDonald R, Macones GA. The association between fetal nasal bone hypoplasia and aneuploidy. *Obstetrics & Gynecology* 2004;**104**(6):1229-33.

Ognibene 1999 {published data only}

Ognibene A, Ciuti R, Tozzi P, Messeri G. Maternal serum superoxide dismutase (SOD): a possible marker for screening Down syndrome affected pregnancies.[see comment]. *Prenatal Diagnosis*. 1999;**19**(11):1058-60.

Olajide 1989 {published data only}

Olajide F, Kitau MJ, Chard T. Maternal serum AFP levels in the first trimester of pregnancy. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 1989;**30**(2):123-8.

Onda 1996 {published data only}

Onda T, Kitagawa M, Takeda O, Sago H, Kubonoya K, Iinuma K, et al. Triple marker screening in native Japanese women. *Prenatal Diagnosis* 1996;**16**(8):713-7.

Onda 1998 {published data only}

Onda T, Tanaka T, Takeda O, Kitagawa M, Kuwabara Y, Yamamoto H, et al. Agreement between predicted risk and prevalence of Down syndrome in second-trimester triple-marker screening in Japan. *Prenatal Diagnosis* 1998;**18**(9):956-8.

Onda 2000 {published data only}

Onda T, Tanaka T, Yoshida K, Nakamura Y, Kudo R, Yamamoto H, et al. Triple marker screening for trisomy 21, trisomy 18 and open neural tube defects in singleton pregnancies of native Japanese pregnant women. *Journal of Obstetrics & Gynaecology Research* 2000;**26**(6):441-7.

Orlandi 2002 {published data only}

Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T, Orlandi E, et al. First trimester screening with free β -hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. *Prenatal Diagnosis* 2002;**22**(8):718-21.

Páez 2004 {published data only}

Páez L, Peña E, González F, Bello F, Bellorín J, Espinoza F, et al. Plasma protein "A" and chorionic gonadotropin at first trimester pregnancy. *Informe Medico* 2004;**6**(2):99-109.

Palka 1998 {published data only}

Palka G, Guanciali Franchi P, Papponetti M, Marcuccitti J, Morizio E, Calabrese G, et al. Prenatal diagnosis using the triple test. *Minerva Ginecologica* 1998;**50**(10):411-5.

Palomaki 1989 {published data only}

Palomaki GE, Williams J, Haddow JE. Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. *American Journal of Obstetrics and Gynecology* 1989;**160**(3):575-81.

Palomaki 1993 {published data only}

Palomaki GE, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: Impact on Down syndrome screening. *Obstetrics and Gynecology* 1993;**81**(5):675-8.

Palomaki 1994 {published data only}

Palomaki GE, Knight GJ, Haddow JE. Human chorionic gonadotropin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. *Prenatal Diagnosis* 1994;**14**(1):65-8.

Palomaki 1996 {published data only}

Palomaki GE, Neveux LM, Haddow JE. Can reliable Down's syndrome detection rates be determined from prenatal

screening intervention trials?. *Journal of Medical Screening* 1996;**3**(1):12-7.

Palomaki 2005 {published data only}

Palomaki GE, Knight GJ, Neveux LM, Pandian R, Haddow JE. Maternal serum invasive trophoblast antigen and first-trimester Down syndrome screening. *Clinical Chemistry* 2005;**51**(8):1499-504.

Panburana 2001 {published data only}

Panburana P, Ajjimakorn S, Tungkajiwangoon P. First trimester Down Syndrome screening by nuchal translucency in a Thai population. *International Journal of Gynaecology & Obstetrics* 2001;**75**(3):311-2.

Pandya 1994 {published data only}

Pandya PP, Brizot ML, Kuhn P, Snijders RJ, Nicolaides KH. First-trimester fetal nuchal translucency thickness and risk for trisomies. *Obstetrics & Gynecology* 1994;**84**(3):420-3.

Pandya 1995 {published data only}

Pandya PP, Santiago C, Snijders RJM, Nicolaides KH. First trimester fetal nuchal translucency. *Current Opinion in Obstetrics and Gynecology* 1995;**7**(2):95-102.

Paul 2001 {published data only}

Paul C, Krampl E, Skentou C, Jurkovic D, Nicolaides KH. Measurement of fetal nuchal translucency thickness by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(5):481-4.

Peralta 2005 {published data only}

Peralta CF, Falcon O, Wegrzyn P, Faro C, Nicolaides KH. Assessment of the gap between the fetal nasal bones at 11 to 13 + 6 weeks of gestation by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(5):464-7.

Perenc 1998 {published data only}

Perenc M, Dudarewicz L, Kaluzewski B. Analysis of triple test results in 27 cases of twin pregnancies. *Acta Geneticae Medicae et Gemellologiae* 1998;**47**(3-4):249-54.

Perheentupa 2002 {published data only}

Perheentupa A, Ruokonen A, Tuomivaara L, Ryyänen M, Martikainen H. Maternal serum (β)-HCG and (alpha)-fetoprotein concentrations in singleton pregnancies following assisted reproduction. *Human Reproduction* 2002;**17**(3):794-7.

Perona 1998 {published data only}

Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A. Influence of smoking habits on Down's syndrome risk evaluation at mid-trimester through biochemical screening. *International Journal of Clinical & Laboratory Research* 1998;**28**(3):179-82.

Petervari 2000 {published data only}

Petervari L, Varga A, Tanko A, Szabo L, Godo G. [Significance of nuchal edema in fetuses of pregnant women under 35 years of age]. [Hungarian]. *Orvosi Hetilap* 2000;**141**(8):399-402.

Petrocic 1989 {published data only}

Petrocic E, Wassman ER, Kelly JC. Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels.[see comment]. *American Journal of Obstetrics & Gynecology* 1989;**161**(5):1168-73.

Phillips 1992 {published data only}

Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. *Obstetrics & Gynecology* 1992;**80**(3):353-8.

Phillips 1993 {published data only}

Phillips OP, Shulman LP, Elias S, Simpson JL. Maternal serum screening for fetal Down syndrome using alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol in adolescents. *Adolescent and Pediatric Gynecology* 1993;**6**(2):91-4.

Pinette 2003 {published data only}

Pinette MG, Egan JF, Wax JR, Blackstone J, Cartin A, Benn PA. Combined sonographic and biochemical markers for Down syndrome screening. *Journal of Ultrasound in Medicine* 2003;**22**(11):1185-90.

Platt 2004 {published data only}

Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. *Obstetrics and Gynecology* 2004;**104**(4):661-6.

Podobnik 1995 {published data only}

Podobnik M, Singer Z, Podobnik Sarkanji, Bulic M. First trimester diagnosis of cystic hygromata using transvaginal ultrasound and cytogenetic evaluation. *Journal of Perinatal Medicine* 1995;**23**(4):283-91.

Prefumo 2002 {published data only}

Prefumo F, Thilaganathan B. Agreement between predicted risk and prevalence of Down syndrome in first trimester nuchal translucency screening. *Prenatal Diagnosis* 2002;**22**(10):917-8.

Prefumo 2004 {published data only}

Prefumo F, Sairam S, Bhide A, Penna L, Hollis B, Thilaganathan B. Maternal ethnic origin and fetal nasal bones at 11-14 weeks of gestation. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004;**111**(2):109-12.

Price 1998 {published data only}

Price KM, Van Lith JM, Silman R, Mantingh A, Grudzinskas JG. First trimester maternal serum concentrations of fetal antigen 2 in normal pregnancies and those affected by trisomy 21. *Human Reproduction* 1998;**13**(6):1706-8.

Raty 2000 {published data only}

Raty R, Virtanen A, Koskinen P, Laitinen P, Forsstrom J, Salonen R, et al. Maternal midtrimester serum AFP and free β -hCG levels in in vitro fertilization twin pregnancies. *Prenatal Diagnosis* 2000;**20**(3):221-3.

Räty 2002 {published data only}

Räty R, Virtanen A, Koskinen P, Anttila L, Forsström J, Laitinen P, et al. Serum free (β)-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. *Human Reproduction* 2002;**17**(2):481-4.

Rembouskos 2004 {published data only}

Rembouskos G, Cicero S, Longo D, Vandecruys H, Nicolaides KH. Assessment of the fetal nasal bone at 11-14 weeks of gestation by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2004;**23**(3):232-6.

Ren 1992 {published data only}

Ren S-G, Braunstein GD. Human chorionic gonadotropin. *Seminars in Reproductive Endocrinology* 1992;**10**(2):95-105.

Renier 1998 {published data only}

Renier MA, Vereecken A, Van Herck E, Straetmans D, Ramaekers P, Buytaert P. Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome. *Human Reproduction* 1998;**13**(3):744-8.

Resta 1990 {published data only}

Resta RG, Nyberg D. The role of ultrasound in screening for Down syndrome. *Birth Defects: Original Article Series* 1990;**26**(3):104.

Reynders 1997 {published data only}

Reynders CS, Pauker SP, Benacerraf BR. First trimester isolated fetal nuchal lucency: significance and outcome. *Journal of Ultrasound in Medicine* 1997;**16**(2):101-5.

Reynolds 1989 {published data only}

Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. *Annals of Clinical Biochemistry* 1989;**27**(5):452-8.

Reynolds 1999 {published data only}

Reynolds TM, Schaeffer HJ, Schlensker S. Estimation of Down's syndrome risks in the first trimester of pregnancy: Experience of testing with PAPP-A, total hCG and free β -hCG levels in maternal blood samples in a German population. *Clinical Laboratory* 1999;**45**(1-2):49-53.

Ribbert 1996 {published data only}

Ribbert LS, Kornman LH, de Wolf BT, Simons AH, Jansen CA, Beekhuis JR, Mantingh A. Maternal serum screening for fetal Down syndrome in IVF pregnancies. *Prenatal Diagnosis* 1996;**16**(1):35-8.

Rice 2005 {published data only}

Rice JD, McIntosh SF, Halstead AC. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. *Prenatal Diagnosis* 2005;**25**(3):234-8.

Rich 1991 {published data only}

Rich N, Boots L, Davis R, Finley S. Efficiency of maternal serum hCG AFP and free estriol in the identification of trisomy 21 and

other complications of pregnancy. *Journal of the Alabama Academy of Science* 1991;**62**(2-3):135.

Roberts 1995 {published data only}

Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester fetal nuchal translucency: problems with screening the general population. 1. *British Journal of Obstetrics & Gynaecology* 1995;**102**(5):381-5.

Robertson 1991 {published data only}

Robertson EF. Maternal serum screening for neural tube defects and Down's syndrome.[see comment]. *Medical Journal of Australia* 1991;**155**(2):67-8.

Rode 2003 {published data only}

Rode L, Wojdemann KR, Shalmi AC, Larsen SO, Sundberg K, Norgaard-Pedersen B, et al. Combined first- and second-trimester screening for Down syndrome: an evaluation of proMBP as a marker. *Prenatal Diagnosis* 2003;**23**(7):593-8.

Ronge 2006 {published data only}

Ronge R. Combined first trimester screening for Down's syndrome is superior to quadruple test. *Geburtshilfe und Frauenheilkunde* 2006;**66**(4):332.

Rose 1995 {published data only}

Rose NC, Mennuti MT. Multiple marker screening for women 35 and older. *Contemporary OB/GYN* 1995;**40**(9):55-6.

Ross 1997 {published data only}

Ross HL, Elias S. Maternal serum screening for fetal genetic disorders. *Obstetrics & Gynecology Clinics of North America* 1997;**24**(1):33-47.

Rotmensch 1996 {published data only}

Rotmensch S, Liberati M, Kardana A, Copel JA, Ben-Rafael Z, Cole LA. Nicked free β -subunit of human chorionic gonadotropin: A potential new marker for Down syndrome screening. *American Journal of Obstetrics and Gynecology* 1996;**174**(2):609-11.

Rotmensch 1999 {published data only}

Rotmensch S, Celentano C, Shalev J, Vishne TH, Lipitz S, Ben-Rafael Z, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. *Journal of Assisted Reproduction and Genetics* 1999;**16**(1):8-12.

Rozenberg 2006 {published data only}

Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida L, Cuckle H, et al. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. *American Journal of Obstetrics & Gynecology* 2006;**195**(5):1379-87.

Rudnicka 2002 {published data only}

Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. *Prenatal Diagnosis* 2002;**22**(10):893-7.

Ryall 1992 {published data only}

Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses. *Prenatal Diagnosis* 1992;**12**(4):251-61.

Ryall 2001 {published data only}

Ryall RG, Callen D, Cocciolone R, Duvnjak A, Esca R, Frantzis N, et al. Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screening. *Prenatal Diagnosis* 2001;**21**(7):553-7.

Sabriá 2002 {published data only}

Sabriá J, Cabrero D, Bach C. Aneuploidy screening: Ultrasound versus biochemistry. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(4):221-8.

Sacchini 2003 {published data only}

Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G, Nicolaides KH. Ear length in trisomy 21 fetuses at 11-14 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2003;**22**(5):460-3.

Saller 1997 {published data only}

Saller DN Jr, Canick JA, Kellner LH, Rose NC, Garza J, French CA, et al. Maternal serum analyte levels in pregnancies with fetal Down syndrome resulting from translocations. *American Journal of Obstetrics & Gynecology* 1997;**177**(4):879-81.

Salomon 2001 {published data only}

Salomon LJ, Bernard JP, Taupin P, Benard C, Ville Y. Relationship between nuchal translucency at 11-14 weeks and nuchal fold at 20-24 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(6):636-7.

Salonen 1997 {published data only}

Salonen R, Turpeinen U, Kurki L, Lappalainen M, Ammala P, Hiilesmaa V, et al. Maternal serum screening for Down's syndrome on population basis. *Acta Obstetrica et Gynecologica Scandinavica* 1997;**76**(9):817-21.

Saltvedt 2005 {published data only}

Saltvedt S, Almstrom H, Kublickas M, Valentin L, Bottinga R, Bui TH, et al. Screening for Down syndrome based on maternal age or fetal nuchal translucency: a randomized controlled trial in 39,572 pregnancies. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(6):537-45.

Saridogan 1996 {published data only}

Saridogan E, Djahanbakhch O, Naftalin AA. Screening for Down's syndrome: experience in an inner city health district. *British Journal of Obstetrics & Gynaecology* 1996;**103**(12):1205-11.

Savoldelli 1993 {published data only}

Savoldelli G, Binkert F, Achermann J, Schmid W. Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy. *Prenatal Diagnosis* 1993;**13**(6):513-8.

Schiott 2006 {published data only}

Schiott KM, Christiansen M, Petersen OB, Sorensen TL, Uldbjerg N. The "Consecutive Combined Test"--using double

test from week 8 + 0 and nuchal translucency scan, for first trimester screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(12):1105-9.

Schuchter 1998 {published data only}

Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart E. The distribution of nuchal translucency at 10-13 weeks of pregnancy. *Prenatal Diagnosis* 1998;**18**(3):281-6.

Scott 1995 {published data only}

Scott F, Boogert A, Smart S, Anderson J. Maternal serum screening and routine 18-week ultrasound in the detection of all chromosomal abnormalities. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 1995;**35**(2):165-8.

Seeds 1990 {published data only}

Seeds JW, Watson WJ. Ultrasound and maternal serum alpha-fetoprotein screening: A complementary relationship. *Ultrasound Quarterly* 1990;**8**(2):145-66.

Seki 1995 {published data only}

Seki K, Mitsui C, Nagata I. Measurement of urinary free β -human chorionic gonadotropin by immunoradiometric assay. *Gynecologic and Obstetric Investigation* 1995;**40**(3):162-7.

Shenhav 2003 {published data only}

Shenhav S, Gerner O, Sherman DJ, Peled R, Segal S. Midtrimester triple-test levels in women with chronic hypertension and altered renal function. *Prenatal Diagnosis* 2003;**23**(2):166-7.

Shintaku 1989 {published data only}

Shintaku Y, Takabayashi T, Sasaki H, Ozawa N, Shinkawa O, Hamazaki Y, et al. [Screening for chromosomal anomalies with maternal serum alpha-fetoprotein]. [Japanese]. *Nippon Sanka Fujinka Gakkai Zasshi - Acta Obstetrica et Gynaecologica Japonica* 1989;**41**(2):185-90.

Shulman 2003 {published data only}

Shulman A, Maymon R. Mid-gestation Down syndrome screening test and pregnancy outcome among unstimulated assisted-conception pregnancies. *Prenatal Diagnosis* 2003;**23**(8):625-8.

Simon-Bouy 1999 {published data only}

Simon-Bouy B. [Markers for trisomy 21][French]. *Fertilite Contraception Sexuelle* 1999;**27**(9):289-91.

Simpson 1986 {published data only}

Simpson JL, Baum LD, Marder R, Elias S, Ober C, Martin AO. Maternal serum alpha-fetoprotein screening: low and high values for detection of genetic abnormalities. *American Journal of Obstetrics & Gynecology* 1986;**155**(3):593-7.

Smith 1990 {published data only}

Smith C, Grube GL, Wilson S. Maternal serum alpha-fetoprotein screening and the role of ultrasound. *Journal of Diagnostic Medical Sonography* 1990;**6**(6):312-6.

Smith 1996 {published data only}

Smith ER, Petersen J, Okorodudu AO, Bissell MG. Does the addition of unconjugated estriol in maternal serum screening improve the detection of trisomy 21? A meta-analysis. *Clinical Laboratory Management Review* 1996;**10**(2):176-81.

Smith 1999 {published data only}

Smith NC, Hau C. A six year study of the antenatal detection of fetal abnormality in six Scottish health boards. *British Journal of Obstetrics & Gynaecology* 1999;**106**(3):206-12.

Smith-Bindman 2001 {published data only}

Smith-Bindman R, Hosmer W, Feldstein VA, Deeks JJ, Goldberg JD. Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis.[see comment]. *JAMA* 2001;**285**(8):1044-55.

Smith-Bindman 2003 {published data only}

Smith-Bindman R, Chu P, Bacchetti P, Waters JJ, Mutton D, Alberman E. Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes. *American Journal of Obstetrics & Gynecology* 2003;**187**(4):980-5.

Snijders 1995 {published data only}

Snijders RJM, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risk for chromosomal defects. *Fetal Diagnosis and Therapy* 1995;**10**(6):356-67.

Snijders 1999 {published data only}

Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. *Ultrasound in Obstetrics and Gynecology* 1999;**13**(3):167-70.

Soergel 2006 {published data only}

Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany. *Fetal Diagnosis & Therapy* 2006;**21**(3):264-8.

Sokol 1998 {published data only}

Sokol AI, Kramer RL, Yaron Y, O'Brien JE, Muller F, Johnson MP, et al. Age-specific variation in aneuploidy incidence among biochemical screening programs. *American Journal of Obstetrics & Gynecology* 1998;**179**(4):971-3.

Sonek 2003 {published data only}

Sonek JD. Nasal bone evaluation with ultrasonography: A marker for fetal aneuploidy. *Ultrasound in Obstetrics and Gynecology* 2003;**22**(1):11-5.

Spencer 1985 {published data only}

Spencer K, Carpenter P. Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution. *British Medical Journal Clinical Research Education* 1985;**290**(6486):1940-3.

Spencer 1991a {published data only}

Spencer K. Evaluation of an assay of the free β -subunit of choriogonadotropin and its potential value in screening for Down's syndrome. *Clinical Chemistry* 1991;**37**(6):809-14.

Spencer 1991b {published data only}

Spencer K. Maternal serum CA125 is not a second trimester marker for Down's syndrome. *Annals of Clinical Biochemistry* 1991;**28**(3):299-300.

Spencer 1992 {published data only}

Spencer K, Coombes EJ, Mallard AS, Ward AM. Free β human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers.[see comment]. *Annals of Clinical Biochemistry* 1992;**29**(5):506-18.

Spencer 1993a {published data only}

Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free β human chorionic gonadotropin.[see comment]. *BMJ* 1993;**307**(6907):764-9.

Spencer 1993b {published data only}

Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free β -hCG subunit. *Clinical Chemistry* 1993;**39**(6):1064-8.

Spencer 1993c {published data only}

Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. *Annals of Clinical Biochemistry* 1993;**30**(Pt 2):219-20.

Spencer 1993d {published data only}

Spencer K, Macri JN, Anderson RW, Aitken DA, Berry E, Crossley JA, et al. Dual analyte immunoassay in neural tube defect and Down's syndrome screening: results of a multicentre clinical trial. *Annals of Clinical Biochemistry* 1993;**30**(4):394-401.

Spencer 1993e {published data only}

Spencer K. Free alpha-subunit of human chorionic gonadotropin in Down syndrome. *American Journal of Obstetrics and Gynecology* 1993;**168**(1):132-5.

Spencer 1995 {published data only}

Spencer K. The influence of gravidity on Down's syndrome screening with free β hCG. *Prenatal Diagnosis* 1995;**15**(1):87-9.

Spencer 1996a {published data only}

Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down's syndrome screening. *Prenatal Diagnosis* 1996;**16**(12):1101-10.

Spencer 1997 {published data only}

Spencer K, Noble P, Snijders RJ, Nicolaides KH. First-trimester urine free β hCG, β core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free β hCG. *Prenatal Diagnosis* 1997;**17**(6):525-38.

Spencer 1998a {published data only}

Spencer K. The influence of smoking on maternal serum AFP and free β hCG levels and the impact on screening for Down syndrome. *Prenatal Diagnosis* 1998;**18**(3):225-34.

Spencer 1998b {published data only}

Spencer K, Carpenter P. Is prostate-specific antigen a marker for pregnancies affected by Down syndrome?. *Clinical Chemistry* 1998;**44**(11):2362-5.

Spencer 1999a {published data only}

Spencer K. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free β hCG: a seven year review. *British Journal of Obstetrics & Gynaecology* 1999;**106**(12):1287-93.

Spencer 1999b {published data only}

Spencer K. Accuracy of Down's syndrome risks produced in a prenatal screening program. *Annals of Clinical Biochemistry* 1999;**36**(1):101-3.

Spencer 2000a {published data only}

Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides KH. Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?. *Prenatal Diagnosis*. 2000;**20**(4):311-7.

Spencer 2000b {published data only}

Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free β -hCG and PAPP-A, combined with fetal nuchal translucency thickness. *Prenatal Diagnosis*. 2000;**20**(2):91-5.

Spencer 2000c {published data only}

Spencer K. The influence of smoking on maternal serum PAPP-A and free β hCG levels in the first trimester of pregnancy. *Prenatal Diagnosis*. 1999;**19**(11):1065-6.

Spencer 2000d {published data only}

Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. *Prenatal Diagnosis* 2000;**20**(10):792-4.

Spencer 2000e {published data only}

Spencer K. The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free β -hCG. *Prenatal Diagnosis* 2000;**20**(8):648-51.

Spencer 2000f {published data only}

Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. *Prenatal Diagnosis* 2000;**20**(6):491-4.

Spencer 2000g {published data only}

Spencer K, Tul N, Nicolaides KH. Maternal serum free β -hCG and PAPP-A in fetal sex chromosome defects in the first trimester. *Prenatal Diagnosis*. 2000;**20**(5):390-4.

Spencer 2000h {published data only}

Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. *Prenatal Diagnosis*. 2000;**20**(8):652-6.

Spencer 2000i {published data only}

Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free β -hCG and PAPP-A at 10-14 weeks of gestation. *Prenatal Diagnosis*. 2000;**20**(8):673-5.

Spencer 2001 {published data only}

Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free β hCG and PAPP-A. *BJOG: An International Journal of Obstetrics & Gynaecology* 2001;**108**(10):1043-6.

Spencer 2001a {published data only}

Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. First trimester maternal serum placenta growth factor (PIGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18. *Prenatal Diagnosis* 2001;**21**(9):718-22.

Spencer 2001b {published data only}

Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. Maternal serum levels of dimeric Inhibin A in pregnancies affected by trisomy 21 in the first trimester. *Prenatal Diagnosis* 2001;**21**(6):441-4.

Spencer 2001c {published data only}

Spencer K, Liao AW, Skentou H, Ong CY, Nicolaides KH. Maternal serum levels of total activin-A in first-trimester trisomy 21 pregnancies. *Prenatal Diagnosis* 2001;**21**(4):270-3.

Spencer 2001d {published data only}

Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free β -hCG or PAPP-A levels?. *Prenatal Diagnosis* 2001;**21**(9):715-7.

Spencer 2002a {published data only}

Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β -hCG and PAPP-A. *Prenatal Diagnosis* 2002;**22**(10):877-9.

Spencer 2002b {published data only}

Spencer K. Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. *Prenatal Diagnosis* 2002;**22**(3):244-6.

Spencer 2002c {published data only}

Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?. *Prenatal Diagnosis* 2002;**22**(10):903-6.

Spencer 2002d {published data only}

Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. *Annals of Clinical Biochemistry* 2002;**39**(6):567-76.

Spencer 2003a {published data only}

Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical

markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. *Annals of Clinical Biochemistry* 2003;**40**(3):219-31.

Spencer 2003b {published data only}

Spencer K. The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system. *Annals of Clinical Biochemistry* 2003;**40**(2):166-8.

Spencer 2003c {published data only}

Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free β -hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. *Prenatal Diagnosis* 2003;**23**(10):851-5.

Spencer 2003d {published data only}

Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. *BJOG: An International Journal of Obstetrics & Gynaecology* 2003;**110**(3):279-80.

Spencer 2004 {published data only}

Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. *Prenatal Diagnosis* 2004;**24**(3):169-73.

Spencer 2005a {published data only}

Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. *Prenatal Diagnosis* 2005;**25**(10):927-9.

Spencer 2005b {published data only}

Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. *Prenatal Diagnosis* 2005;**25**(5):365-9.

Spencer 2005c {published data only}

Spencer K. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free β -hCG and pregnancy-associated plasma protein-A assays.[see comment]. *Annals of Clinical Biochemistry* 2005;**42**(1):30-40.

Spong 1999 {published data only}

Spong CY, Ghidini A, Stanley-Christian H, Meck JM, Seydel FD, Pezzullo JC. Risk of abnormal triple screen for Down syndrome is significantly higher in women with female fetuses. *Prenatal Diagnosis*. 1999;**19**(4):337-9.

Stevens 1998 {published data only}

Stevens SL. The use of nuchal lucency as a screening tool in first trimester sonography. *Journal of Diagnostic Medical Sonography* 1998;**14**(6):251-4.

Stoll 1992 {published data only}

Stoll C. A new approach of prenatal prevention of constitutional disabilities - the study of markers of maternal serum. *Journal de Medecine de Strasbourg* 1992;**23**(1):25-7.

Su 2002a {published data only}

Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ. Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome. *Prenatal Diagnosis* 2002;**22**(1):8-12.

Suchet 1995 {published data only}

Suchet IB. Ultrasonography of the fetal neck in the first and second trimesters. Part 2. Anomalies of the posterior nuchal region. *Canadian Association of Radiologists Journal* 1995;**46**(5):344-52.

Suchy 1990 {published data only}

Suchy SF, Yeager MT. Down syndrome screening in women under 35 with maternal serum hCG. *Obstetrics & Gynecology* 1990;**76**(1):20-4.

Summers 2003a {published data only}

Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR. Maternal serum screening in Ontario using the triple marker test. *Journal of Medical Screening* 2003;**10**(3):107-11.

Summers 2003b {published data only}

Summers AM, Huang T, Meier C, Wyatt PR. The implications of a false positive second-trimester serum screen for Down syndrome. *Obstetrics & Gynecology* 2003;**101**(6):1301-6.

Suntharasaj 2005 {published data only}

Suntharasaj T, Ratanasiri T, Chanprapaph P, Kengpol C, Kor-anantakul O, Leetanaporn R, et al. Variability of nuchal translucency measurement: a multicenter study in Thailand. *Gynecologic & Obstetric Investigation* 2005;**60**(4):201-5.

Sutton 2004 {published data only}

Sutton JM, Cole LA. Sialic acid-deficient invasive trophoblast antigen (sd-ITA): a new urinary variant for gestational Down syndrome screening. *Prenatal Diagnosis* 2004;**24**(3):194-7.

Suzuki 1998 {published data only}

Suzuki Y, Takada J, Iwaki T, Isaka K, Takayama M. Screening for trisomy 21 in the first trimester by measurement of serum PAPP-A and free β -hCG. *Acta Obstetrica et Gynaecologica Japonica* 1998;**50**(1):37-40.

Tabor 1987 {published data only}

Tabor A, Larsen SO, Nielsen J, Nielsen J, Philip J, Pilgaard B, et al. Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level. *British Journal of Obstetrics & Gynaecology* 1987;**94**(7):636-42.

Tanski 1999 {published data only}

Tanski S, Rosengren SS, Benn PA. Predictive value of the triple screening test for the phenotype of Down syndrome. *American Journal of Medical Genetics* 1999;**85**(2):123-6.

Thilaganathan 1998 {published data only}

Thilaganathan B, Khare M, Williams B, Wathen NC. Influence of ethnic origin on nuchal translucency screening for Down's syndrome. *Ultrasound in Obstetrics & Gynecology* 1998;**12**(2):112-4.

Thilaganathan 1999 {published data only}

Thilaganathan B. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: A happy union?. *Ultrasound in Obstetrics and Gynecology* 1999;**13**(4):229-30.

Tislaric 2002 {published data only}

Tislaric D, Brajenovic-Milic B, Ristic S, Latin V, Zuvic-Butorac M, Bacic J, et al. The influence of smoking and parity on serum markers for Down's syndrome screening. *Fetal Diagnosis & Therapy* 2002;**17**(1):17-21.

Torok 1997 {published data only}

Torok O, Veress L, Szabo M, Zsupan I, Buczko Z, Bolodar A, et al. [Biochemical and ultrasonic screening of chromosomal aneuploidies in the second trimester of pregnancy]. [Hungarian]. *Orvosi Hetilap* 1997;**138**(3):123-7.

Tsai 2001 {published data only}

Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK. Combined measurement of fetal nuchal translucency, maternal serum free β -hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. *Journal of the Formosan Medical Association* 2001;**100**(5):319-25.

Valerio 1996 {published data only}

Valerio D, Aiello R, Altieri V, Fagnoni P. Maternal serum screening of fetal chromosomal abnormalities by AFP, UE3, hCG and free- β hCG. Prospective and retrospective results. *Minerva Ginecologica* 1996;**48**(5):169-73.

Van Blerk 1992 {published data only}

Van Blerk M, Smitz J, De Catte L, Kumps C, Van der Elst J, Van Steirteghem AC. Second-trimester cancer antigen 125 and Down's syndrome.[see comment]. *Prenatal Diagnosis* 1992;**12**(12):1062-6.

Van Heesch, 2006 {published data only}

Van Heesch, Schielen PCJ I, Wildhagen MF, Den Hollander, Steegers EAP, Wildschut HIJ. Combined first trimester screening for trisomy 21: Lack of agreement between risk calculation methods. *Journal of Perinatal Medicine* 2006;**34**(2):162-5.

Van Lith 1991 {published data only}

Van Lith JM, Mantingh A, Beekhuis JR, De Bruijn HW, Breed AS. First trimester CA 125 and Down's syndrome. *British Journal of Obstetrics & Gynaecology* 1991;**98**(5):493-4.

Van Lith 1993 {published data only}

Van Lith, Mantingh A, De Bruijn. Maternal serum CA 125 levels in pregnancies with chromosomally-normal and -abnormal fetuses. Dutch Working Party on Prenatal Diagnosis. *Prenatal Diagnosis* 1993;**13**(12):1123-31.

Van Lith 1994 {published data only}

Van Lith, Mantingh A, Pratt JJ. First-trimester maternal serum immunoreactive inhibin in chromosomally normal and abnormal pregnancies. Dutch Working Party on Prenatal Diagnosis. *Obstetrics and Gynecology* 1994;**83**(5 Pt 1):661-4.

Veress 1986 {published data only}

Veress L, Szabo M, Horvath K, Polgar K, Papp Z. [Low maternal serum alpha-fetoprotein concentration and Down syndrome]. [Hungarian]. *Orvosi Hetilap* 1986;**127**(20):1232-3.

Veress 1988 {published data only}

Veress L, Szabo M, Polgar K, Takacs L, Papp Z. [Prenatal screening for Down's syndrome by measuring the AFP concentration in the maternal serum]. [Hungarian]. *Orvosi Hetilap* 1988;**129**(31):1677.

Vintzileos 2003 {published data only}

Vintzileos A, Walters C, Yeo L. Absent nasal bone in the prenatal detection of fetuses with trisomy 21 in a high-risk population. *Obstetrics & Gynecology* 2003;**101**(5):905-8.

Wald 1988a {published data only}

Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. *BMJ* 1988;**297**(6653):883-7.

Wald 1988b {published data only}

Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. *British Journal of Obstetrics & Gynaecology* 1988;**95**(4):334-41.

Wald 1991 {published data only}

Wald N, Cuckle H, Wu TS, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. *British Journal of Obstetrics & Gynaecology* 1991;**98**(9):905-8.

Wald 1992a {published data only}

Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.[see comment]. *BMJ* 1992;**305**(6850):391-4.

Wald 1992b {published data only}

Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. *British Journal of Obstetrics & Gynaecology* 1992;**99**(1):51-3.

Wald 1992c {published data only}

Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.[see comment]. *British Journal of Obstetrics & Gynaecology* 1992;**99**(2):144-9.

Wald 1993 {published data only}

Wald N, Densem J, Stone R, Cheng R. The use of free β -hCG in antenatal screening for Down's syndrome.[see comment]. *British Journal of Obstetrics & Gynaecology* 1993;**100**(6):550-7.

Wald 1994a {published data only}

Wald NJ, Densem JW. Maternal serum free alpha-human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1994;**14**(8):717-9.

Wald 1994b {published data only}

Wald NJ, Watt HC. Choice of serum markers in antenatal screening for Down's syndrome. *Journal of Medical Screening* 1994;**1**(2):117-20.

Wald 1996a {published data only}

Wald NJ, Watt HC. Serum markers for Down's syndrome in relation to number of previous births and maternal age. *Prenatal Diagnosis* 1996;**16**(8):699-703.

Wald 1996b {published data only}

Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. [see comment]. *British Journal of Obstetrics & Gynaecology* 1996;**103**(5):407-12.

Wald 1996d {published data only}

Wald NJ, Watt HC, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(10):923-6.

Wald 1996e {published data only}

Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.. *Prenatal Diagnosis* 1996;**16**(2):143-53.

Wald 1997 {published data only}

Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. [see comment]. *Prenatal Diagnosis* 1997;**17**(9):821-9.

Wald 1998 {published data only}

Wald NJ, Watt HC, Haddow JE, Knight GJ. Screening for Down syndrome at 14 weeks of pregnancy. *Prenatal Diagnosis* 1998;**18**(3):291-3.

Wald 1999a {published data only}

Wald NJ, Hackshaw AK, Diamandis EP, Melegos DN. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. *Prenatal Diagnosis* 1999;**19**(7):674-6.

Wald 1999b {published data only}

Wald NJ, Watt HC, Norgaard Pederson, Christiansen M. SP1 in pregnancies with Down syndrome in the first trimester of pregnancy. *Prenatal Diagnosis* 1999;**19**(6):517-20.

Wald 1999c {published data only}

Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. *British Journal of Obstetrics & Gynaecology* 1999;**106**(12):1304-6.

Wald 1999d {published data only}

Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.[see comment]. *New England Journal of Medicine* 1999;**341**(7):461-7.

Wald 2003b {published data only}

Wald NJ, Rish S, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. *Prenatal Diagnosis* 2003;**23**(7):588-92.

Wald 2003c {published data only}

Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test.[see comment]. *Lancet* 2003;**361**(9360):835-6.

Wald 2006 {published data only}

Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(9):769-77.

Wallace 1994 {published data only}

Wallace EM, Harkness LM, Burns S, Liston WA. Evaluation of maternal serum immunoreactive Inhibin A as a first trimester marker of Down's syndrome. *Clinical Endocrinology* 1994;**41**(4):483-6.

Wallace 1997 {published data only}

Wallace EM, Crossley JA, Ritoe SC, Groome NP, Aitken DA. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus. *British Journal of Obstetrics & Gynaecology* 1997;**104**(8):946-8.

Ward 2005 {published data only}

Ward A. Nuchal translucency measurement. Synergy (<http://www.highbeam.com/doc/1P3-866108421.html>) (accessed 2007) 2005.

Watt 1996a {published data only}

Watt HC, Wald NJ, Smith D, Kennard A, Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(8):691-8.

Watt 1996b {published data only}

Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(10):927-9.

Weinans 2001 {published data only}

Weinans MJN, Pratt JJ, De Wolf, Mantingh A. First-trimester maternal serum human thyroid-stimulating hormone in chromosomally normal and Down syndrome pregnancies. *Prenatal Diagnosis* 2001;**21**(9):723-5.

Weinans 2004 {published data only}

Weinans MJN, Kooij L, Müller MA, Bilardo KM, Van Lith, Tymstra T. A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: A pilot study. *Prenatal Diagnosis* 2004;**24**(5):347-51.

Welborn 1994 {published data only}

Welborn JL, Timm NS. Trisomy 21 and cystic hygromas in early gestational age fetuses. *American Journal of Perinatology* 1994;**11**(1):19-20.

Wenstrom 1993 {published data only}

Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP. Evaluation of multiple-marker screening for Down syndrome in a statewide population. *American Journal of Obstetrics and Gynecology* 1993;**169**(4):793-7.

Wenstrom 1995a {published data only}

Wenstrom KD, Owen J, Boots L, Ethier M. The influence of maternal weight on human chorionic gonadotropin in the multiple-marker screening test for fetal Down syndrome. *American Journal of Obstetrics & Gynecology* 1995;**173**(4):1297-300.

Wenstrom 1995b {published data only}

Wenstrom KD, Desai R, Owen J, Dubard MB, Boots L. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women greater than or equal 35 years old. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1287-92.

Whitlow 1998a {published data only}

Whitlow BJ, Lazanakis ML, Kadir RA, Chatzipapas I, Economides DL. The significance of choroid plexus cysts, echogenic heart foci and renal pyelectasis in the first trimester. *Ultrasound in Obstetrics & Gynecology* 1998;**12**(6):385-90.

Whitlow 1998b {published data only}

Whitlow BJ, Economides DL. First trimester detection of fetal abnormalities in an unselected population. *Contemporary Reviews in Obstetrics and Gynaecology* 1998;**10**(4):245-53.

Whitlow 1999 {published data only}

Whitlow BJ, Chatzipapas IK, Lazanakis ML, Kadir RA, Economides DL. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. *British Journal of Obstetrics & Gynaecology* 1999;**106**(9):929-36.

Williamson 1994 {published data only}

Williamson R. Expanded maternal serum alpha fetoprotein screening. *Iowa Medicine* 1994;**84**(9):397-400.

Wilson 2000 {published data only}

Wilson K. New first-trimester prenatal screening for down syndrome. *Laboratory Medicine* 2000;**31**(11):591.

Wojdemann 2001 {published data only}

Wojdemann KR, Larsen SO, Shalmi A, Sundberg K, Christiansen M, Tabor A. First trimester screening for Down

syndrome and assisted reproduction: no basis for concern. *Prenatal Diagnosis* 2001;**21**(7):563-5.

Wong 2003 {published data only}

Wong SF, Choi H, Ho LC. Nasal bone hypoplasia: is it a common finding amongst chromosomally normal fetuses of southern Chinese women?. *Gynecologic & Obstetric Investigation* 2003;**56**(2):99-101.

Wright 2006 {published data only}

Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A, Standing S, et al. Three-stage contingent screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(6):528-34.

Yagel 1998 {published data only}

Yagel S, Anteby EY, Hochner-Celnikier D, Ariel I, Chaap T, Ben Neriah Z. The role of midtrimester targeted fetal organ screening combined with the "triple test" and maternal age in the diagnosis of trisomy 21: a retrospective study. *American Journal of Obstetrics & Gynecology* 1998;**178**(1):40-4.

Yamamoto 2001a {published data only}

Yamamoto R, Azuma M, Kishida T, Yamada H, Satomura S, Fujimoto S. Total alpha-fetoprotein and Lens culinaris agglutinin-reactive alpha-fetoprotein in fetal chromosomal abnormalities. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2001;**108**(11):1154-8.

Yamamoto 2001b {published data only}

Yamamoto R, Azuma M, Hoshi N, Kishida T, Satomura S, Fujimoto S. Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome. *Human Reproduction* 2001;**16**(11):2438-44.

Yamamoto 2001c {published data only}

Yamamoto R, Azuma M, Wakui Y, Kishida T, Yamada H, Okuyama K, et al. Alpha-fetoprotein microheterogeneity: a potential biochemical marker for Down's syndrome. *Clinica Chimica Acta* 2001;**304**(1-2):137-41.

Yaron 2001 {published data only}

Yaron Y, Wolman I, Kupferminc MJ, Ochshorn Y, Many A, Orr Urtreger. Effect of fetal gender on first trimester markers and on Down syndrome screening. *Prenatal Diagnosis* 2001;**21**(12):1027-30.

Ye 1995 {published data only}

Ye G, Liao S, Zhao X. The possibility of prenatal screening for fetal abnormalities in second-trimester pregnancies by measuring AFP, β -HCG and uE-3 levels. *Xi'an Yike Daxue Xuebao* 1995;**16**(4):408-11.

Yoshida 2000 {published data only}

Yoshida K, Kuwabara Y, Tanaka T, Onda T, Kudo R, Yamamoto H, et al. Dimeric Inhibin A as a fourth marker for Down's syndrome maternal serum screening in native Japanese women. *Journal of Obstetrics and Gynaecology Research* 2000;**26**(3):171-4.

Zeitune 1991 {published data only}

Zeitune M, Aitken DA, Crossley JA, Yates JR, Cooke A, Ferguson-Smith MA. Estimating the risk of a fetal autosomal trisomy at mid-trimester using maternal serum alpha-fetoprotein and age: A retrospective study of 142 pregnancies. *Prenatal Diagnosis* 1991;**11**(11):847-57.

Zelop 2005 {published data only}

Zelop CM, Milewski E, Brault K, Benn P, Borgida AF, Egan JFX. Variation of fetal nasal bone length in second-trimester fetuses according to race and ethnicity. *Journal of Ultrasound in Medicine* 2005;**24**(11):1487-9.

Zhao 1998 {published data only}

Zhao Xiaolan, Ye Guoling, Liu Qi. Using maternal serum PAPP-A and other pregnancy-associated proteins in screening for fetal abnormalities. *Xi'an Yike Daxue Xuebao* 1998;**19**(1):94-6, 110.

Zoppi 2003 {published data only}

Zoppi MA, Ibba RM, Floris M, Manca F, Axiana C, Monni G. Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2003;**110**(6):584-8.

Additional references

Alfirevic 2003

Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database of Systematic Reviews* 2003, Issue 3. [DOI: [10.1002/14651858.CD003252](https://doi.org/10.1002/14651858.CD003252)]

Alfirevic 2004

Alfirevic Z, Neilson JP. Antenatal screening for Down's syndrome. *BMJ* 2004;**9**(329(7470)):811-2.

Allred 2010

Allred SK, Deeks JJ, Neilson JP, Alfirevic Z. Antenatal screening for Down's syndrome: generic protocol (Protocol). *Cochrane Database of Systematic Reviews* 2010, Issue 4. [DOI: [10.1002/14651858.CD007384.pub2](https://doi.org/10.1002/14651858.CD007384.pub2)]

Bersinger 1995

Bersinger NA, Zakher A, Huber U, Pescia G, Schneider H. A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies. *Archives of Gynecology and Obstetrics* 1995;**256**(4):185-92.

Bogart 1987

Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. *Prenatal Diagnosis* 1987;**7**(9):623-30.

Cuckle 1995

Cuckle HS, Holding S, Jones R, Wallace EM, Groome NP. Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnancies. *Prenatal Diagnosis* 1995; Vol. 15, issue 4:385-6.

Macri 1990

Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. *American Journal of Obstetrics and Gynecology* 1990;**163**(4 Pt 1):1248-53.

Macri 1993

Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD, Muller F, et al. First-trimester free beta (hCG) screening for Down syndrome. *Prenatal Diagnosis* 1993;**13**(7):557-62.

Mol 1999

Mol BW, Lijmer JG, Van der Meulen J, Pakr E, Bilardo CM, Bossuyt PM. Effect of study design on the association between nuchal translucency measurement and Down syndrome. *Obstetrics and Gynecology* 1999;**94**(5 Pt 2):864-9..

Penrose 1933

Penrose LS. The relative effects of parental and maternal age in mongolism. *Journal of Genetics* 1933;**27**:219-24.

Steele 1966

Steele MW, Breg WR. Chromosome analysis of human amniotic-fluid cells. *Lancet* 1966;**i**:383-5.

Vaklenti 1968

Vaklenti C, Schutta E.J, Kehaty T. Prenatal diagnosis of Down's syndrome. *Lancet* 1968;**ii**:220.

Wallace 1995

Wallace EM, Grant VE, Swanston IA, Groome NP. Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down's syndrome. *Prenatal Diagnosis* 1995;**15**(4):359-62.

Whiting 2003

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Medical Research Methodology* 2003;**3**:25.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Anandakumar 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing based on age
Participants	1208 participants Singapore - single centre 1989-1991 Pregnant women over 35 years of age Singleton pregnancies Karyotyping performed at same time as serum sampling 12-22 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 7 affected cases Reference standard - Amniocentesis
Index and comparator tests	Maternal age Second trimester serum AFP - Amerlite AFP assay Second trimester serum β hCG - Amerlite HCG-60 assay
Follow-up	100% karyotype

Anandakumar 1999 (Continued)

Aim of study To test the sensitivity of the trivariate analysis using maternal serum AFP, hCG and maternal age in screening for fetal aneuploidy in mothers above the age of 35

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference stan- dard? All tests	Yes	Amniocentesis
Partial verification avoid- ed? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Unclear	No information given
Withdrawals explained? All tests	Yes	No withdrawals

Audibert 2001a

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy Routine screening
Participants	3790 participants France - single centre May 1994-December 1997

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Audibert 2001a (Continued)

	Pregnant women Singleton pregnancies CRL between 38 and 84 mm Under 38 years of age
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 10 affected cases Reference standards; Amniocentesis CVS Postnatal karyotype Miscarriage with cytogenetic testing Neonatal examination
Index and comparator tests	Maternal age Second trimester serum hCG Second trimester serum AFP (Nuchal Translucency - see 1st trimester US review) Amerlite, Orthoclinical diagnostics machine Prenata software
Follow-up	Delivery and postnatal paediatric examination 35 lost to follow-up and excluded from analysis
Aim of study	To compare NT and second trimester maternal serum measurements as alternative methods of antenatal screening.
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Typical pregnant population with exception that women over 38 years of age excluded
Acceptable reference standard? All tests	Yes	Amniocentesis CVS Postnatal karyotype Miscarriage with cytogenetic testing Neonatal examination

Second trimester serum tests for Down's Syndrome screening (Review)

Audibert 2001a (Continued)

Partial verification avoided? All tests	Yes	All pregnancies verified by acceptable reference standard
Differential verification avoided? All tests	No	Different reference standards used within same population
Incorporation avoided? All tests	Yes	Index and reference tests separate
Reference standard results blinded? All tests	Yes	Results of index tests known prior to reference standard being performed
Index test results blinded? All tests	Yes	Results of index test unknown to operator providing reference standard
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Bahado-Singh 1999a

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	926 participants USA November 1995 - March 1999 Pregnant women Singleton pregnancies Serum screening performed 15-24 weeks gestation Euploid/Down's karyotype only
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 21 affected cases Reference standard - Amniocentesis

Second trimester serum tests for Down's Syndrome screening (Review)

Bahado-Singh 1999a (Continued)

Index and comparator tests	Maternal age 2nd trimester urinary β core fragment 2nd trimester serum AFP 2nd trimester serum uE3 2nd trimester serum β hCG Spot specimens of urine - 2 step sandwich assay B120 monoclonal antibody Serum not described
Follow-up	100% karyotype
Aim of study	To compare Down's syndrome screening efficiency of elevated maternal urine level of β core fragment with that of a traditional serum triple test
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Typical pregnant population
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Performed after index test
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained?	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Bahado-Singh 1999a (Continued)

All tests

Bahado-Singh 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	2371 participants USA January 1992 - November 1997 Pregnant women Singleton pregnancies 14-24 weeks gestation Euploid/Down's karyotype only
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 46 affected cases Reference standard - amniocentesis
Index and comparator tests	Maternal age 2nd trimester serum AFP 2nd trimester serum uE3 2nd trimester serum β hCG Not described
Follow-up	100% karyotype
Aim of study	Compare Down's syndrome screening efficacy of the standard serum triple analyte screen compared to that of a 4 component screen consisting of ultrasound biometry and serum markers in the second trimester
Notes	Serum data analysed only

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Typical pregnant population
Acceptable reference standard? All tests	Yes	Amniocentesis

Second trimester serum tests for Down's Syndrome screening (Review)

Bahado-Singh 2000 (Continued)

Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Reference standard performed after index test performed
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Bartels 1990

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	325 participants Germany and USA Dates not specified Known normal outcome or known aneuploidy 14-24/40 gestation
Study design	Retrospective multi-centre case-control study
Target condition and reference standard(s)	Down's syndrome 43 affected cases Reference standard not specified, but known karyotype
Index and comparator tests	2nd trimester hCG 2nd trimester SP-1 Tandem E hCG immunoenzymetric assay

Second trimester serum tests for Down's Syndrome screening (Review)

Bartels 1990 (Continued)

Enzygnost SP1 assay

Follow-up	100% methods not specified
Aim of study	Compare hCG and SP1 levels in Down's syndrome pregnancy

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Unclear	Implied karyotype - known outcome
Partial verification avoided? All tests	Yes	All outcomes known
Differential verification avoided? All tests	Unclear	No information given regarding method of karyotype
Incorporation avoided? All tests	Yes	Reference and index test separate
Reference standard results blinded? All tests	Yes	Known prior to index test
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Bartels 1994a

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk women referred for invasive testing
Participants	370 participants Germany

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bartels 1994a (Continued)

14-21 weeks gestation

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 50 affected cases Reference standard - Amniocentesis
Index and comparator tests	Second trimester hCG, SP-1, uE3 and AFP with or without age Amerlex M 2nd trimester kit for AFP, hCG and uE3 Enzygnost SP-1 for SP-1
Follow-up	100% Karyotype
Aim of study	Evaluate sensitivity and specificity of hCG, SP-1, uE3 and AFP alone and in various combinations on the basis of retrospective data

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk women referred for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bartels 1994a (Continued)

Withdrawals explained?	Yes	None
All tests		

Bartels 1994b

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk women referred for invasive testing
Participants	655 participants Germany 14-21 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 10 affected cases Reference standard - Amniocentesis
Index and comparator tests	Second trimester hCG, SP-1, uE3 and AFP with or without age Amerlex M 2nd trimester kit for AFP, hCG and uE3 Enzygnost SP-1 for SP-1
Follow-up	100% Karyotype
Aim of study	Evaluate sensitivity and specificity of hCG, SP-1, uE3 and AFP alone and in various combinations on the basis of retrospective data
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk women referred for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standard separate

Second trimester serum tests for Down's Syndrome screening (Review)

Bartels 1994b (Continued)

Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Beekhuis 1993

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	2282 participants Netherlands multi-centre October 1st 1990-December 1st 1991 Pregnant women Singleton pregnancies 15-20 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 6 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	Maternal age Second trimester serum hCG Second trimester serum AFP EIA Alpha software
Follow-up	100% karyotype

Second trimester serum tests for Down's Syndrome screening (Review)

Beekhuis 1993 (Continued)

Aim of study	To examine feasibility of maternal serum screening for DS in the Dutch decentralised obstetric organisation

Notes	Dutch language paper

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs according to index test result
Incorporation avoided? All tests	Yes	Index and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Benattar 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme

Participants	1649 participants France January to December 1995

Benattar 1999 (Continued)

Pregnant women

Singleton pregnancies

Less than 13 weeks gestation at enrolment

15-18 weeks at time of second trimester serum screening

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 5 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	Maternal age Second trimester serum AFP Second trimester serum free β hCG Second trimester serum hCG No test characteristics specified
Follow-up	Birth
Aim of study	To evaluate the sequential combination of ultrasound screening for fetal aneuploidy at 11-14 weeks with maternal biochemistry at 12-14 and 15-18 weeks

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standard separate
Reference standard results blinded?	Unclear	No information given

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Benattar 1999 (Continued)

All tests

Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	12 lost to follow-up

Brajenovic 1998

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	3188 participants Croatia January 1996-December 1996 Pregnant women Same ethnic group (not specified) 14-22 weeks
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 9 affected cases Reference standard; Amniocentesis Maternity record, cytogenetics records and patient questionnaires
Index and comparator tests	Second trimester maternal serum AFP Second trimester maternal serum free β hCG EMIA coated tubes ELISA assay - CIS Bio international
Follow-up	3 months after delivery
Aim of study	To investigate the efficiency of second trimester maternal serum screening for Down's syndrome and open neural tube defects using MSAFP and free β hCG

Second trimester serum tests for Down's Syndrome screening (Review)

Brajenovic 1998 (Continued)

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Maternity record, cytogenetics records and patient questionnaires
Partial verification avoid- ed? All tests	Yes	All pregnancies verified by reference standard
Differential verification avoided? All tests	No	High risk received amniocentesis, low risk received postnatal verification as stated above
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to references standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information provided
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Brizzi 1989a

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	1472 participants Italy Dates not specified Pregnant women

Brizzi 1989a (Continued)

Biparietal diameter 32-48 mm

Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 27 affected cases Amniocentesis
Index and comparator tests	Second trimester Maternal serum AFP No technical information provided
Follow-up	100% Karyotype
Aim of study	To verify if it is possible to increase the percentage of affected fetuses diagnosed without modifying the total number of amniocenteses by using different screening parameters such as the rating of low MSAFP
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Brizzi 1989a (Continued)

Withdrawals explained? All tests	Yes	None

Chao 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	10098 participants Taiwan 1st July 1994- 30th April 1996 Pregnant women 15-23 weeks gestation Singleton pregnancies
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 15 affected cases Reference standards; Amniocentesis Postnatal examination Telephone follow-up of high-risk cases
Index and comparator tests	Maternal age Second trimester maternal serum AFP Second trimester maternal serum free β hCG Beta hCG - solid phase 2 site immunoradiometric assay AFP - enzyme immunoassay kit
Follow-up	85% Known outcome
Aim of study	To determine the incidence of chromosomal abnormalities in Taiwanese women undergoing prenatal chromosome analysis after second trimester Down's syndrome screening
Notes	85% follow up only

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme

Chao 1999 (Continued)

Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination Telephone follow-up of high-risk cases
Partial verification avoided? All tests	No	Outcome known in 85% only, but all high-risk women offered invasive testing
Differential verification avoided? All tests	No	Reference standard differed depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	No	15% loss to follow-up not explained

Christiansen 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	261 participants Denmark Dates not specified Pregnant women Known outcome 5-20 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 105 affected cases

Second trimester serum tests for Down's Syndrome screening (Review)

Christiansen 1999 (Continued)

Karyotyping

Index and comparator tests	1st trimester serum ProMBP 2nd trimester serum ProMBP 2 site immunoradiometric assay samples reduced and alkylated and added to microtitre wells coated with monoclonal antibody J13 6B6
Follow-up	100% Birth/karyotype
Aim of study	To examine whether the maternal serum concentration of ProMBP was influenced by the presence of a Down's syndrome fetus. To evaluate its potential as a screening marker for Down's syndrome in the first and second trimester of pregnancy. To examine the performance characteristics of a serum screening programme using ProMBP in combination with age as risk markers
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Typical screening population
Acceptable reference standard? All tests	Yes	Karyotyping
Partial verification avoided? All tests	Yes	All women received karyotyping
Differential verification avoided? All tests	No	All women received karyotyping
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Christiansen 2004

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	334 participants Denmark Dates not specified Pregnant women Singletons
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 107 affected cases Reference standard; Amniocentesis CVS Postnatal karyotype
Index and comparator tests	Maternal age Second trimester maternal serum β hCG Second trimester maternal serum AFP Second trimester maternal serum Pro MBP Pro-MBP - 2 site immunoradiometric assay (IRMA) Free β hCG and AFP - AutoDELFIA analytical system
Follow-up	Retrospective - Known outcome
Aim of study	To evaluate 6 markers of fetal Down's syndrome pregnancies (includes first trimester markers)
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis CVS Postnatal karyotype

Christiansen 2004 (Continued)

Partial verification avoided? All tests	Yes	All outcomes known
Differential verification avoided? All tests	No	Different reference standards used within population
Incorporation avoided? All tests	Yes	Index test and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Outcome unknown to assessor
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Cioffi 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	717 participants Italy Dates not specified Pregnant women 15-21 weeks gestation No family history of NTD/DM/DS
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 17 affected cases Reference standard; Amniocentesis Postnatal follow-up

Second trimester serum tests for Down's Syndrome screening (Review)

Cioffi 2000 (Continued)

Index and comparator tests	Maternal age
	Second trimester maternal serum uE3
	Second trimester maternal serum AFP
	Second trimester maternal serum β hCG
	Isotopic methods
	uE3 - Bio rad clin division
	AFP and β hCG - Immunosystems company
Follow-up	Postnatal period
Aim of study	To define median values from pregnant women then to establish cut off values and to identify the largest number of at risk pregnancies and to evaluate the reliability and agreement of the results using the triple test in the second trimester

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal follow-up
Partial verification avoided? All tests	Yes	All outcomes verified
Differential verification avoided? All tests	No	High risk only received amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained?	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cioffi 2000 (Continued)

All tests

Crossley 1994

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	30084 participants UK 1991-1992 Singleton pregnancies 15-20 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 37 affected cases Reference standards; Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing Postnatal examination
Index and comparator tests	Maternal age 2nd Trimester serum AFP 2nd Trimester serum total hCG Serone MAIA clone
Follow-up	100% birth/karyotype
Aim of study	To evaluate the impact of a large scale population screening programme on the birth incidence of Down's syndrome in the west of Scotland over a 12-month period
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal karyotype

Second trimester serum tests for Down's Syndrome screening (Review)

Crossley 1994 (Continued)

		Miscarriage with cytogenetic testing
		Postnatal examination
Partial verification avoided? All tests	Yes	All verified by reference standard
Differential verification avoided? All tests	No	Different women received different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	No	No explanation given
Withdrawals explained? All tests	Yes	None

David 1996

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	9500 participants Israel June 1991-October 1993 Pregnant women Singleton pregnancies
Study design	Case-control study - controls collected prospectively and cases collected retrospectively
Target condition and reference standard(s)	Down's syndrome 47 affected cases Amniocentesis Postnatal examination

Second trimester serum tests for Down's Syndrome screening (Review)

David 1996 (Continued)

Index and comparator tests	Maternal age Second trimester maternal serum uE3 Second trimester maternal serum AFP Second trimester maternal serum hCG DELFI Wallac - AFP and hCG Amerlex radioimmunoassay - uE3
Follow-up	Not stated
Aim of study	To ascertain the contribution of uE3 as an additional marker for prenatal detection of Down's syndrome in an ongoing screening programme
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	No	Reference standard differed
Differential verification avoided? All tests	No	Different women received different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Debieve 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	218 participants Belgium Dates not specified Pregnant women 15-20 weeks gestation Singletons
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 18 affected pregnancies Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	Maternal age Second trimester maternal serum hCG Second trimester maternal serum uE3 Second trimester maternal serum AFP Second trimester maternal serum Inhibin A Amerlex M 2T RIA kits for hCG, uE3 and AFP 2 monoclonal antibody solid-phase sandwich microtitre plate ELISA Serotec Oxford for Inhibin A
Follow-up	Known outcome
Aim of study	To evaluate the contribution of Inhibin A and 2T ultrasound parameters to 3 other markers used for Down's syndrome screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination

Debieve 2000 (Continued)

Partial verification avoided? All tests	Yes	All outcomes verified
Differential verification avoided? All tests	No	Only high-risk women had amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Extermann 1998

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	2539 participants Switzerland June 1992 - June 1993 Pregnant women Known outcome 15-18 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 23 affected cases Reference standard - amniocentesis and implied postnatal verification but not specified
Index and comparator tests	Maternal age Second trimester maternal serum hCG

Second trimester serum tests for Down's Syndrome screening (Review)

Extermann 1998 (Continued)

Second trimester maternal serum free β hCG

Second trimester maternal serum AFP

Second trimester maternal serum uE3

AFP - IMX (Abbott)/ES 600

Total hCG - IMX/Status (Baxter)

uE3 and free β hCG - RIA using Kodak Amerlex M Estriol kit

Follow-up	Birth
Aim of study	To perform a direct comparison of three screening protocols for second trimester Down's syndrome screening in the same serum samples
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis and implied postnatal verification
Partial verification avoided? All tests	Yes	All outcomes ascertained
Differential verification avoided? All tests	No	Reference standard offered depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Forest 1995

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	511 participants Canada June 1989 - October 1993 Singleton pregnancies 9-18 weeks gestation
Study design	Prospective consecutive series
Target condition and reference standard(s)	Down's syndrome 11 affected cases Reference standard; Amniocentesis Review of maternal and neonatal records
Index and comparator tests	AFP uE3 Total hCG Free alpha hCG Free β hCG AFP/hCG - Enzymum test enzyme immunoassay (Boehringer Mannheim, Canada) uE3 - Radioimmunometric assay (DSL Canada) Free alpha and β hCG - Radioimmunometric assay (Bioclone Austria pty Ltd)
Follow-up	100% Birth/Karyotype
Aim of study	Evaluate the impact of risk estimation parameters for screening for Down's syndrome during the first and second trimesters of pregnancy
Notes	3 different models used for risk calculation (Wald, Spencer and Ryall)

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Maternity and neonatal records

Forest 1995 *(Continued)*

Partial verification avoided? All tests	Yes	All outcomes verified
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Greenberg 1991

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	3282 participants USA 1985 onwards Pregnant women Singleton pregnancy
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 51 affected cases Reference standards; Amniocentesis Postnatal karyotype Postnatal examination

Second trimester serum tests for Down's Syndrome screening (Review)

Greenberg 1991 (Continued)

Index and comparator tests	Second trimester serum AFP alone Clinical assays, Cambridge, Massachusetts
Follow-up	100% - known outcome
Aim of study	To assess the effect of gestational age on the detection rate of Down's syndrome by maternal serum AFP screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting -screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal karyotype Postnatal examination
Partial verification avoided? All tests	Yes	All women received verification by reference standard
Differential verification avoided? All tests	No	Different reference standards used depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Known outcome - retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Haddow 1994

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	5336 participants USA December 1990 - October 1992 Pregnant women 35 years of age and over
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 54 affected cases Reference standard - Amniocentesis
Index and comparator tests	2nd trimester serum AFP 2nd trimester serum uE3 2nd trimester serum hCG Maternal age at delivery AFP - In house assay uE3 - Amerlex M radioimmunoassay kit specific for uE3 hCG - Amerlex M extended range hCG radioimmunoassay kit
Follow-up	100% karyotype
Aim of study	To investigate whether offering amniocentesis only to selected women 35 years of age and older who were identified by screening measurements in serum might prove a useful alternative to the current practice
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided?	Yes	All women had amniocentesis

Second trimester serum tests for Down's Syndrome screening (Review)

Haddow 1994 (Continued)

All tests

Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Index test result not known to operator
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Haddow 1998

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing	
Participants	308 participants USA December 1990 - October 1992 Pregnant women 35 years of age and over	
Study design	Retrospective case-control study	
Target condition and reference standard(s)	Down' syndrome 52 affected cases Reference standard - amniocentesis	
Index and comparator tests	2nd trimester serum Inhibin A Inhibin A measured in duplicate using a solid phase sandwich enzyme linked immunosorbent assay (ELISA)	
Follow-up	100% karyotype	
Aim of study	To determine second trimester Down's syndrome screening performance of maternal serum dimeric Inhibin A both alone and in combination with existing markers	
Notes		

Second trimester serum tests for Down's Syndrome screening (Review)

Haddow 1998 (Continued)

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Index test result unknown to operator
Index test results blinded? All tests	Yes	Carried out prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Heyl 1990

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	101 participants USA January 1986 - January 1990 Greater than 35 years Singleton pregnancies

Heyl 1990 (Continued)

Study design	Retrospective single-centre case-control study
Target condition and reference standard(s)	Down's syndrome 16 affected cases Reference standard - Amniocentesis
Index and comparator tests	2nd trimester AFP 2nd trimester hCG 2nd trimester uE3 Maternal Age 1 in 365 risk AFP - Abbott enzyme immunoassay hCG - IMx system total β hCG assay uE3 - Amerlex M unconjugated oestriol
Follow-up	100%
Aim of study	Evaluate efficacy of screening for the detection of aneuploidy in women of 35 years and over
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Index test result not known at time of reference standard being carried out
Index test results blinded? All tests	Unclear	No information given

Heyl 1990 (Continued)

Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Hsu 1997a

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	8265 participants Taiwan 1992-1996 Pregnant women Singletons 14-23 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 47 affected cases Reference standards; Amniocentesis Neonatal examination
Index and comparator tests	Maternal age Second trimester serum free β hCG Second trimester serum AFP Abbott EIA-AFP Free β hCG ELSA kit Cuckle 1987 formula
Follow-up	Birth/Karyotype
Aim of study	To estimate two analyte screening combining serum free β hCG and AFP with maternal age in Asia
Notes	

Hsu 1997a (Continued)

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Neonatal examination
Partial verification avoided? All tests	Yes	All women had reference standard performed
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Reference standard performed prior to index test
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Huderer-Duric 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	2833 participants Croatia 1996-1998 Pregnant women Singletons 15-22 weeks gestation

Huderer-Duric 2000 (Continued)

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 12 affected cases Amniocentesis
Index and comparator tests	Maternal age Second trimester maternal serum uE3 Second trimester maternal serum hCG Second trimester maternal serum AFP Amerlax M Prenata software
Follow-up	Karyotype
Aim of study	To review the contribution of uE3 in Down's syndrome detection and the influence on maternal age, cut-off choice and population specificity on the balance between the triple marker test sensitivity and specificity

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Operator not aware of index test result at time of amniocentesis
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information?	Yes	Appropriate clinical information given

Second trimester serum tests for Down's Syndrome screening (Review)

Huderer-Duric 2000 (Continued)

All tests

Uninterpretable results reported? All tests	Yes	None

Withdrawals explained? All tests	Yes	None

Jou 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme

Participants	17742 participants Taiwan June 1994-July 1998 Pregnant women 14-22 weeks gestation Singletons

Study design	Prospective consecutive series study

Target condition and reference standard(s)	Down's syndrome 16 affected cases Reference standard; Amniocentesis Postnatal examination Postnatal karyotype

Index and comparator tests	Maternal age Second trimester maternal serum hCG Second trimester maternal serum AFP AFP - microparticle enzyme immunoassay kit hCG - CMEIA AFP kit and MEIA β hCG kit RAM programme - body weight corrected MoM and maternal age

Follow-up	Birth/Karyotype

Aim of study	To evaluate the efficacy of second trimester maternal serum screening programme using AFP and total hCG in an Asian population

Notes

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Jou 2000 (Continued)

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination Postnatal karyotype
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Refence standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Kadir 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	4427 participants England 1/4/93 - 31/3/95
Study design	Prospective consecutive series study

Kadir 1999 (Continued)

Target condition and reference standard(s)	Down's syndrome 13 affected cases Reference standards; Amniocentesis Postnatal examination
Index and comparator tests	2nd trimester AFP 2nd trimester free β hCG Maternal age 1 in 250 risk at EDD AFP - immunoradiometric assay (omnia alpha FP) Free β hCG - specific solid phase 2 site immunoradiometric assay (ELISA fBhCG)
Follow-up	100% karyotype or postnatal examination
Aim of study	Examine the effect of introducing mid trimester biochemical screening in a maternity unit with a high population of women over 37 years of age
Notes	9.4% of study population older than 37 years

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women had reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Index test performed prior to reference standard
Relevant clinical information?	Yes	Appropriate clinical information given

Second trimester serum tests for Down's Syndrome screening (Review)

Kadir 1999 (Continued)

All tests

Uninterpretable results re- ported? All tests	Yes	None

Withdrawals explained? All tests	Yes	None

Kishida 2000

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme, but 63% of women over 35 yrs of age

Participants	1055 participants Japan May 1995-Feb 1998 Pregnant women Singleton pregnancies 14-20 weeks No major pregnancy complications

Study design	Prospective consecutive series study

Target condition and ref- erence standard(s)	Down's syndrome 10 affected cases Reference standards; Amniocentesis Clinical neonatal examination

Index and comparator tests	Maternal age Second trimester maternal serum AFP Second trimester maternal serum hCG Second trimester maternal serum uE3 AFP - Abbott laboratories hCG - Wallac uE3 - Diagnostic products, LA

Follow-up	100% birth/karyotype

Aim of study	To assess the efficacy of maternal serum screening for use in prenatal diagnosis of fetal anomaly and chromosome imbalance in Japanese women

Second trimester serum tests for Down's Syndrome screening (Review)

Kishida 2000 (Continued)

Notes 63% of women over 35 yrs of age

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Neonatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Index test results unknown to operator
Index test results blinded? All tests	Yes	Index test performed prior to reference standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Knight 1998

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	5117 participants USA December 1990 - October 1992 Pregnant women

Knight 1998 (Continued)

35 years of age and over

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 52 affected pregnancies reference standard - Amniocentesis
Index and comparator tests	Second trimester serum hCG Second trimester serum free β hCG Second trimester serum AFP Second trimester serum uE3 Maternal age Free β hCG and AFP - Wallac DELFIA hAFP/free β hCG dual assay hCG - hCG MAIA clone uE3 - Amerlex M radioimmunoassay kit specific for uE3
Follow-up	100% Karyotype
Aim of study	To evaluate the potential of substituting free β hCG for hCG in second trimester screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Yes	Results of index test unknown to operator
Index test results blinded? All tests	Yes	Index test performed prior to reference standard

Second trimester serum tests for Down's Syndrome screening (Review)

Knight 1998 (Continued)

Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Lam 2002

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	16237 participants Taiwan June 1994-July 1998 Pregnant women 15-20 weeks gestation for serum analysis
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 35 affected cases Reference standards; Amniocentesis CVS Neonatal examination
Index and comparator tests	Maternal age Second trimester maternal serum AFP Second trimester maternal serum hCG Test characteristics not described in paper
Follow-up	Birth/karyotype
Aim of study	To compare the efficacy of different combinations of screening markers
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description

Second trimester serum tests for Down's Syndrome screening (Review)

Lam 2002 (Continued)

Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis CVS Neonatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	No	Index test result known to operator
Index test results blinded? All tests	Yes	Index test performed prior to reference standard
Relevant clinical informa- tion? All tests	Unclear	No clear information given
Uninterpretable results re- ported? All tests	Yes	Miscarriages etc excluded from analysis
Withdrawals explained? All tests	Yes	None

Lemay 1995

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	18600 participants France October 1989 to December 1993 Pregnant women 15-18 weeks gestation
Study design	Prospective consecutive series study
Target condition and ref- erence standard(s)	Down's syndrome

Second trimester serum tests for Down's Syndrome screening (Review)

Lemay 1995 (Continued)

	32 affected cases
	Reference standards;
	Amniocentesis
	Postnatal karyotype
	Postnatal examination
Index and comparator tests	Second trimester serum total hCG
	Second trimester serum total AFP
	Maternal age
	Arcus 1230 2 site immunofluorimetric assay (DELFA)
Follow-up	100% birth/karyotype
Aim of study	To compare the efficacy of screening using maternal age and hCG alone with maternal age plus hCG plus AFP

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal karyotype Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index test and reference standard separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Results not available to operator
Relevant clinical information? All tests	Yes	Appropriate clinical information given

Lemay 1995 *(Continued)*

Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Malone 2005

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	35236 participants USA - 15 centres October 1999 - December 2002 Pregnant women Maternal age >16 years Singleton live fetus Fetal CRL 36-79 mm (10+3 - 13+6/40 at recruitment)
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 87 affected cases Reference standards; Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing Neonatal examination
Index and comparator tests	Maternal age Second trimester maternal serum AFP Second trimester maternal serum total hCG Second trimester maternal serum uE3 Second trimester maternal serum Inhibin A Test characteristics not specified
Follow-up	Birth/karyotype
Aim of study	To compare first and second trimester tests against and combined with each other in screening for Down's syndrome

Malone 2005 (Continued)

Notes Cystic hygroma analysed separately

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing Neonatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Mancini 1991

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	731 participants Italy 1989-1990

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Mancini 1991 (Continued)

	Pregnant women
	15-18 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 9 affected cases Reference standard - amniocentesis
Index and comparator tests	2nd trimester serum uE3 2nd trimester serum hCG 2nd trimester serum AFP Maternal age AFP - DELFIA hAFP kit hCG - DELFIA hCG uE3 - Unconjugated RIA
Follow-up	100% karyotype
Aim of study	To assess the application of second trimester serum screening for AFP, uE3 and hCG and then predictive value of each marker alone and in various combinations for Down's syndrome in a high-risk group

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	No	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index test and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded?	Yes	Performed prior to reference standard

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Mancini 1991 (Continued)

All tests

Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Milunsky 1993

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	511 participants USA Dates not specified Normal singleton pregnancy versus known Down's pregnancy
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 31 affected cases Reference standards; Amniocentesis Postnatal examination
Index and comparator tests	Intact hCG Free β hCG MSAFP Maternal age Cases that had not undergone more than 2 freeze thaw cycles Free β by commercial immunoradiometric assay (CIS UK Ltd) Intact hCG by immunoradiometric solid phase assay (Serone MAIA clone)
Follow-up	100% Birth/karyotype
Aim of study	Compare detection rate for Down's syndrome with intact MShCG vs free β hCG in the second trimester of pregnancy
Notes	

Milunsky 1993 (Continued)

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Yes	Performed without knowledge of reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information provided
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Muller 1996a

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	51048 participants France 1989-1993 15-17/40 gestation Singleton pregnancies

Muller 1996a (Continued)

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 135 affected cases Reference standard; Amniocentesis Postnatal Karyotype Postnatal examination
Index and comparator tests	2nd trimester maternal serum hCG Greater than or equal to 1% risk of Down's hCG high values, SFRI, Bordeaux, France
Follow-up	100% by karyotype or postnatal examination
Aim of study	Examine hCG measurement at 15-17/40 for Down's syndrome detection
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting- screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal Karyotype Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given

Second trimester serum tests for Down's Syndrome screening (Review)

Muller 1996a (Continued)

Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Palomaki 2004

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing	
Participants	283 participants USA 14 centres 1990-1992 Pregnant women 14-21 weeks gestation Singleton pregnancies	
Study design	Retrospective case-control study	
Target condition and reference standard(s)	Down's syndrome 45 affected cases Reference standard - amniocentesis	
Index and comparator tests	2nd trimester serum Invasive trophoblast antigen Maternal age Automated immuno chemiluminometric assay	
Follow-up	100% birth/karyotype	
Aim of study	To provide a better definition of screening performance of serum ITA in the second trimester of pregnancy	
Notes		

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis

Palomaki 2004 (Continued)

Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Yes	Outcome unknown to operator
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Palomaki 2006

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	540 participants USA single centre Dec 1 1999-October 31 2003 Pregnant women Known Down's or normal pregnancy
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 32 affected cases Reference standard - Outcome obtained from Ontario Multiple Marker screening database
Index and comparator tests	Second trimester maternal serum PAPP-A Alpha logical medical systems software Repeated measures method

Second trimester serum tests for Down's Syndrome screening (Review)

Palomaki 2006 (Continued)

Perkin Elmer assay

Follow-up	Known outcome
Aim of study	To confirm that measuring PAPP-P in both first and second trimester serum samples improves Down's syndrome screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Genetic database Karyotyping
Partial verification avoided? All tests	Yes	All women had known outcome
Differential verification avoided? All tests	No	Reference standard differed
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Pandian 2004

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme AND High-risk referral for invasive testing
Participants	100 participants

Second trimester serum tests for Down's Syndrome screening (Review)

Pandian 2004 (Continued)

	USA
	Dates not specified
	Pregnant women
	Singleton pregnancies
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 16 affected cases Reference standard ; Amniocentesis Known pregnancy outcome
Index and comparator tests	Second trimester maternal serum ITA Second trimester maternal serum AFP Second trimester maternal serum uE3 Second trimester maternal serum hCG Second trimester maternal serum Inhibin A ITA - Diagnostic System Laboratories AFP/uE3/hCG/Inhibin A - Immulite 2000
Follow-up	Birth/karyotype
Aim of study	To examine whether serum ITA would improve current screening for Down's syndrome
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme AND High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis 'Known pregnancy outcome'
Partial verification avoided? All tests	Yes	All had reference standard
Differential verification avoided? All tests	No	Reference standard differed
Incorporation avoided? All tests	Yes	Index and reference standards separate

Second trimester serum tests for Down's Syndrome screening (Review)

Pandian 2004 *(Continued)*

Reference standard results blinded? All tests	Yes	Performed prior to index test analysis
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Perona 1997

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	20856 participants Italy October 1991-December 1995 Pregnant women Singleton pregnancies 30-35 years of age 15-18 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 41 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	2nd trimester serum uE3 2nd trimester serum hCG 2nd trimester serum AFP Maternal age ALPHA software package

Second trimester serum tests for Down's Syndrome screening (Review)

Perona 1997 (Continued)

	AFP - DELFIA hAFP kit
	hCG - DELFIA hCG
	uE3 - Unconjugated RIA
Follow-up	100% birth/karyotype
Aim of study	To observe trends of markers when two serum samples are collected at different points in a pregnancy (i.e. repeat serum samples) Reports the results of a five year screening programme
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women had reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Piggott 1994

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	6990 participants UK January 1991-December 1992 Pregnant women Singleton pregnancies 15-22 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 11 affected cases Reference standard; Amniocentesis Neonatal examination and birth registers
Index and comparator tests	Maternal age Second trimester maternal serum AFP Second trimester maternal serum uE3 Second trimester maternal serum hCG AFP and hCG - Delfia kits uE3 - Amerlex M Alpha software
Follow-up	Birth/karyotype
Aim of study	To evaluate the introduction to two health districts of an antenatal serum screening programme for Down's syndrome using the triple test
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Neonatal examination and birth registers
Partial verification avoided?	Yes	All women received reference standard

Second trimester serum tests for Down's Syndrome screening (Review)

Piggott 1994 (Continued)

All tests

Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to references standard
Relevant clinical information? All tests	Unclear	No information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Qin 1997

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	352 participants Denmark - single centre Dates not specified Pregnant women Known Down's or normal pregnancy 5-9 weeks (for USS) or 14-20 weeks for serum
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 116 affected pregnancies Reference standard; Amniocentesis CVS Postnatal karyotype

Qin 1997 (Continued)

	Postnatal examination
Index and comparator tests	Second trimester maternal serum SP1 Non-competitive time resolved immuno fluorometric assay using rabbit antibody against SP1 Multicalc software package
Follow-up	Birth/Karyotype
Aim of study	To analyse the diagnostic accuracy of maternal serum SP1 as a marker for Down's syndrome in the first and second trimesters of pregnancy
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis CVS Postnatal karyotype Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Roberts 2000

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	26080 participants England February 1992 - January 1997
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 41 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	2nd trimester AFP 2nd trimester hCG Maternal age 1 in 250 risk Amerlex-M 2T kit, ortho clinical diagnostics
Follow-up	100% karyotype/postnatal examination
Aim of study	Determine the number of trisomy 1 affected pregnancies detected by 2nd trimester screening and karyotyping in 2 British hospitals
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result
Incorporation avoided?	Yes	Index and reference standards separate

Second trimester serum tests for Down's Syndrome screening (Review)

Roberts 2000 (Continued)

All tests

Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Rose 1994

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	3896 participants USA 1974-1990 Pregnant women Greater than 35 years of age
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 33 affected cases Reference standard; Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing
Index and comparator tests	Maternal age Second trimester maternal serum AFP Test characteristics not described
Follow-up	Birth/Karyotype

Rose 1994 (Continued)

Aim of study To determine the detection and false positive rate for maternal serum AFP to screen for Down's and other abnormalities in women aged 35 and over

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differed depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Rosen 2002

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	1006 participants Belgium

Rosen 2002 (Continued)

January 1991-September 1992

Pregnant women

14-24 weeks by USS

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 13 affected cases Reference standard - Amniocentesis
Index and comparator tests	Maternal age Second trimester maternal serum uE3 Second trimester maternal serum hCG Second trimester maternal serum AFP Dried blood samples on blotting paper card Non radioactive immunologic step followed by colorimetric quantification of a horseradish pre oxidase
Follow-up	Birth/Karyotype
Aim of study	To examine the feasibility of large scale Down's syndrome maternal screening with dried blood samples and non-radioactive methods

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Performed immediately after venepuncture for index test
Index test results blinded?	Yes	Reference standard results not known

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Rosen 2002 (Continued)

All tests

Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Rozenberg 2002

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	8297 participants France (multi-centre) March 1994 - December 1997 18-37 years of age Singleton pregnancy No family history of Down's syndrome 12-14 weeks gestation at time of scan and 14+1 to 17 weeks at time of serum sample
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 20 affected cases Reference standards; Amniocentesis Postnatal examination
Index and comparator tests	NT Second trimester serum free β hCG Second trimester serum AFP Second trimester serum Maternal age NT - FMF methods SERUM - β hCG ELISA immunoradiometric assay AFP ELISA immunoradiometric assay
Follow-up	100% Birth/karyotype

Second trimester serum tests for Down's Syndrome screening (Review)

Rozenberg 2002 (Continued)

Aim of study	Assess combination of first trimester sonographic screening and second trimester serum screening as a single assessment

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different references standard depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Sancken 2003

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	221 participants Germany Dates not specified

Sancken 2003 (Continued)

	Pregnant women
	15-22 weeks gestation
	Known pregnancy outcome
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 33 affected cases Reference standard; Amniocentesis Postnatal karyotype Postnatal examination
Index and comparator tests	Maternal Age Total hCG Free β hCG AFP uE3 Second trimester serum samples AFP and uE3 - Radioimmunoassay Free β hCG - Immunoradiometric assay
Follow-up	100% birth/karyotype
Aim of study	To compare the discriminating efficiency of total hCG vs free β hCG in Down's screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal karyotype Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Different reference standard depending on index test result

Second trimester serum tests for Down's Syndrome screening (Review)

Sancken 2003 (Continued)

Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	One outlier excluded from analysis

Su 2002

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	356 participants Taiwan January 1995 - November 1998 Singleton pregnancies 14-21 weeks gestation
Study design	Retrospective case-control study
Target condition and ref- erence standard(s)	Down's syndrome 36 affected cases Reference standard; Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing
Index and comparator tests	Placental growth factor 95th percentile Sandwich enzyme immunoassay technique (R and D systems, Minneapolis USA)
Follow-up	100% karyotype

Second trimester serum tests for Down's Syndrome screening (Review)

Su 2002 (Continued)

Aim of study   Compare early second trimester maternal placental growth factor concentrations in Down's syndrome pregnancies with those in normal pregnancies

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Postnatal karyotype Miscarriage with cytogenetic testing
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Refence standard differs
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Suzumori 1997

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	1078 participants 15-18 weeks gestation

Suzumori 1997 (Continued)

Japan

April 1994 - March 1996

Singleton pregnancy

Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 14 affected cases Reference standard - amniocentesis
Index and comparator tests	Second trimester serum AFP Second trimester serum hCG Second trimester serum uE3 Maternal age AFP - Abbott Ltd USA hCG - Wallac Finland uE3 - Diagnostic products corps, USA
Follow-up	100% Karyotype
Aim of study	A retrospective evaluation of AFP/hCG/uE3 in maternal blood in the second trimester for aneuploidy screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women had amniocentesis
Differential verification avoided? All tests	Yes	All women had amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study

Second trimester serum tests for Down's Syndrome screening (Review)

Suzumori 1997 (Continued)

Index test results blinded? All tests	Yes	Outcome unknown to operator
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results re-reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Talbot 2003

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	328 participants UK Dates not specified Singleton pregnancies 2nd trimester
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 50 affected cases Reference standards; Amniocentesis Postnatal examination
Index and comparator tests	Second trimester serum hCG glycoform Second trimester serum free β hCG Second trimester serum AFP Maternal age hCG Glycoforms - Lectin immunoassay free β hCG, AFP, total hCG - Kryptor analyser (TRACE)
Follow-up	100% Birth/Karyotype
Aim of study	To assess whether glycoform variants of hCG are presented in altered concentrations in the maternal serum in pregnancies affected by Down's syndrome

Talbot 2003 (Continued)

Notes

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting- screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Poonatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differed according to index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Index test results not known to operator
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Van Lith 1992

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	90 participants The Netherlands Dates not specified Pregnant women

Van Lith 1992 (Continued)

14-18 weeks gestation

Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 10 affected cases Reference standard - Amniocentesis
Index and comparator tests	2nd trimester serum Inhibin A 2 site enzyme immunoassay specific for alpha peptide of human Inhibin AEASIA apparatus
Follow-up	100% karyotype
Aim of study	To assess the usefulness of Inhibin A as a marker for Down's syndrome in the second trimester
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical information? All tests	Yes	Appropriate information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained?	Yes	None

Van Lith 1992 (Continued)

All tests

Verloes 1995

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	10454 participants Belgium January 1991-September 1992 Pregnant women 14-24 weeks by USS
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 15 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	Maternal age Second trimester maternal serum uE3 Second trimester maternal serum hCG Second trimester maternal serum AFP Dried blood samples on blotting paper card Non radioactive immunologic step followed by colorimetric quantification of a horseradish pre oxidase
Follow-up	Birth/Karyotype
Aim of study	To examine the feasibility of large scale Down's syndrome maternal screening with dried blood samples and non-radioactive methods
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination

Second trimester serum tests for Down's Syndrome screening (Review)

Verloes 1995 (Continued)

Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differed
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Analysed without knowledge of karyotype
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Wald 2003a

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	1092 participants UK and Austria (multi-centre trial) September 1996 to April 2000 Pregnant women booking at 8-14 weeks gestation by LMP and confirmed by USS Viable pregnancy
Study design	Prospective nested case-control study
Target condition and reference standard(s)	Down's syndrome 82 affected cases Reference standard; Amniocentesis Postnatal examination

Wald 2003a (Continued)

Index and comparator tests	NT at 9-13 weeks Serum AFP, hCG, uE3, PAPP-A, free β hCG, Inhibin A - 1st and 2nd trimester Urinary β core fragment, total hCG, ITA and free β hCG - 1st and 2nd trimester NT - midsagittal section, optimal magnification of thickness of translucent space between inner skin surface and fascia covering cervical spine (white black interface (outer) - black white interface (inner)) 41 models of ultrasound machine 20 minutes allotted scanning time SERUM - Each Down's pregnancy matched with 5 controls AFP, free β hCG, total hCG, uE3 and PAPP-A measured with time resolved fluoroimmunoassay (AutoDELFIA) Inhibin A - Sandwich enzyme linked immunosorbent assay (Oxford bio innovation) URINE - ITA and β core fragment (Quest diagnostics USA) Total hCG and free β hCG as per serum
Follow-up	96% Birth/Karyotype full outcome documentation obtained
Aim of study	To identify the most effective, safe and cost effective strategy for antenatal screening for Down's syndrome using nuchal translucency, maternal serum and urine markers in the first and second trimesters of pregnancy and maternal age in various combinations
Notes	Performance of screening assessed at 17 weeks gestation

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference standard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoided? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differed depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	No	Known to operator prior to performing reference standard

Second trimester serum tests for Down's Syndrome screening (Review)

Wald 2003a (Continued)

Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Ward 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy Clinical setting - screening programme
Participants	13613 participants UK - single centre 1992-1997 Singleton pregnancies 15-18 weeks gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 16 affected cases Reference standard; Amniocentesis Postnatal examination
Index and comparator tests	2nd trimester serum AFP 2nd trimester serum uE3 2nd trimester serum hCG Maternal age AFP - Amerlite 2T hCG and uE3 - Amerlex M2T
Follow-up	100% birth/karyotype
Aim of study	Analyse triple test results from 1992-1997
Notes	

Table of Methodological Quality

Ward 1999 (Continued)

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Clinical setting - screening programme
Acceptable reference stan- dard? All tests	Yes	Amniocentesis Postnatal examination
Partial verification avoid- ed? All tests	Yes	All women received reference standard
Differential verification avoided? All tests	No	Reference standard differs depending on index test result
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Yes	Performed prior to reference standard
Relevant clinical informa- tion? All tests	Yes	Appropriate clinical information given
Uninterpretable results re- ported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Watanabe 2002

Clinical features and set- tings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	25 participants Japan Dates not specified Singleton pregnancies 15-17 weeks gestation
Study design	Prospective case-control study

Watanabe 2002 (Continued)

Target condition and reference standard(s)	Down's syndrome 5 affected cases Reference standard - Amniocentesis
Index and comparator tests	Second trimester serum PAPP-A Second trimester serum Inhibin A Maternal age PAPP-A - Amerlex M PAPP-A IRMA kit Inhibin A - serotec dimeric Inhibin A immunoassay kit
Follow-up	100% Birth/Karyotype
Aim of study	To determine whether fetal trisomy is associated with altered levels of second trimester maternal PAPP-A and Inhibin A
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	No	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Index test result unknown to operator
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None

Second trimester serum tests for Down's Syndrome screening (Review)

Watanabe 2002 (Continued)

Withdrawals explained?	Yes	None
All tests		

Wenstrom 1997

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	349 participants USA 1992-1996 Pregnant women 14-20 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 33 affected pregnancies Reference standard - Amniocentesis
Index and comparator tests	Second trimester serum Inhibin A Second trimester serum AFP Second trimester serum uE3 Second trimester serum hCG Maternal age Inhibin A - ELISA (Serotec, Oxford) Other serum tests see Wenstrom 1997a
Follow-up	100% karyotype
Aim of study	Determine whether second trimester dimeric Inhibin A levels distinguish Down syndrome pregnancies from euploid pregnancies
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis

Second trimester serum tests for Down's Syndrome screening (Review)

Wenstrom 1997 (Continued)

Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Wenstrom 1997a

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	344 participants USA 1992-1996 Pregnant women 14-20 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 31 affected cases Reference standard - amniocentesis
Index and comparator tests	Second trimester serum AFP Second trimester serum uE3 Second trimester serum hCG

Second trimester serum tests for Down's Syndrome screening (Review)

Wenstrom 1997a (Continued)

Second trimester serum free β hCG

Second trimester serum

Maternal age

AFP - Sarofi Pasteur

Intact hCG - Nichols institute

uE3 - Diagnostic systems laboratory

Free β hCG - CIS - US Bedford, solid phase 2 site sandwich immunoradiometric assay

Follow-up	100% karyotype
Aim of study	Assess the ability of second trimester maternal serum free β hCG to detect fetal Down's syndrome and to compare free β hCG to intact hCG in the multiple marker screening test for Down's syndrome
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained?	Yes	None

Wenstrom 1997a (Continued)

All tests

Wenstrom 1997b

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	328 participants USA 1993-1995 Pregnant women 14-20 weeks gestation
Study design	Retrospective case-control study
Target condition and reference standard(s)	Down's syndrome 22 affected cases Reference standard - amniocentesis
Index and comparator tests	Maternal age Second trimester maternal serum CA125 Second trimester maternal serum AFP Second trimester maternal serum hCG CA125 - ELISA (Centocor) AFP - Sanofi pasteur hCG - Nichols institute
Follow-up	Birth/Karyotype
Aim of study	To determine the ability of second trimester maternal serum CA125 levels to detect fetal Down's syndrome
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis

Wenstrom 1997b (Continued)

Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Yes	Retrospective study
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained? All tests	Yes	None

Wenstrom 1999

Clinical features and settings	Request for Down's syndrome screening in pregnancy High-risk referral for invasive testing
Participants	1256 participants USA August 1996 - August 1998 Pregnant women 14-20/40 gestation
Study design	Prospective consecutive series study
Target condition and reference standard(s)	Down's syndrome 13 affected cases Reference standard - amniocentesis
Index and comparator tests	Second trimester serum AFP Second trimester serum uE3 Second trimester serum total hCG

Second trimester serum tests for Down's Syndrome screening (Review)

Wenstrom 1999 (Continued)

Second trimester serum free β hCG

Second trimester serum Inhibin A

Maternal age

uE3 - Diagnostic systems laboratory, Texas

Inhibin A - Serotec, Oxford

AFP and total hCG - Chemoluminescent procedure on Chiron ACS automatic analyser

Free β hCG - Solid phase 2 site immunoradiometric assay

Follow-up	100% karyotype
Aim of study	To prospectively evaluate the use of free β subunit of hCG and dimeric Inhibin A for the detection of trisomy 21 and other aneuploidies
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	High-risk referral for invasive testing
Acceptable reference standard? All tests	Yes	Amniocentesis
Partial verification avoided? All tests	Yes	All women received amniocentesis
Differential verification avoided? All tests	Yes	All women received amniocentesis
Incorporation avoided? All tests	Yes	Index and reference standards separate
Reference standard results blinded? All tests	Unclear	No information given
Index test results blinded? All tests	Unclear	No information given
Relevant clinical information? All tests	Yes	Appropriate clinical information given
Uninterpretable results reported? All tests	Yes	None
Withdrawals explained?	Yes	None

Wenstrom 1999 (Continued)

All tests

AFP: alpha-fetoprotein

CVS: chorionic villus sampling

hCG: human chorionic gonadotrophin

MoM: multiples of the median

NTD: neural tube defect

PAPP-A: pregnancy-associated plasma protein A

ProMBP: Proform of Eosinophil Major Basic Protein

uE3: unconjugated oestriol

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Abbas 1995	Unable to extract useful data.
Abdul-Hamid 2004	No Down's syndrome pregnancies.
Abraha 1999	Unable to extract useful data.
Adekunle 1999	Unable to extract useful information.
Aitken 1993	Unable to extract useful data.
Aitken 1996a	Fewer than 80% of pregnancies had gestational age confirmed by USS.
Aitken 1996b	Fewer than 80% of pregnancies had gestational age confirmed by USS.
Akbas 2001	Less than 5 Down's syndrome pregnancies.
Antona 1998	Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999	Women screened at greater than 24 weeks gestation.
Ashwood 1987	Unable to extract useful data.
Asrani 2005	Review article.
Audibert 2001b	Unable to ascertain whether part of screening population in Rozenberg et al. No response from authors therefore excluded to reduce risk of data replication.
Axt-Fleider 2006	Unable to extract useful data.
Azuma 2002	Unable to extract useful data.
Baghagho 2004	Unable to obtain paper.
Bahado-Singh 1995	USS markers greater than 14 weeks gestation.
Bahado-Singh 1996	USS markers greater than 14 weeks gestation.
Bahado-Singh 1999b	USS markers greater than 14 weeks gestation.
Bahado-Singh 2002	USS markers greater than 14 weeks gestation.

Study	Reason for exclusion
Bahado-Singh 2003	Review article.
Bar-Hava 2001	No Down's pregnancies in study population.
Barkai 1996	No Down's pregnancies in study population.
Barnabei 1995	No Down's pregnancies in study population.
Bartels 1988	Unable to extract useful data.
Bartels 1993	No Down's pregnancies in study population.
Barth 1991	Second trimester ultrasound study.
Baviera 2004	Unclear method of confirmation of gestational age.
Bazzett 1998	Male versus female fetuses.
Bellver 2005	No Down's syndrome pregnancies in study.
Benn 1995	Less than 80% follow-up.
Benn 1996	Less than 80% follow-up.
Benn 1997	No Down's pregnancies in study population.
Benn 1998	Less than 80% follow-up.
Benn 2001	Statistical modelling (computer simulation).
Benn 2002	Modelled data.
Benn 2003a	Less than 80% of pregnancies dated by USS.
Benn 2003b	Editorial.
Benn 2005a	No Down's pregnancies included.
Benn 2005b	Mathematical model.
Berry 1995	Less than 80% of pregnancies USS dated.
Berry 1997	Less than 80% of pregnancies USS dated.
Bersinger 1994	Gestational age not USS estimated.
Bersinger 2000	Unable to extract useful data.
Bersinger 2001	No Down's syndrome pregnancies in study population.
Bersinger 2003	Unable to extract useful data.
Bersinger 2004	No Down's syndrome pregnancies in study population.
Bersinger 2005	No Down's syndrome pregnancies in study population.

Study	Reason for exclusion
Biggio 2004	Cost-effectiveness analysis.
Bindra 2002	Review article.
Blundell 1999	Unable to extract useful data.
Boots 1989	Population risk factor calculations.
Borruto 2002	Unable to extract useful data.
Boue 1990	Review article.
Bradley 1994	Screen negative population gestations not confirmed by ultrasound.
Braithwaite 1996	Review article.
Brambati 1995	USS screening inclusive of women greater than 14 weeks gestation.
Brambati 1996	Review article.
Brizot 1995a	Unable to extract useful data.
Brizot 1995b	Unable to extract useful data.
Brizzi 1989b	Second trimester ultrasound.
Brock 1990	Unable to extract useful data.
Campogrande 2001	Unable to extract useful data.
Canick 1988	Unable to extract useful data.
Canick 1995b	Unable to extract useful data.
Canini 2002	No Down's syndrome pregnancies in study population.
Cans 1998	Second trimester ultrasound.
Carreras 1991	Second trimester ultrasound.
Chen 1999	Review article.
Chen 2002	No Down's syndrome pregnancies in study population.
Chen 2004	Less than 5 Down's cases in study population.
Chen 2005	Unable to extract useful data.
Cheng 1993	Likely that fewer than 80% of gestational age confirmed by USS.
Cheng 1999	Case series. No Down's syndrome pregnancies in study population.
Cheng 2004a	No Down's syndrome pregnancies in study population.
Cheng 2004b	No Down's syndrome pregnancies in study population.

Study	Reason for exclusion
Chitayat 2002	Less than 5 Down's cases in study population.
Christiansen 2002	Unable to extract useful data.
Christiansen 2007	Unable to extract useful data.
Chung 2000	Less than 5 Down's syndrome pregnancies in study population.
CNGOF 1996	Unable to obtain translation.
Cole 1996	Review article.
Comas 2001	USS at greater than 14 weeks.
Comas 2002a	USS at greater than 14 weeks.
Comas 2002b	USS at greater than 14 weeks.
Comstock 2006	Unable to extract useful data.
Conde 1998	Review article.
Crossley 1991	Less than 80% of pregnancies had gestational age confirmation by ultrasound.
Crossley 1993	Less than 80% of pregnancies had gestational age confirmation by ultrasound.
Crossley 1996	No Down's syndrome pregnancies in study population.
Crossley 2002a	Adjustment factors for smokers.
Cuckle 1984	Gestational age not confirmed by USS.
Cuckle 1987a	Gestational age not confirmed by USS.
Cuckle 1987b	No gestational age limits given.
Cuckle 1990	Paper presenting adjustment factors.
Cuckle 1996	Data modelled on 4 meta-analysed studies.
Cuckle 1999a	Unable to extract useful data.
Cuckle 1999b	Review article.
Cullen 1990	Abnormal scans only in study population.
Cusick 2004	Less than 5 Down's syndrome pregnancies in study population.
D'Ottavio 1997	Second trimester USS.
Dancoine 2001	No Down's syndrome pregnancies in study population.
De Biasio 2000	Unable to extract useful information.

Study	Reason for exclusion
De Biasio, 1999	Unable to ascertain whether overlapping populations between several papers - attempted to contact author with no response.
De Biasio, 2001	Unable to ascertain whether overlapping populations between several papers - attempted to contact author with no response.
De Graaf 1991	Unable to extract useful data.
De Graaf 1999	Modelled data.
DeVore 2001	Second trimester ultrasound.
Dickerson 1994	Comment.
Dimaio 1987	Gestational age by USS only in screen positive population.
Doran 1986	Ultrasound confirmation of gestational age performed in screen positive women only.
Drugan 1996a	Second trimester ultrasound.
Drugan 1996b	Unable to extract useful data.
Drysdale 2002	Fewer than 5 Down's syndrome pregnancies in population.
Ebell 1999	Review article.
Economides 1998	Unable to extract useful data.
Erickson 2004	No Down's syndrome pregnancies in population.
Evans 1996	No Down's syndrome pregnancies in population.
Falcon 2005	Unable to extract useful data.
Falcon 2006	Unable to extract useful data.
Ford 1998	Audit.
Frishman 1997	No Down's syndrome pregnancies in population.
Fukada 2000	Unable to extract useful data.
Ghidini 1998	Comparison of male versus female fetuses.
Goldie 1995	Fewer than 80% of study population had gestational age confirmed by USS.
Gonçalves 2004	Greater than 14 weeks USS screening.
Goodburn 1994	Likely that fewer than 80% of pregnancies had gestational age estimated by USS.
Grozdea 2002	Unable to extract useful data.
Gyselaers 2004a	Less than 80% follow-up.
Gyselaers 2004b	Less than 80% follow-up.

Study	Reason for exclusion
Gyselaers 2006a	Unaffected pregnancies only.
Gyselaers 2006b	Unable to extract useful data.
Hackshaw 1995	No Down's syndrome pregnancies in population.
Hackshaw 2001	No Down's syndrome pregnancies in population
Haddow 1992	Less than 80% of pregnancies had gestational age confirmed by ultrasound scan.
Hafner 1995	Less than 5 Down's pregnancies in study population.
Hallahan 1998	Gestational age greater than 24 weeks.
Harrison 2006	Less than 80% of pregnancies had gestational age confirmed by ultrasound scan.
Harry 2006	Editorial.
Hayashi 1995	Unable to extract useful data.
Hayashi 1996	Less than 5 Down's pregnancies in study population.
Heikkila 1997	Fewer than 80% of pregnancies had gestational age confirmed by USS.
Heinonen 1996	No Down's syndrome pregnancies in population.
Herman 2000	No Down's syndrome pregnancies in study population.
Herman 2003	Correlation between markers, not evaluation of screening tests.
Herrou 1992	Unable to extract useful data.
Hershey 1985	Gestation unclear.
Hershey 1986	Gestation based on LMP.
Hewitt 1993	Unable to extract useful data.
Hogdall 1992	Unclear method of determination of gestational age. Unable to extract useful data.
Hong Kong Practitioner	CME.
Howe 2000	Second trimester ultrasound scans.
Hsiao 1991	Unable to obtain translation.
Hsieh 1999	No Down's syndrome pregnancies in study population.
Hsu 1997b	Adjustment factors.
Hsu 1998a	No Down's syndrome pregnancies in study population.
Hsu 1999b	No Down's pregnancies.
Huang 2003	No Down's syndrome pregnancies in study population.

Study	Reason for exclusion
Huggon 2004	Study of cardiac function in pregnancies with normal and abnormal NT results.
Hui 2003	No Down's syndrome pregnancies in population.
Hui 2005	No Down's syndrome pregnancies in population.
Hultén 2004	Editorial/commentary.
Hung 2003	Modelling.
Hurley 1993	Unable to extract useful data.
Huttly 2004	No Down's syndrome pregnancies in population.
Hwa 2004	Less than 5 Down's pregnancies in population.
Iles 1996	Review.
Ind 1994	Unable to extract useful data.
Jean-Pierre 2005	Review article.
Johnson 1991	Gestational age estimated by USS in fewer than 80% of cases.
Johnson 1993	Normal pregnancies only.
Jorgensen 1999	Gestation greater than 14 weeks for USS.
Josefsson 1998	No Down's syndrome pregnancies in study population.
Jou 2001	Less than 5 Down's syndrome pregnancies in study population.
Jun-Tao 2003	Unable to obtain translation.
Kagan 2006	Screen positive pregnancies only.
Kautzmann 1995	Fewer than 80% pregnancies had gestational age estimated by USS.
Keith 1992	Summary article.
Kelekci 2004	Less than 5 Down's syndrome pregnancies in population.
Kellner 1995a	Less than 5 Down's syndrome pregnancies in population.
Kellner 1995b	Less than 80% follow-up. Unable to ascertain proportion of population with gestational age confirmed by USS.
Kellner 1997	Assumption of normal karyotype without reference standard in significant proportion of control pregnancies.
Knight 1990	Review article.
Knight 2001	Validation of a specific assay.
Knight 2005	Less than 80% of pregnancies had gestational age confirmed by ultrasound scan.

Study	Reason for exclusion
Koos 2006	Review article.
Kornman 1996	Less than 5 Down's syndrome pregnancies in population.
Kornman 1997	Unable to extract useful information.
Kramer 1998	No Down's syndrome pregnancies in study population.
Krantz 1996	Modelled data.
Krantz 2005	Adjustment factor.
Kulch 1993	No Down's cases in population.
Lai 1998	Modelled population..
Lai 2003	No Down's syndrome pregnancies in study population.
Laigaard 2006a	Unable to extract useful data.
Laigaard 2006b	Simulation.
Lam 1997	Unable to extract useful data.
Lam 1998	Fewer than 80% pregnancies had gestational age estimated by USS.
Lam 1999a	No Down's syndrome pregnancies in population
Lam 1999b	Unable to extract useful data
Lam 2000	Study of women's decisions about screening.
Lam 2001	Male versus female fetuses.
Lambert-Messerlian 1996	Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998	Unable to extract useful data.
Lehavi 2005	Down's syndrome pregnancies only.
Leung 2006	Unable to separate twins from singletons therefore unable to extract useful data.
Leymarie 1993	Appears to be a review article (French).
Li 1998	Unable to obtain translation.
Li 1999	Unable to obtain translation.
Liao 1997	Unable to obtain translation.
Liao 2001	Unable to extract useful data.
Lim 2002	Second trimester ultrasound.
Lippman 1987	Editorial.

Study	Reason for exclusion
Lustig 1988	Gestational age by LMP only.
MacDonald 1991	Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994	Unable to extract useful data.
Macintosh 1997	Unable to extract useful data.
Macri 1994	Likely fewer than 80% evaluated for gestational age by ultrasound examination.
Macri 1996	Likely fewer than 80% evaluated for gestational age by ultrasound examination.
Malone 1998	Review article.
Malone 2003	Review article.
Mangione 2001	Abnormal screening results only.
Maymon 2001a	No Down's syndrome pregnancies in study population.
Maymon 2001b	No normal test results included therefore unable to extract meaningful data.
Maymon 2002	No Down's syndrome pregnancies in study population.
Maymon 2004	No Down's syndrome pregnancies in study population.
Maymon 2005	Modelled data.
McDuffie 1996	USS dating on screen positive women only.
Meier 2002	Observed vs expected cases of Down's syndrome in a population.
Merkatz 1984	Gestational age not confirmed by ultrasound scan.
Merz 2005	Editorial.
Metzenbauer 2001	Normal pregnancies only.
Metzenbauer 2002	Unable to extract useful data.
Mikic 1999	No Down's syndrome pregnancies in study population.
Miller 1991	Unable to extract useful data.
Milunsky 1989	Fewer than 80% gestational age estimated by USS.
Milunsky 1996	Fewer than 80% gestational age estimated by USS.
Minobe 2002	Gestational age greater than specified limits.
Miyamura 1999	Unable to extract useful data.
Moghadam 1998	Unable to extract useful data.
Monni 2000	Less than 5 Down's syndrome pregnancies.

Study	Reason for exclusion
Monni 2002	Review article.
Mooney 1994	Greater than 24 weeks gestation.
Muller 1994	No Down's syndrome pregnancies in study population.
Muller 1996b	Unable to extract useful data.
Muller 1999	Unable to extract useful data.
Muller 2002a	Gestational age greater than 24 weeks.
Muller 2002b	Unable to extract meaningful data - unable to separate double and triple test data.
Muller 2003	No Down's syndrome pregnancies in study population.
Murta 2002	Unable to extract useful data.
Musone 2000	Unable to extract useful data.
Musto 1986	Fewer than 80% USS dated.
Myrick 1990	Unable to extract useful data.
Neveux 1996a	No Down's syndrome pregnancies in population.
Neveux 1996b	Unable to extract useful data.
Ng 2004	Unable to extract useful data.
Nicolaidis 1992	Study of outcomes of abnormal NT results.
Nicolaidis 2000	Review article.
Nicolaidis 2004	Review article.
Nicolaidis 2005a	Unable to obtain translation - appears to be a review article.
Nicolaidis 2005b	Unable to obtain translation - appears to be a review article.
Nicolaidis 2005c	Unable to obtain translation - appears to be a review article.
Nicolaidis 2005d	Unable to obtain translation - appears to be a review article.
Nicolaidis 2005e	Unable to obtain translation - appears to be a review article.
Nicolaidis 2005f	Review article.
Niemimaa 2001	No Down's pregnancies in study population.
Niemimaa 2002	No Down's syndrome pregnancies in population.
Niemimaa 2003	No Down's syndrome pregnancies in population.
Noble 1997	Unable to extract useful data.

Study	Reason for exclusion
Norgaard 1990	Less than 80% of gestational ages confirmed by USS.
Norton 1992	Unable to extract useful data.
O'Brien 1997a	No Down's syndrome pregnancies in population.
O'Brien 1997b	No Down's syndrome pregnancies in population.
Odibo 2004	Gestational age of greater than 14 weeks in USS population.
Ognibene 1999	Unable to extract useful data.
Olajide 1989	Unable to extract useful data.
Onda 1996	Unable to extract useful data
Onda 1998	Unable to extract useful data.
Onda 2000	Less than 80% follow-up.
Orlandi 2002	No Down's syndrome pregnancies in study population
Palka 1998	Twin data used in calculation of the median.
Palomaki 1989	Fewer than 80% USS dated.
Palomaki 1993	No Down's syndrome pregnancies in population.
Palomaki 1994	No Down's syndrome pregnancies in population.
Palomaki 1996	Meta-analysis.
Palomaki 2005	Unable to extract meaningful data.
Panburana 2001	Less than 5 Down's syndrome pregnancies in population.
Pandya 1994	Study of outcomes of abnormal NT results.
Pandya 1995	Review article.
Paul 2001	Unable to extract useful data.
Peralta 2005	Unable to extract useful data.
Perenc 1998	No Down's syndrome pregnancies in study population.
Perheentupa 2002	No Down's syndrome pregnancies in population.
Perona 1998	Smokers versus non smokers.
Petervari 2000	Unable to extract useful data.
Petrocik 1989	Likely fewer than 80% USS dated.
Phillips 1992	Gestational age confirmed by USS in less than 80% of population.

Study	Reason for exclusion
Phillips 1993	Gestational age confirmed by USS in less than 80% of population.
Pinette 2003	Women screened prior to recruitment.
Platt 2004	Unable to extract useful data.
Podobnik 1995	Abnormal results only.
Prefumo 2002	Comparison of prevalence and prediction.
Prefumo 2004	Comparison of a marker in women of different ethnic origins.
Price 1998	Unable to extract useful data.
Páez 2004	Unable to obtain translation.
Raty 2000	No Down's syndrome pregnancies in population.
Rembouskos 2004	Unable to extract useful data.
Ren 1992	Review article.
Renier 1998	Method of ascertainment of gestational age unclear. Twin gestations included in general population.
Resta 1990	Second trimester USS.
Reynders 1997	Fewer than 5 Down's cases.
Reynolds 1989	Explanation of mathematical techniques.
Reynolds 1999	Unable to extract useful data.
Ribbert 1996	No Down's syndrome pregnancies in study population.
Rice 2005	Down's syndrome pregnancies excluded from study.
Rich 1991	Unable to extract useful data.
Roberts 1995	No Down's syndrome pregnancies in study population.
Robertson 1991	Editorial.
Rode 2003	No Down's pregnancies.
Ronge 2006	Editorial - summary of FASTER results.
Rose 1995	Review article.
Ross 1997	Review article.
Rotmensch 1996	Unable to extract useful data.
Rotmensch 1999	No Down's syndrome pregnancies in study population.

Study	Reason for exclusion
Rozenberg 2006	USS greater than 14 weeks gestation.
Rudnicka 2002	No Down's syndrome pregnancies in population.
Ryall 1992	Unable to determine method of confirmation of gestational age.
Ryall 2001	High-risk results only included (i.e. no screen negative group for comparison).
Räty 2002	No Down's pregnancies in population.
Sabriá 2002	Unable to ascertain how numbers calculated and from which populations.
Sacchini 2003	Unable to extract useful data.
Saller 1997	Down's syndrome secondary to Robertsonian translocation only. No controls.
Salomon 2001	No Down's syndrome pregnancies in population.
Salonen 1997	Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005	Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996	Down's syndrome and Edward's syndrome affected pregnancies only.
Savoldelli 1993	Unable to extract useful data.
Schiott 2006	Unable to extract useful data.
Schuchter 1998	No Down's pregnancies in study population.
Scott 1995	Less than 5 Down's syndrome pregnancies in study population.
Seeds 1990	Review article.
Seki 1995	No Down's syndrome pregnancies in study population.
Shenhav 2003	No Down's syndrome pregnancies.
Shintaku 1989	Unable to extract useful data.
Shulman 2003	No Down's syndrome pregnancies in population.
Simon-Bouy 1999	Review article.
Simpson 1986	Gestational age confirmed by USS in less than 80% of population.
Smith 1990	Analysis of screen positive results.
Smith 1996	Review/meta-analysis.
Smith 1999	Unable to extract useful data.
Smith-Bindman 2001	Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003	Population study, not examining DTA.

Study	Reason for exclusion
Snijders 1995	Study of prevalence, not screening.
Snijders 1999	Study of prevalence, not screening.
Soergel 2006	Less than 80% follow-up.
Sokol 1998	Observation of Down's prevalence stratified by age.
Sonek 2003	Editorial.
Spencer 1985	Fewer than 80% USS dated.
Spencer 1991a	Likely fewer than 80% USS dated.
Spencer 1991b	Unable to extract useful data.
Spencer 1992	Unable to extract useful data.
Spencer 1993a	Fewer than 80% USS dated.
Spencer 1993b	No Down's pregnancies in study population.
Spencer 1993c	Unable to extract useful data.
Spencer 1993d	Fewer than 80% of pregnancies had gestational age confirmed by USS.
Spencer 1993e	Unable to extract useful data.
Spencer 1995	No Down's pregnancies in population.
Spencer 1996a	Fewer than 80% of pregnancies had gestational age confirmed by USS.
Spencer 1997	Statistical modelling, aneuploid pregnancies only in study population.
Spencer 1998a	No Down's pregnancies in population.
Spencer 1998b	Unable to extract useful data.
Spencer 1999a	Review.
Spencer 1999b	Statistical methods paper.
Spencer 2000a	Examination of median shifts rather than an evaluation of screening.
Spencer 2000b	No Down's syndrome pregnancies in population.
Spencer 2000c	No Down's syndrome pregnancies in population.
Spencer 2000d	No Down's cases.
Spencer 2000e	Male versus female fetuses.
Spencer 2000f	No Down's cases in population.
Spencer 2000g	No Down's pregnancies in population.

Study	Reason for exclusion
Spencer 2000h	No Down's pregnancies in population.
Spencer 2000i	Comparison of fetal sex.
Spencer 2001	No Down's syndrome pregnancies in population.
Spencer 2001a	Unable to extract useful data.
Spencer 2001b	Unable to extract useful data.
Spencer 2001c	Unable to extract useful data.
Spencer 2001d	No Down's syndrome pregnancies in population.
Spencer 2002a	No Down's pregnancies.
Spencer 2002b	Risk validation study.
Spencer 2002c	No Down's syndrome pregnancies in population.
Spencer 2002d	Demonstration of median changes with time, rather than evaluation of screening.
Spencer 2003a	No Down's pregnancies in population.
Spencer 2003b	No Down's pregnancies in population.
Spencer 2003c	Calculation of weight correction factor.
Spencer 2003d	Fewer than 5 Down's syndrome pregnancies.
Spencer 2004	Calculation of smoking correction factor.
Spencer 2005a	No Down's pregnancies.
Spencer 2005b	No Down's pregnancies.
Spencer 2005c	Comparison of two different assays - not actual screening evaluation.
Spong 1999	Comparison of male and female fetuses.
Stevens 1998	Literature review.
Stoll 1992	Review article.
Su 2002a	Unable to extract useful data.
Suchet 1995	Review article.
Suchy 1990	Unable to ascertain method of confirmation of gestational age.
Summers 2003a	Only 55% gestational ages estimated by USS.
Summers 2003b	No Down's syndrome pregnancies in study population.
Suntharasaj 2005	Examination of inter-observer variation in NT scanning.

Study	Reason for exclusion
Sutton 2004	Unable to extract useful data.
Suzuki 1998	Unable to extract useful data.
Tabor 1987	Geststional age not confirmed by USS.
Tanski 1999	Information on screen positive pregnancies only.
Thilaganathan 1998	No Down's syndrome pregnancies in study population.
Thilaganathan 1999	Editorial.
Tislaric 2002	No Down's syndrome pregnancies in population.
Torok 1997	Unable to extract useful data.
Tsai 2001	Less than 5 Down's syndrome pregnancies in study population.
Valerio 1996	Fewer than 80% pregnancies had gestational age estimated by USS.
Van Blerk 1992	Unable to extract useful data.
Van Heesch, 2006	No Down's syndrome pregnancies in study population. Software comparison study.
Van Lith 1991	Unable to extract useful data.
Van Lith 1993	Unable to extract useful data.
Van Lith 1994	Unable to extract useful data.
Veress 1986	Unable to extract useful data.
Veress 1988	Unable to extract useful data.
Vintzileos 2003	Second trimester USS.
Wald 1988a	Less than 80% had gestational age confirmed by ultrasound.
Wald 1988b	Gestational age not confirmed by USS.
Wald 1991	No Down's pregnancies in study.
Wald 1992a	Less than 80% had gestational age confirmed by ultrasound.
Wald 1992b	No Down's pregnancies in study.
Wald 1992c	No Down's pregnancies in study.
Wald 1993	No USS dating.
Wald 1994a	No Down's syndrome pregnancies in population.
Wald 1994b	Review article.
Wald 1996a	No Down's pregnancies.

Study	Reason for exclusion
Wald 1996b	Dated by LMP.
Wald 1996d	No Down's syndrome pregnancies in population.
Wald 1996e	Gestational age greater than 24 weeks.
Wald 1997	Data modelled on 3 separate populations of women.
Wald 1998	Unable to extract useful data.
Wald 1999a	Unable to extract useful data.
Wald 1999b	Gestational age not confirmed by USS.
Wald 1999c	No Down's syndrome pregnancies.
Wald 1999d	Modelled on several studies, some of which have no USS dating.
Wald 2003b	No cases.
Wald 2003c	Less than 80% had gestational age confirmed by USS.
Wald 2006	Modelled on SURRUS data.
Wallace 1994	Unable to extract useful data.
Wallace 1997	No Down's syndrome pregnancies in study population.
Ward 2005	Review article.
Watt 1996a	No Down's syndrome pregnancies in study population.
Watt 1996b	No Down's syndrome pregnancies in study population.
Weinans 2001	Unable to extract useful data.
Weinans 2004	Study of women's views on screening.
Welborn 1994	Abnormal results only (cystic hygroma).
Wenstrom 1993	Less than 80% of pregnancies had gestational age confirmed by USS.
Wenstrom 1995a	Adjustment factors.
Wenstrom 1995b	Less than 80% of pregnancies had gestational age confirmed by USS.
Whitlow 1998a	Unable to extract useful data.
Whitlow 1998b	Unable to extract useful data.
Whitlow 1999	Unable to extract useful data.
Williamson 1994	Likely fewer than 80% USS dated.
Wilson 2000	Review.

Study	Reason for exclusion
Wojdemann 2001	No Down's syndrome pregnancies in study population.
Wong 2003	Less than 5 Down's syndrome pregnancies in population.
Wright 2006	Mathematical model.
Yagel 1998	Second trimester USS.
Yamamoto 2001a	Unable to extract useful data.
Yamamoto 2001b	Method of determination of gestational age unclear.
Yamamoto 2001c	Unable to extract useful data.
Yaron 2001	Male versus female fetuses.
Ye 1995	Unable to obtain translation.
Yoshida 2000	Fewer than 80% pregnancies had gestational age estimated by USS.
Zeitune 1991	Only aneuploid pregnancies included in study.
Zelop 2005	No Down's cases in population.
Zhao 1998	Unable to obtain translation.
Zoppi 2003	Inappropriate study design.

LMP: last menstrual period

USS: ultrasound screening

DATA

Presented below are all the data for all of the tests entered into the review.

Table Tests. Data tables by test

Test	No. of studies	No. of participants
1 Inhibin A at mixed cutpoints	4	1590
2 Inhibin A at 5% FPR	2	1192
3 Inhibin A at 2.4MoM	1	90
4 Inhibin A at 2 MoM	2	398
5 SP1 at mixed cutpoints	3	777
6 SP1 at 2.5MoM	1	325

Test	No. of studies	No. of participants
7 SP1 at 5% FPR	2	452
8 AFP at mixed cutpoints	5	14201
9 AFP at 0.8MoM	1	3272
10 AFP at 5% FPR	3	9457
11 AFP at SD (specified in paper)	1	1472
12 Total hCG at 5% FPR	2	1192
13 Total hCG at 2.5MoM	1	246
14 Total hCG at mixed cutpoints	3	1438
15 Free β hCG at 5% FPR	2	9357
16 uE3 at 5% FPR	2	1192
17 Troponin at 5% FPR	1	283
18 Free β hCG to AFP ratio at 5% FPR	1	8265
19 PAPP-A at 5% FPR	1	1092
20 PGF at 95th percentile	1	356
21 CA125 at 1.5MoM	1	328
22 Age and Total hCG at 5% FPR/95th percentile	3	57257
23 Age and Total hCG at mixed cutpoints	4	57768
24 Age and Total hCG at 1:384 risk	1	511
25 Age and AFP at 1:270 risk	1	3896
26 Age and AFP at 5% FPR	2	9357
27 Age and AFP at mixed cutpoints	4	13764
28 Age and Free β hCG at mixed cutpoints	4	14985
29 Age and Free β hCG at 1:384 risk	1	511
30 Age and uE3 at mixed cutpoints	2	1603
31 Age and uE3 at 1:384 risk	1	511
32 Age and Free β hCG to AFP at 5% FPR	1	8265
33 Age and inhibin at 5% FPR	2	1117

Test	No. of studies	No. of participants
34 Age and PAPP-A at 5% FPR	2	1117
35 Age and ProMBP at 1:250 risk	1	256
36 Age and Free α hCG at 1:384 risk	1	511
37 Age, Total hCG and Free β hCG at 1:384 risk	1	511
38 Age, Total hCG and uE3 at 5% FPR	1	370
39 Age, Total hCG and uE3 at 1:384 risk	1	511
40 Age, Total hCG and uE3 at mixed cutpoints	2	881
41 Age, Total hCG and AFP at 5% FPR	4	22816
42 Age, Total hCG and AFP at 1:250 risk	6	43519
43 Age, Total hCG and AFP at mixed cutpoints	15	133783
44 Age, Total hCG and SP1at 5% FPR	1	370
45 Age, Total hCG and Free α hCG at 1:384 risk	1	511
46 Age, Free β hCG and uE3 at 1:384 risk	1	511
47 Age, Free β hCG and AFP at 1:250 risk	3	15912
48 Age, Free β hCG and AFP at 5% FPR	5	23979
49 Age, Free β hCG and AFP at mixed cutpoints	12	45597
50 Age, Free β hCG and Free α hCG at 1:384 risk	1	511
51 Age, AFP and uE3 at 1:384 risk	1	511
52 Age, AFP and uE3 at 5% FPR	1	370
53 Age, AFP and uE3 at mixed cutpoints	2	881
54 Age, uE3 and Free α hCG at 1:384 risk	1	511
55 Age, uE3 and SP1 at 5% FPR	1	370
56 Age, AFP and SP1 at 5% FPR	1	370
57 Age, AFP and Hyperglycosylated hCG at 5% FPR	1	328
58 Age, AFP and Free α hCG 1:384 risk	1	511
59 Age, Total hCG, Free β hCG and AFP at 1:266 risk	1	344
60 Age, Total hCG, AFP and uE3 at 5% FPR	7	15453

Test	No. of studies	No. of participants
61 Age, Total hCG, AFP and uE3 at 1:250 risk	5	30910
62 Age, Total hCG, AFP and uE3 at mixed cutpoints	24	89047
63 Age, Total hCG, uE3 and SP1 at 5% FPR	1	370
64 Age, Total hCG, AFP and Inhibin A at 1:190 risk	2	564
65 Age, Total hCG, AFP and Inhibin A at 1:250 risk	1	218
66 Age, Total hCG, AFP and SP1 at 5% FPR	1	370
67 Age, Total hCG, AFP and CA125 at 1:190 risk	1	328
68 Age, Free β hCG, AFP and uE3 at 5% FPR	3	6430
69 Age, Free β hCG, AFP and uE3 at 1:250 risk	2	1809
70 Age, Free β hCG, AFP and uE3 at mixed cutpoints	7	10541
71 Age, Free β hCG, AFP and Inhibin A at 1:190 risk	1	1256
72 Age, Free β hCG, AFP and ProMBP at 5% FPR	1	334
73 Age, Free β hCG, AFP and ProMBP at 1:250 risk	1	334
74 Age, AFP, uE3 and Free α hCG at 1:384 risk	1	511
75 Age, AFP, uE3 and Inhibin A at 1:233 risk	1	346
76 Age, AFP, uE3 and SP1 at 5% FPR	1	370
77 Age, Total hCG, Free β hCG, AFP and uE3 at 1:384 risk	1	511
78 Age, Total hCG, AFP, uE3 and Inhibin A at 5% FPR	1	1092
79 Age, Total hCG, AFP, uE3 and Inhibin A at 1:150 risk	3	2014
80 Age, Total hCG, AFP, uE3 and Inhibin A at 1:250 risk	2	758
81 Age, Total hCG, AFP, uE3 and Inhibin A at mixed cutpoints	5	38342
82 Age, Total hCG, AFP, uE3 and Free α hCG at 1:384 risk	1	511
83 Age, Total hCG, AFP, uE3 and SP1 at 5% FPR	1	370
84 Age, Free β hCG, AFP, uE3 and Inhibin A at 5% FPR	1	1092
85 Age, Free β hCG, AFP, uE3 and Inhibin A at 1:250 risk	1	1092
86 Age, Free β hCG, AFP, uE3 and Inhibin A at mixed cutpoints	2	2348
87 Age, Total hCG, AFP, uE3, Inhibin A and PAPP-A at 5% FPR	1	1092

Test	No. of studies	No. of participants
88 Age, Total hCG, Free β hCG, AFP, uE3 and Free α hCG at 1:384 risk	1	511
89 Age, Free β hCG, AFP, uE3, Inhibin A and PAPP-A at 5%FPR	1	1092

Test 1. Inhibin A at mixed cutpoints.

Test 2. Inhibin A at 5% FPR.

Test 3. Inhibin A at 2.4MoM.

Test 4. Inhibin A at 2 MoM.

Test 5. SP1 at mixed cutpoints.

Test 6. SP1 at 2.5MoM.

Test 7. SP1 at 5% FPR.

Test 8. AFP at mixed cutpoints.

Test 9. AFP at 0.8MoM.

Test 10. AFP at 5% FPR.

Test 11. AFP at SD (specified in paper).

Test 12. Total hCG at 5% FPR.

Test 13. Total hCG at 2.5MoM.

Test 14. Total hCG at mixed cutpoints.

Test 15. Free β hCG at 5% FPR.

Test 16. uE3 at 5% FPR.

Test 17. Troponin at 5% FPR.

Test 18. Free β hCG to AFP ratio at 5% FPR.

Test 19. PAPP-A at 5% FPR.

Test 20. PGF at 95th percentile.

Test 21. CA125 at 1.5MoM.

Test 22. Age and Total hCG at 5% FPR/95th percentile.

Test 23. Age and Total hCG at mixed cutpoints.

Test 24. Age and Total hCG at 1:384 risk.

Test 25. Age and AFP at 1:270 risk.

Test 26. Age and AFP at 5% FPR.

Test 27. Age and AFP at mixed cutpoints.

Test 28. Age and Free β hCG at mixed cutpoints.

Test 29. Age and Free β hCG at 1:384 risk.

Test 30. Age and uE3 at mixed cutpoints.

Test 31. Age and uE3 at 1:384 risk.

Test 32. Age and Free β hCG to AFP at 5% FPR.

Test 33. Age and inhibin at 5% FPR.

Test 34. Age and PAPP-A at 5% FPR.

Test 35. Age and ProMBP at 1:250 risk.

Test 36. Age and Free α hCG at 1:384 risk.

Test 37. Age, Total hCG and Free β hCG at 1:384 risk.

Test 38. Age, Total hCG and uE3 at 5% FPR.

Test 39. Age, Total hCG and uE3 at 1:384 risk.

Test 40. Age, Total hCG and uE3 at mixed cutpoints.

Test 41. Age, Total hCG and AFP at 5% FPR.

Test 42. Age, Total hCG and AFP at 1:250 risk.

Test 43. Age, Total hCG and AFP at mixed cutpoints.

Test 44. Age, Total hCG and SP1at 5% FPR.

Test 45. Age, Total hCG and Free α hCG at 1:384 risk.

Test 46. Age, Free β hCG and uE3 at 1:384 risk.

Test 47. Age, Free β hCG and AFP at 1:250 risk.

Test 48. Age, Free β hCG and AFP at 5% FPR.

Test 49. Age, Free β hCG and AFP at mixed cutpoints.

Test 50. Age, Free β hCG and Free α hCG at 1:384 risk.

Test 51. Age, AFP and uE3 at 1:384 risk.

Test 52. Age, AFP and uE3 at 5% FPR.

Test 53. Age, AFP and uE3 at mixed cutpoints.

Test 54. Age, uE3 and Free α hCG at 1:384 risk.

Test 55. Age, uE3 and SP1 at 5% FPR.

Test 56. Age, AFP and SP1 at 5% FPR.

Test 57. Age, AFP and Hyperglycosylated hCG at 5% FPR.

Test 58. Age, AFP and Free α hCG 1:384 risk.

Test 59. Age, Total hCG, Free β hCG and AFP at 1:266 risk.

Test 60. Age, Total hCG, AFP and uE3 at 5% FPR.

Test 61. Age, Total hCG, AFP and uE3 at 1:250 risk.

Test 62. Age, Total hCG, AFP and uE3 at mixed cutpoints.

Test 63. Age, Total hCG, uE3 and SP1 at 5% FPR.

Test 64. Age, Total hCG, AFP and Inhibin A at 1:190 risk.

Test 65. Age, Total hCG, AFP and Inhibin A at 1:250 risk.

Test 66. Age, Total hCG, AFP and SP1 at 5% FPR.

Test 67. Age, Total hCG, AFP and CA125 at 1:190 risk.

Test 68. Age, Free β hCG, AFP and uE3 at 5% FPR.

Test 69. Age, Free β hCG, AFP and uE3 at 1:250 risk.

Test 70. Age, Free β hCG, AFP and uE3 at mixed cutpoints.

Test 71. Age, Free β hCG, AFP and Inhibin A at 1:190 risk.

Test 72. Age, Free β hCG, AFP and ProMBP at 5% FPR.

Test 73. Age, Free β hCG, AFP and ProMBP at 1:250 risk.

Test 74. Age, AFP, uE3 and Free α hCG at 1:384 risk.

Test 75. Age, AFP, uE3 and Inhibin A at 1:233 risk.

Test 76. Age, AFP, uE3 and SP1 at 5% FPR.

Test 77. Age, Total hCG, Free β hCG, AFP and uE3 at 1:384 risk.

Test 78. Age, Total hCG, AFP, uE3 and Inhibin A at 5% FPR.

Test 79. Age, Total hCG, AFP, uE3 and Inhibin A at 1:150 risk.

Test 80. Age, Total hCG, AFP, uE3 and Inhibin A at 1:250 risk.

Test 81. Age, Total hCG, AFP, uE3 and Inhibin A at mixed cutpoints.

Test 82. Age, Total hCG, AFP, uE3 and Free α hCG at 1:384 risk.

Test 83. Age, Total hCG, AFP, uE3 and SP1 at 5% FPR.

Test 84. Age, Free β hCG, AFP, uE3 and Inhibin A at 5% FPR.

Test 85. Age, Free β hCG, AFP, uE3 and Inhibin A at 1:250 risk.

Test 86. Age, Free β hCG, AFP, uE3 and Inhibin A at mixed cutpoints.

Test 87. Age, Total hCG, AFP, uE3, Inhibin A and PAPP-A at 5% FPR.

Test 88. Age, Total hCG, Free β hCG, AFP, uE3 and Free α hCG at 1:384 risk.

Test 89. Age, Free β hCG, AFP, uE3, Inhibin A and PAPP-A at 5%FPR.

ADDITIONAL TABLES

Second trimester serum tests for Down's Syndrome screening (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Table 1. Direct comparisons of the diagnostic accuracy of the 12 test strategies

Ratio of DOR (95% CI); P value (studies)	Free β hCG AFP uE3 Inhibin PAPP (quintuple)	Total hCG AFP uE3 Inhib- in PAPP (quintuple)	Total hCG AFP Inhib- in (triple)	Total hCG AFP uE3 Inhibin (quadruple)	Free β hCG AFP uE3 In- hibin (quadruple)	Free β hCG AFP uE3 (triple)	Total hCG AFP (double)	Free β hCG AFP (double)
Total hCG AFP uE3 Inhibin PAPP	1.1 (0.4,2.7); P=0.85 (K=1)	-	-	-	-	-	-	-
Total hCG AFP In- hibin	-	-	-	-	-	-	-	-
Total hCG AFP uE3 Inhibin	1.3 (0.5,3.2); P=0.58 (K=1)	1.2 (0.5,2.9); P=0.72 (K=1)	1.6 (0.2,10.1); P=0.64 (K=1)	-	-	-	-	-
Free β hCG AFP uE3 Inhibin	1.1 (0.5,2.9); P=0.77 (K=1)	1.0 (0.4,2.6); P=0.92 (K=1)	-	0.8 (0.4,1.7); P=0.60 (K=2)	-	-	-	-
Free β hCG AFP uE3	1.8 (0.7,4.4); P=0.19 (K=1)	1.6 (0.7,4.0); P=0.26 (K=1)	-	1.4 (0.6,3.3); P=0.44 (K=1)	1.6 (0.7,3.8); P=0.31 (K=1)	-	-	-
Total hCG AFP	2.8 (1.2,6.4); P=0.02 (K=1)	2.5 (1.1,5.8); P=0.03 (K=1)	4.4 (0.8,25.7); P=0.10 (K=1)	2.3 (1.1,4.7); P=0.03 (K=2)	2.4 (1.0,5.6); P=0.04 (K=1)	1.2 (0.7,1.9); P=0.56 (K=3)	-	-
Free β hCG AFP	2.2 (0.9,5.2); P=0.07 (K=1)	2.0 (0.9,4.7); P=0.11 (K=1)	-	1.7 (0.7,3.9); P=0.21 (K=1)	1.9 (0.8,4.5); P=0.14 (K=1)	1.2 (0.8,1.9); P=0.34 (K=5)	1.0 (0.6,1.6); P=0.91 (K=4)	-
Total hCG AFP uE3	1.8 (0.8,4.4); P=0.17 (K=1)	1.7 (0.7,3.9); P=0.24 (K=1)	2.0 (0.3,12.7); P=0.47 (K=1)	1.2 (0.6,2.3); P=0.55 (K=3)	1.6 (0.8,3.2); P=0.22 (K=2)	1.0 (0.7,1.6); P=0.93 (K=6)	0.9 (0.6,1.3); P=0.66 (K=6)	0.9 (0.6,1.4); P=0.56 (K=5)
Free β hCG	3.4 (1.5,7.9); P=0.004 (K=1)	3.1 (1.4,7.1); P=0.007 (K=1)	-	2.6 (1.2,5.9); P=0.02 (K=1)	3.0 (1.3,6.8); P=0.01 (K=1)	2.0 (1.2,3.3); P=0.008 (K=3)	1.7 (1.0,2.8); P=0.04 (K=3)	1.5 (1.0,2.3); P=0.06 (K=4)

Table 1. Direct comparisons of the diagnostic accuracy of the 12 test strategies (Continued)

Total hCG	4.8 (2.1,11.1); P=0.0002 (K=1)	4.4 (1.9,10.0); P=0.0004 (K=1)	-	3.7 (1.7,8.4); P=0.001 (K=1)	4.2 (1.8,9.6); P=0.0007 (K=1)	2.2 (1.3,3.6); P=0.003 (K=3)	1.9 (1.1,3.1); P=0.01 (K=3)	1.8 (1.1,3.0); P=0.02 (K=3)
AFP	7.5 (3.2,17.3); P=<0.0001 (K=1)	6.9 (3.0,15.7); P<0.0001 (K=1)	-	5.8 (2.6,13.1); P<0.0001 (K=1)	6.5 (2.8,15.1); P<0.0001 (K=1)	3.1 (1.5,6.2); P=0.002 (K=2)	2.2 (1.2,4.4); P=0.02 (K=2)	2.7 (1.6,4.5); P=0.0001 (K=3)
Ratio of DOR (95% CI); P-value (stud- ies)	Total hCG AFP uE3 (triple)	Free β hCG (single)	Total hCG (single)					
Free β hCG	2.0 (1.2,3.4); P=0.005 (K=3)							
Total hCG	2.2 (1.4,3.7); P=0.002 (K=3)	1.1 (0.7,1.8); P=0.70 (K=3)						
AFP	2.9 (1.5,5.8); P=0.002 (K=2)	1.9 (1.1,3.0); P=0.01 (K=3)	1.1 (0.6,2.1); P=0.81 (K=2)					

Direct comparisons are made only using data from studies which compare each pair of tests on the same women. Relative DOR are computed by division of the DOR for the column by the DOR for the row. If the relative DOR is greater than one then the diagnostic accuracy of the test for the column is higher than that for the row, if less than one the diagnostic accuracy of the test in the row is higher than in the column. All test combinations include maternal age. - indicates that no comparative study is available.

Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies

Ratio of DOR (95% CI); P val- ue	Free βhCG AFP uE3 Inhibin PAPP (quintuple)	Total hCG AFP uE3 In- hibin PAPP (quintuple)	Total hCG AFP Inhibin (triple)	Total hCG AFP uE3 In- hibin (quadruple)	Free β hCG AFP uE3 Inhib- in (quadru- ple)	Free β hCG AFP uE3 (triple)	Total hCG AFP (double)	Free β hCG AFP (double)

Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies (Continued)

	DOR (95% CI) Studies	88 (35,224) <i>k</i> =1	80 (32,201) <i>k</i> =1	71 (23,220) <i>k</i> =2	50 (30,84) <i>k</i> =5	41 (18,94) <i>k</i> =2	34 (21,53) <i>k</i> =7	27 (19,39) <i>k</i> =15	26 (18,38) <i>k</i> =12
Total hCG AFP uE3 Inhibin PAPPA	80 (32,201) <i>k</i> =1	1.1 (0.3,4.1); <i>P</i> =0.87							
Total hCG AFP Inhibin	71 (23,220) <i>k</i> =2	1.2 (0.3,5.3); <i>P</i> =0.77	1.1 (0.3,4.8); <i>P</i> =0.88						
Total hCG AFP uE3 Inhibin	50 (30,84) <i>k</i> =5	1.8 (0.6,5.1); <i>P</i> =0.29	1.6 (0.6,4.6); <i>P</i> =0.39	1.4 (0.4,4.9); <i>P</i> =0.58					
Free β hCG AFP uE3 Inhibin	41 (18,84) <i>k</i> =2	2.1 (0.6,7.4); <i>P</i> =0.23	1.9 (0.6,6.7); <i>P</i> =0.30	1.7 (0.4,7.0); <i>P</i> =0.44	1.2 (0.5,3.2); <i>P</i> =0.69				
Free β hCG AFP uE3	34 (21,53) <i>k</i> =7	2.6 (0.9,7.4); <i>P</i> =0.06	2.4 (0.9,6.6); <i>P</i> =0.10	2.1 (0.6,7.2); <i>P</i> =0.23	1.5 (0.8,2.9); <i>P</i> =0.24	1.2 (0.5,3.2); <i>P</i> =0.67			
Total hCG AFP	27 (19,39) <i>k</i> =15	3.3 (1.2,8.7); <i>P</i> =0.02	2.9 (1.1,7.8); <i>P</i> =0.03	2.6 (0.8,8.6); <i>P</i> =0.11	1.8 (1.0,3.4); <i>P</i> =0.05	1.5 (0.6,3.7); <i>P</i> =0.37	1.2 (0.7,2.1); <i>P</i> =0.43		
Free β hCG AFP	26 (18,38) <i>k</i> =12	3.4 (1.3,9.3); <i>P</i> =0.01	3.1 (1.2,8.3); <i>P</i> =0.03	2.8 (0.8,9.1); <i>P</i> =0.09	1.9 (1.0,3.6); <i>P</i> =0.04	1.6 (0.6,4.0); <i>P</i> =0.31	1.3 (0.7,2.3); <i>P</i> =0.35	1.1 (0.7,1.7); <i>P</i> =0.81	
Total hCG AFP uE3	21 (16,28) <i>k</i> =24	4.3 (1.6,11.2); <i>P</i> =0.003	3.8 (1.5,10.0); <i>P</i> =0.006	3.4 (1.1,11.0); <i>P</i> =0.04	2.4 (1.4,4.3); <i>P</i> =0.003	2.0 (0.8,4.7); <i>P</i> =0.12	1.6 (1.0,2.7); <i>P</i> =0.06	1.3 (0.9,1.9); <i>P</i> =0.18	1.2 (0.8,1.9); <i>P</i> =0.33
Free β hCG	14 (8,24) <i>k</i> =4	6.4 (2.2,18.5); <i>P</i> =0.0005	5.8 (2.0,16.6); <i>P</i> =0.001	5.2 (1.5,18.2); <i>P</i> =0.01	3.6 (1.8,7.5); <i>P</i> =0.0004	3.0 (1.1,8.0); <i>P</i> =0.03	2.4 (1.3,4.7); <i>P</i> =0.007	2.0 (1.1,3.5); <i>P</i> =0.02	1.9 (1.0,3.4); <i>P</i> =0.04
Total hCG	12 (8,20) <i>k</i> =4	7.3 (2.6,20.4); <i>P</i> =0.0002	6.6 (2.3,18.4); <i>P</i> =0.0004	5.9 (1.7,20.1); <i>P</i> =0.005	4.1 (2.1,8.2); <i>P</i> <0.0001	3.4 (1.3,8.7); <i>P</i> =0.01	2.8 (1.5,5.2); <i>P</i> =0.001	2.2 (1.3,3.8); <i>P</i> =0.003	2.1 (1.2,3.7); <i>P</i> =0.009

Table 2. Indirect comparisons of the diagnostic accuracy of the 12 test strategies (Continued)

AFP	8 (5,14) k=4	10.8 (3.7,31.4); P=<0.0001	9.7 (3.3,28.1) P<0.0001	8.6 (2.4,30.6); P=0.0008	6.1 (2.9,12.8); P<0.0001	5.0 (1.8,13.5); P=0.002	4.1 (2.1,8.0) P<0.0001	3.3 (1.8,6.0) P<0.0001	3.1 (1.7,5.8) P=0.0003
Ratio of DOR (95%CI); P-val- ue		Total hCG AFP uE3 (triple)	Free βhCG (single)	Total hCG (single)					
	DOR (95%CI) Studies	21 (16,28) k=24	14 (8,24) k=4	12 (8,20) k=4					
Free β hCG	14 (8,24) k=4	1.5 (0.9,2.6); P=0.14							
Total hCG	12 (8,20) k=4	1.7 (1.0,2.9); P=0.04	1.1 (0.6,2.2); P=0.71						
AFP	8 (5,14) k=4	2.5 (1.4,4.5); P=0.002	1.7 (0.8,3.4); P=0.15	1.5 (0.8,2.9); P=0.26					

Indirect comparisons are made using all available data. Relative DORs are computed by division of the DOR for the test in the column by the DOR for the test in the row. If the relative DOR is greater than one then the diagnostic accuracy of the test for the column is higher than that for the row, if less than one the diagnostic accuracy of the test in the row is higher than in the column. All test combinations include maternal age.

Table 3. Investigation of sources of heterogeneity

Test combination	Relative DOR (95% CI)	P value	Sensitivity at 5% FPR (95% CI) (studies)	
Effect of maternal age			≤ 35 years	> 35 years
Free β hCG, AFP and age	0.56 (0.33, 0.96)	P=0.03	66.4 (58.8, 73.2) k=9	51.7 (39.1, 64.1) k=3
Total hCG, AFP, uE3 and age	0.43 (0.29, 0.63)	P< 0.0001	68.6 (62.3, 74.3) k=11	48.4 (40.7, 56.2) k=13
Total hCG, AFP and age	0.41 (0.12, 1.38)	P=0.15	69.1 (64.1, 73.7) k=13	54.2 (44.1, 64.1) k=2
Bias in both fitting and evaluating in derivation datasets			Derivation dataset	Validation dataset
Free β hCG, AFP and age	0.67 (0.40, 1.09)	P=0.11	67.0 (58.9, 74.5) k=6	57.2 (47.1, 66.6) k= 6
Total hCG, AFP, uE3 and age	1.48 (0.86, 2.56)	P=0.15	54.0 (43.2, 64.4) k=8	63.0 (54.6, 70.6) k=16
Total hCG, AFP and age	0.99 (0.64,1.52)	P=0.95	66.1 (59.2, 72.3) k=6	65.8 (59.3, 71.7) k=9

Table 4. Sensitivity analysis of maternal age effect

Correction made for missing false negatives in studies with delayed verification of test negatives	Free β hCG, AFP and age			Total hCG, AFP, uE3 and age			Total hCG, AFP and age		
	Relative DOR (P value)	Sensitivity(%) at 5%FPR		Relative DOR (P value)	Sensitivity(%) at 5%FPR		Relative DOR (P value)	Sensitivity(%) at 5%FPR	
		> 35yrs (n = 3)	$\leq$ 35yrs (n = 9)		> 35 yrs (n = 13)	$\leq$ 35 yrs (n = 11)		> 35yrs (n = 2)	$\leq$ 35yrs (n = 13)
No FN correction	ROR=0.56 (P=0.03)	51.7%	66.4%	ROR = 0.43 (P < 0.0001)	48.4%	68.6%	ROR=0.41 (P=0.15)	54.2%	69.1%
FN increased +10%	ROR = 0.61 (P=0.07)	51.7%	64.4%	ROR = 0.46 (P < 0.0001)	48.0%	66.4%	ROR=0.45 (P=0.14)	53.1%	67.1%
FN increased +20%	ROR = 0.66 (P=0.11)	51.6%	62.5%	ROR = 0.50 (P < 0.0001)	47.6%	64.4%	ROR=0.49 (P=0.14)	52.1%	65.3%
FN increased +30%	ROR=0.71 (P=0.18)	51.5%	60.7%	ROR = 0.54 (P < 0.0001)	47.2%	62.5%	ROR=0.53 (P=0.15)	51.1%	63.5%
FN increased +40%	ROR=0.75 (P=0.27)	51.5%	59.0%	ROR = 0.57 (P < 0.0001)	46.8%	60.7%	ROR=0.57 (P=0.16)	50.3%	61.8%
FN increased +50%	ROR=0.80 (P=0.39)	51.4%	57.4%	ROR = 0.61 (P = 0.01)	46.5%	59.0%	ROR=0.61 (P=0.18)	49.6%	60.2%

APPENDICES

Appendix 1. Search Strategy

Database: Ovid MEDLINE

-
- 1 exp Prenatal Diagnosis/
  - 2 nuchal translucency.mp.
  - 3 exp Pregnancy-Associated Plasma Protein-A/
  - 4 pregnancy associated plasma protein a.mp.
  - 5 papp-a.mp.
  - 6 exp Chorionic Gonadotropin, beta Subunit, Human/
  - 7 (b-hcg or bhcg).mp.
  - 8 human chorionic gonadotropin.mp.
  - 9 exp alpha-Fetoproteins/
  - 10 alphafetoprotein\$.mp.
  - 11 alpha-fetoprotein\$.mp.
  - 12 afp.mp.
  - 13 (unconjugated estriol or unconjugated oestriol).mp.
  - 14 ue3.mp.
  - 15 exp INHIBINS/
  - 16 inhibin a.mp.
  - 17 ultrasound.mp.
  - 18 amniocentesis/
  - 19 chorion\$ vill\$ sampling.mp.
  - 20 Chorionic Villi-Sampling/
  - 21 nasal bone.mp.
  - 22 tricuspid regurgitation.mp.
  - 23 ductus venosus.mp
  - 24 marker\$.mp.
  - 25 screen\$.mp.
  - 26 detect\$.mp.
  - 27 accura\$.mp.
  - 28 predict\$.mp.
  - 29 ROC.mp.
  - 30 ROC curve/

- 31 AUC.mp.
- 32 Area under curve/
- 33 exp false negative reactions/ or exp false positive reactions/
- 34 (false positive\$ or false negative\$).mp.
- 35 likelihood ratio\$.mp.
- 36 sensitiv\$.mp.
- 37 specific\$.mp.
- 38 diagnos\$.ti,ab.
- 39 "reproducibility of results".mp.
- 40 reference value\$.mp.
- 41 reference standard\$.mp.
- 42 exp Down Syndrome/
- 43 downs syndrome.mp.
- 44 down syndrome.mp.
- 45 trisomy 21.mp.
- 46 Aneuploidy/
- 47 aneuploidy.mp.
- 48 Mosaicism/
- 49 mosaicism.mp.
- 50 or/1-41
- 51 or/42-49
- 52 50 and 51
- 53 (antenatal\$ or prenatal\$ or trimester\$ or pregnan\$ or fetus or foetus or fetal or foetal).mp.
- 54 52 and 53
- 55 animal/ not (humans/ and animal/)
- 56 54 not 55

*****

EMBASE via Dialog Datastar

1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.

7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN\$
10. ALPHAFETOPROTEIN\$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER OR MARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE\$
28. FALSE ADJ NEGATIVE\$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA\$
38. PREDICT\$
39. REPRODUCIBILITY.DE.

40. REFERENCE ADJ VALUE\$
41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD\$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ '21'
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL\$ OR PRENATAL\$ OR PREGNANCY OR PREGNANT OR TRIMESTER\$ OR MATERNAL OR FETUS OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 37 OR 38 OR 39 OR 40 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52

ADJ = adjacent   AB = abstract

TI = title   \$ = truncation symbol   DE = descriptor (similar to MeSH)

*****

CINAHL via OVID

-
- 1 exp Prenatal Diagnosis/
  - 2 nuchal translucency.mp.
  - 3 pregnancy associated plasma protein.mp.
  - 4 papp\$.ti,ab.
  - 5 exp Gonadotropins, chorionic/
  - 6 (b-hcg or bhcg).mp.
  - 7 human chorionic gonadotropin.mp.
  - 8 exp alpha-Fetoproteins/
  - 9 alphafetoprotein\$.mp.
  - 10 alpha-fetoprotein\$.mp.
  - 11 afp.mp.
  - 12 (unconjugated estriol or unconjugated oestriol).mp.
  - 13 ue3.mp.
  - 14 inhibin\$.mp.

- 15 ultrasound.mp.
- 16 amniocentesis/
- 17 chorion\$ vill\$ sampling.mp.
- 18 Chorionic Villi-Sampling/
- 19 nasal bone.mp.
- 20 tricuspid regurgitation.mp.
- 21 ductus venosus.mp.
- 22 marker\$.mp.
- 23 screen\$.mp.
- 24 detect\$.mp.
- 25 accura\$.mp.
- 26 predict\$.mp.
- 27 ROC.mp.
- 28 ROC curve/
- 29 AUC.mp.
- 30 "area under curve".mp.
- 31 exp false negative reactions/ or exp false positive reactions/
- 32 (false positive\$ or false negative\$).mp.
- 33 likelihood ratio\$.mp.
- 34 sensitiv\$.mp.
- 35 specific\$.mp.
- 36 diagnos\$.ti,ab.
- 37 "reproducibility of results".mp.
- 38 reference value\$.mp.
- 39 reference standard\$.mp.
- 40 exp Down Syndrome/
- 41 downs syndrome.mp.
- 42 down syndrome.mp.
- 43 trisomy 21.mp.
- 44 aneuploidy.mp.
- 45 mosaicism.mp.
- 46 (antenatal\$ or prenatal\$ or trimester\$ or pregnan\$ or fetus or foetus or fetal or foetal).mp.
- 47 or/1-39
- 48 or/40-45
- 49 47 and 48 and 46

*****

Search terms and instructions for Biosis

The following search terms were entered separately in standard search box (select 'Titles/subject/abstract' from the drop-down box on the right of the search box).

1. "reference standard"
2. "reference value"
3. "reproducibility of results"
4. diagnos*
5. sensitiv*
6. specific*
7. "likelihood ratio"
8. "false negative"
9. "false positive"
10. "area under curve"
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accur*
18. "ductus venosus"
19. "nasal bone"
20. "tricuspid regurgitation"
21. "chorion* vill* sampling"
22. amniocentesis
23. ultrasound
24. inhibin*
25. "unconjugated oestriol"
26. "unconjugated estriol"
27. afp
28. "alpha fetoprotein"
29. alphafetoprotein*
30. "bhcg"
31. "human chorionic gonadotrophin"
32. "papp a"
33. "pregnancy associated plasma protein"
34. "nuchal translucency"
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. "trisomy 21"
44. mosaicism

45. "down* syndrome"

The search then used the history function to combine terms:

1-34 – combine using OR

35 – 42 – combine using OR

43 – 45 – combine using OR

The three sets were combined using AND

The combined search strategy had the form

(((((al: "trisomy 21") or (al: (mosaicism))) or (al: "down* syndrome"))) and (((((((((((((((((((((((((((((((((((((((al: "reference standard*") or (al: "reference value*") or (al: "reproducibility of results") or (al: (diagnos*)) or (al: (specific*)) or (al: (sensitiv*)) or (al: "likelihood ratio*") or (al: "false negative*") or (al: "false positive*") or (al: "area under curve") or (al: (auc)) or (al: (roc)) or (al: (predict*)) or (al: (accura*)) or (al: (detect*)) or (al: (screen*)) or (al: (marker*)) or (al: "ductus venosus") or (al: "tricuspid regurgitation") or (al: "nasal bone") or (al: "chorion* vill* sampling") or (al: (amniocentesis)) or (al: (ultrasound)) or (al: (inhibin*)) or (al: "unconjugated oestriol") or (al: "unconjugated estriol") or (al: (afp)) or (al: "alpha feto protein*") or (al: "alpha fetoprotein*") or (al: "b hcg") or (al: "human chorionic gonadotropin") or (al: "papp a") or (al: "pregnancy associated plasma protein") or (al: "nuchal translucency")))) and (((((((((((al: (foetal)) or (al: (fetal)) or (al: (foetus)) or (al: (fetus)) or (al: (pregnan*)) or (al: (trimester*)) or (al: (prenatal*)) or (al: (antenatal*)))))

*****

The Database of Abstracts of Reviews of Effectiveness (DARE), National Research Register and Health Services Research Projects in Progress database

:

1. Down syndrome (MeSH)
2. down* next syndrome
3. trisomy
4. aneuploidy
5. mosaicism
6. OR/ 1-5

*****

MEDION (<http://www.mediondatabase.nl/>)

ICPC code for pregnancy – 'W'.

*****

The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine – download the database to a .pdf file and search for the following terms separately:

Down

Trisomy

Aneuploidy

Pregnant

Pregnancy

Pregnancies

Mosaicism

*****

Appendix 2. Glossary of terms (adapted in part from the UK National Screening Committee Glossary)

Abnormal ductus venosus flow velocity	The ductus venosus is a vessel in the fetus which allows oxygenated blood from the placenta to bypass the fetal liver and flow straight to the heart. In conditions such as Down's syndrome the pressure in this vessel can be abnormally high.
Absent nasal bone	Absence of the bone that forms the bridge of the nose, which may be detected at ultrasound scan during early pregnancy.
Affected individuals	Those individuals who are affected by the disorder for which they are being screened.
Amniocentesis	Amniocentesis is an invasive procedure which involves taking a small sample of the amniotic fluid (liquor) surrounding the baby, using a needle which goes through the abdominal wall into the uterus, and is usually performed after 15 weeks gestation.
Chorionic villus sampling (CVS)	Chorionic villus sampling involves taking a sample of the placental tissue using a needle which goes through the abdominal wall and uterus or a cannula through the cervix. It is usually performed between 10 and 13 weeks gestation.
Combined test	First trimester test (up to 13 + 6 weeks of pregnancy) based on combining nuchal translucency measurement with free beta-hCG, pregnancy-associated plasma protein A (PAPP-A) and the woman's age.
Diagnostic accuracy	The amount of agreement between the information from the index test and the reference standard (see below).
Diagnostic test	A definitive test, performed after a positive screening test result that gives a diagnosis (i.e. yes or no)?
Double test	Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on the measurement of alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG β either free beta-hCG or total hCG), together with the woman's age.
First trimester	Pregnancy from conception up to 13 weeks and 6 days.
Iatrogenic	A disease or condition in a patient occurring as a result of treatment.
Index test	A test or group of tests being evaluated in a systematic review.
Integrated test	Measurements performed at different times of pregnancy combined into a single test result. Unless otherwise specified, 'integrated test' refers to the combination of nuchal translucency measurement and PAPP-A in the first trimester, with the quadruple test (see below) in the second.
Mosaicism	This is a condition in which person has some cells containing a normal number of chromosomes, and some containing an abnormal number. The more abnormal cells there are, the greater the effect.
Multiple of the median (MOM)	The serum test concentration for a pregnant woman divided by the average (median) for unaffected pregnancies in a defined population at the same stage of pregnancy.
Quadruple test	Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on the measurement of AFP, uE3, free beta-hCG (or total hCG), and inhibin-A together with the woman's age.

(Continued)

Reference Standard	The best available method for establishing the presence or absence of the target disease or condition.
Second trimester	Pregnancy from 14 weeks to 28 weeks gestation. Note that for the purposes of this Cochrane review, second trimester testing refers to the period of 14 to 24 weeks gestation.
Tricuspid regurgitation	Leakiness of or backflow of blood through the tricuspid valve of the heart. The tricuspid valve separates the upper and lower chambers of the right side of the heart.
Triple test	Second trimester test (from 14 up to 24 weeks of pregnancy) based on the measurement of AFP, unconjugated oestriol (uE3), and hCG (either total hCG or free beta-hCG) together with the woman's age.
Trisomy	The presence of an extra chromosome resulting in three copies of a particular chromosome instead of the normal two.
Translocation	Part of one chromosome is broken off and attached to another chromosome. This does not usually cause the individual any problems as they have a normal amount of chromosomes, but in an abnormal arrangement. It can be passed on as an extra chromosome to offspring, resulting in conditions such as Down's syndrome.

CONTRIBUTIONS OF AUTHORS

KA undertook the searches, applied eligibility criteria, extracted and entered data and wrote the first draft of the review.

JD supervised and planned the review, checked data extraction, supervised statistical analyses and wrote the second draft of the review.

BG checked data extraction and undertook statistical analyses.

JP applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.

ZA applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- University of Birmingham, UK.

Funding of the research time of JD and BG

External sources

- NIHR Health Technology Assessment Programme, UK.

Project grant - need to have reference number etc. Jim/Zarko can you add please?

- NIHR Health Technology Assessment Programme, UK.

Funding for the Cochrane Reviews of Diagnostic Test Accuracy Support Unit, based at the University of Birmingham (JD).

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies, and where such information was found it was difficult to extract meaningful data to allow for comparison between studies, as data were not reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects of test;

interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in a karyotypically normal pregnancy and following confirmation of Down's Syndrome or following detection of other chromosomal abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.

The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high. We excluded studies that identified fewer than five Down's syndrome pregnancies in their study population. We excluded studies that had less than 80% follow-up of participants.

In addition, the analytical strategy was informed by the volume of tests and studies included, and developed so that we focused on key tests and test combinations by a) only meta-analysed tests that were included in four or more papers or b) showed more than 70% sensitivity for more than 90% specificity. In addition a requirement that a minimum of 10 studies for a single test was required before subgroup analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.

NOTES

This review belongs to a suite of reviews examining antenatal screening for Down's syndrome which include four other titles: '*First trimester serum tests for Down's syndrome screening*'; '*First trimester serum and ultrasound tests for Down's syndrome screening*'; '*First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening*'; and '*Urine tests for Down's syndrome screening*'. The project as a whole has been much larger than initially anticipated, both in terms of size and statistical complexity. The initial search was completed in 2007. After identifying studies appropriate for inclusion, a significant amount of time has been devoted to data management and analysis.

The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new second trimester serum tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in this review. The literature search has recently been updated and work is in progress with the other reviews in this suite, to bring these reviews up to date prior to publication. Following publication of the other reviews in this suite, we plan to update this review and then prepare an umbrella review, examining the overall best performing test combinations for antenatal Down's syndrome screening.

INDEX TERMS

Medical Subject Headings (MeSH)

Biomarkers [*blood]; Down Syndrome [*diagnosis]; Maternal Age; Pregnancy Trimester, Second [blood]; Prenatal Diagnosis [*methods]; Randomized Controlled Trials as Topic

MeSH check words

Adult; Female; Humans; Pregnancy